ࡱ> ;W456789: bjbj}} ?"v::...8fJ%.) 5555:.iL ^v$  5}b::}}::55L8}f:55}*@5P0*l~ZR<i> h> > Y}}}}}}}.\}}}}}}}> }}}}}}}}} :  Southwark and Lambeth Antibiotic Guideline for Primary Care 2019 Approved by the Southwark Medicines Management Committee and Lambeth Borough Prescribing Committee: October 2019. Review date: October 2021 (or sooner if evidence changes) These guidelines have been developed by NHS Southwark CCG, NHS Lambeth CCG, Department of Microbiology and Pharmacy Departments at Kings College Hospital NHS Foundation Trust (KCH) and Guys and St Thomas NHS Foundation Trust (GSTFT), Southwark and Lambeth Public Health. The guideline is based on the Public Health England Management of infection guidance for primary care, Updated September 2019 Please direct any comments or queries to Medicines Optimisation: NHS Southwark CCG (email:  HYPERLINK "mailto:SOUCCG.Medicines-Optimisation@nhs.net" SOUCCG.Medicines-Optimisation@nhs.net, tel: 020 7525 3253), NHS Lambeth CCG (email:  HYPERLINK "mailto:LAMCCG.medicinesoptimisation@nhs.net" LAMCCG.medicinesoptimisation@nhs.net, tel: 020 3049 4197) Aims To provide a simple, empirical approach to the treatment of common infections based on our local community and sensitivity patterns. To promote the safe, cost-effective and appropriate use of antimicrobials by targeting those who may benefit most. To minimise the emergence of antimicrobial resistance in the community. Principles of Treatment This guidance is based on the best available evidence at the time of development. Its application must be modified by professional judgement, based on knowledge about individual patient co-morbidities, potential for drug interactions and involve patients in management decisions. It is important to initiate antibiotic as soon as possible in severe infection or in those immunocompromised, particularly if sepsis is suspected. Refer to the NICE guideline [ HYPERLINK "https://www.nice.org.uk/guidance/ng51/resources" NG51] Sepsis: recognition, diagnosis and early management for further information. This guidance should not be used in isolation; it should be supported with patient information about safety netting, back-up/delayed antibiotics, self care, infection severity and usual duration, clinical staff education, and audits. The RCGP HYPERLINK "http://www.rcgp.org.uk/targetantibiotics"TARGET antibiotics toolkit is available via the RCGP website. The majority of this guidance provides dose and duration of treatment for ADULTS. Doses may need modification for age, weight and renal function. Refer to the  HYPERLINK "https://bnfc.nice.org.uk" BNF for Children for information on paediatric doses. Refer to BNF for further dosing and interaction information (e.g. interaction between macrolides and statins), ALWAYS check for hypersensitivity/allergy. Have a lower threshold for antibiotics in immunocompromised or in those with multiple co- morbidities; send samples for culture and seek advice. Drugs in RED are contra-indicated in true penicillin allergy. Drugs in GREEN are considered safe in penicillin allergy. Prescribe an antimicrobial only when there is likely to be a clear clinical benefit, giving alternative, non-antibiotic self care advice where appropriate. Consider a no, or delayed, antibiotic strategy for acute self-limiting upper respiratory tract infections (e.g. acute sore throat, acute cough and acute sinusitis) and mild UTI symptoms Blind antibiotic prescribing for unexplained pyrexia usually leads to further difficulty in establishing the diagnosis. Limit prescribing over the telephone/eConsult to exceptional cases. Avoid broad spectrum antibiotics (e.g. co-amoxiclav, quinolones and cephalosporins) when narrow spectrum antibiotics remain effective, as they increase the risk of all infections, including Clostridium difficile, MRSA and resistant Urinary Tract Infections (UTIs). Avoid widespread use of topical antibiotics (especially those agents also available as systemic preparations, in most cases, topical use should be limited). If diarrhoea or vomiting occurs due to an antibiotic or the illness being treated, the efficacy of hormonal contraception may be impaired and additional precautions should be recommended. Clarithromycin is now recommended over erythromycin, except in pregnancy and breastfeeding. It has fewer side-effects and twice daily rather than four times daily dosing promotes compliance. Statins should be withheld when macrolide antibiotics are prescribed. In pregnancy, take specimens to inform treatment. Penicillins, cephalosporins and erythromycin are not associated with increased risk of spontaneous abortion. If possible, avoid tetracyclines, quinolones, aminoglycosides, azithromycin (except in chlamydial infection), clarithromycin and high dose metronidazole (2g stat) unless the benefits outweigh the risks. Short-term use of nitrofurantoin is not expected to cause foetal problems (theoretical risk of neonatal haemolysis). Trimethoprim is also unlikely to cause problems unless poor dietary folate intake, or taking another folate antagonist. If you are unsure about a particular drugs use in pregnancy contact the relevant Medicines Optimisation team for further advice. Annual vaccination is essential for all those at clinical risk of severe influenza. Visit HYPERLINK "https://www.gov.uk/government/collections/annual-flu-programme"Annual Flu Programme for further information. For information on Immunisation against infectious disease refer to  HYPERLINK "https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book" The Green Book. For information on causative pathogens, refer to  HYPERLINK "https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care" PHE guidance: Management of infection guidance for primary care for consultation and local adaptation Self Care Promote self-care where appropriate. Refer to the Self Care sections highlighted throughout the guideline. Treatments that are often available to purchase over the counter include: Analgesics (painkillers) for short-term use Topical antifungal treatment for short-term minor ailments Cold sore treatment Colic treatment Cough and cold remedies Eye treatments/lubricating products Head lice treatment and scabies treatment Threadworm tablets Topical acne treatment Warts and verruca treatment For further information see: NHS Lambeth CCG: Self care with over the counter products HYPERLINK "http://www.lambethccg.nhs.uk/your-health/keeping-well/PublishingImages/Pages/Self-care/NHS%20Lambeth%20CCG%20Self%20Care%20Leaflet%20A5%20Oct%2017.pdf"  leaflet NHS Southwark CCG: Are you Self Care Aware?  HYPERLINK "http://www.southwarkccg.nhs.uk/news-and-publications/publications/leaflets-flyers/Documents/Self-care.pdf" leaflet Self-care Forum  HYPERLINK "http://www.selfcareforum.org/" website NHS Choices  HYPERLINK "https://www.nhs.uk/pages/home.aspx" website Patients who are registered with a Southwark GP and entitled to free prescriptions may be eligible to receive treatment free of charge for certain conditions under the Pharmacy First Scheme. For further information see the Pharmacy First  HYPERLINK "http://www.southwarkccg.nhs.uk/your-health/health-services-in-southwark/Pages/Pharmacy-First.aspx" webpage. CONTENTS PAGE  HYPERLINK \l "upperrespiratorytractinfections" UPPER RESPIRATORY TRACT INFECTIONS HYPERLINK \l "LOWERRESPIRATORYTRACTINFECTIONS" LOWER RESPIRATORY TRACT INFECTIONS HYPERLINK \l "acutesorethroat" Acute sore throat  HYPERLINK \l "scarletfever" Scarlet Fever  HYPERLINK \l "Influenza" Influenza HYPERLINK \l "CommunityAcquiredPneumonia" Community acquired pneumonia  HYPERLINK \l "Acutecoughbronchitis" Acute cough, bronchitis HYPERLINK \l "acuterhinosinusitis" Acute rhinosinusitis HYPERLINK \l "COPD" Acute exacerbation of COPD HYPERLINK \l "acuteotitismedia" Acute otitis media HYPERLINK \l "acuteotitisexterna" Acute otitis externa HYPERLINK \l "UTIs" URINARY TRACT INFECTIONS  HYPERLINK \l "SKININFECTIONS" SKIN INFECTIONSHYPERLINK \l "UTIinadults"Lower UTI in adults (no fever or flank pain)HYPERLINK \l "impetigo"Impetigo HYPERLINK \l "RecurrentUTIinwomen" Recurrent UTI in women ( e" 3 UTIs/year)  HYPERLINK \l "RecurrentUTIinmen" Recurrent UTI in men HYPERLINK \l "Cellulitis" Cellulitis and Erysipelas  HYPERLINK \l "Mastitis" Mastitis HYPERLINK \l "Lowerutiinchildren" Lower UTI in children HYPERLINK \l "diabeticfoot" Diabetic foot infections HYPERLINK \l "upperutiinchildren" Upper UTI in children HYPERLINK \l "Acne" Acne HYPERLINK \l "Acuteprostatitis" Acute prostatitis HYPERLINK \l "Eczema" Eczema HYPERLINK \l "Acutepyelonephritis" Acute pyelonephritis HYPERLINK \l "Humananimalbites" Human or animal bites  HYPERLINK \l "VaricellaHerpes" Varicella zoster (chickenpox) / Herpes zoster (shingles)  HYPERLINK \l "TickbitesLymedisease" Tick bites (Lyme disease) HYPERLINK \l "GASTROINTESTINALINFECTIONS" GASTROINTESTINAL INFECTIONS  HYPERLINK \l "Infectiousdiarrhoea" Infectious diarrhoea (or gastroenteritis)  HYPERLINK \l "Clostridiumdifficile" Antibiotic-associated diarrhoea/ pseudomembranous colitis (Clostridium difficile)  HYPERLINK \l "EYECONDITIONS" EYE INFECTIONS  HYPERLINK \l "Conjuctivitis" Conjunctivitis  HYPERLINK \l "Blepharitis" Blepharitis   HYPERLINK \l "DENTALINFECTIONS" DENTAL INFECTIONS  HYPERLINK \l "Suspectedmeningococcaldisease" SUSPECTED MENINGOCOCCAL DISEASE HYPERLINK \l "STI" SEXUALLY TRANSMITTED INFECTIONS  HYPERLINK \l "MRSAinfections" MRSA INFECTIONS InfectionCommentsFirst Choice AntibioticsPregnancy and BreastfeedingNo allergyPenicillin allergyNo allergyPenicillin allergyUPPER RESPIRATORY TRACT INFECTIONSAcute sore throat HYPERLINK "https://www.nice.org.uk/guidance/ng84/resources/visual-summary-pdf-4723226606"PHE  HYPERLINK "http://cks.nice.org.uk/sore-throat-acute" CKS  HYPERLINK "https://www.nice.org.uk/guidance/ng84" NICE   HYPERLINK "https://ctu1.phc.ox.ac.uk/feverpain/index.php" FeverPAIN HYPERLINK "http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashx"Treating your infection patient leaflet  AVOID ANTIBIOTICS or consider back-up/ delayed antibiotic prescription. 82% of cases resolve in 7 days without antibiotics and pain is only reduced by 16 hours. Use FeverPAIN* Score to assess. Criteria include: Fever in last 24h, Purulence, Attend rapidly under 3 days, severely Inflamed tonsils, No cough or coryza). Score 0-1: 13-18% streptococci isolation - use NO antibiotic strategy Score 2-3: 34-40% streptococci isolation - consider no antibiotic or a back-up antibiotic prescription; Score 4-5: 62-65% streptococci isolation. Use clinical judgement to assess severity on baseline symptoms (difficulty swallowing, runny nose, cough, headache, muscle ache, interference with normal activities) and use immediate antibiotic or 48 hour short delayed antibiotic prescription. Always share self-care advice & safety net. Complications are rare. If systemically unwell, refer to emergency department. *Centor criteria can also be used First Line: Fever Pain 0-1: self-care see  HYPERLINK "https://www.nhs.uk/conditions/sore-throat/" NHS Choices Second Line: Fever pain 2-3: delayed prescription of phenoxymethylpenicillin Phenoxymethylpenicillin (oral) 500mg QDS OR 1g BD (if mild) for 5-10 days If severe (refer to comments): 500mg QDS for 10 days Second Line: Fever pain 2-3: delayed prescription of clarithromycin Clarithromycin (oral) 250mg BD for 5 days If severe ( refer to comments): 500mg BD for 5 days Second Line: Fever pain 2-3: delayed prescription of Phenoxymethylpenicillin Phenoxymethylpenicillin (oral) 500mg QDS OR 1g BD (if mild) for 5-10 days If severe (refer to comments): 500mg QDS for 10 daysSecond Line: Fever pain 2-3: delayed prescription of erythromycin Erythromycin (oral) 250mg 500mg QDS for 5 days. Scarlet Fever HYPERLINK "https://www.gov.uk/government/publications/scarlet-fever-symptoms-diagnosis-treatment"PHE Scarlet Fever Prompt treatment with appropriate antibiotics significantly reduces the risk of complications. Vulnerable individuals (immunocompromised, the co-morbid, or those with skin disease) are at increased risk of developing complications This is a notifiable disease First line: Phenoxymethylpenicillin (oral) 500 mg QDS for 10 days First line: Clarithromycin (oral) 250mg-500mg BD for 5 days First Line: Phenoxymethylpenicillin (oral) 500 mg QDS for 10 daysFirst Line: Erythromycin (oral) 250mg 500mg QDS or 500mg 100mg BD for 5 days.Influenza  HYPERLINK "https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents" PHESee the  HYPERLINK "https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents" PHE Influenza guidance for further information.Acute Rhino-sinusitis  HYPERLINK "https://www.nice.org.uk/guidance/ng79" NICE  HYPERLINK "http://cks.nice.org.uk/sinusitis" CKS HYPERLINK "http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashx"Treating your infection patient leaflet Symptoms <10 days: do not offer antibiotics as most resolve in 14 days without. Antibiotics only offer marginal benefit after 7 days. Symptoms >10 days: no antibiotic, or back-up/delayed antibiotic if several episodes of: purulent nasal discharge; severe localised unilateral pain; fever; marked deterioration after initial milder phase. Systemically very unwell or more serious signs and symptoms: immediate antibiotic. Suspected complications: e.g. sepsis, intraorbital or intracranial infection, refers to secondary care. Self-care: paracetamol/ibuprofen for pain/fever. Consider high-dose nasal steroid if >12 years. Little evidence that nasal saline or nasal decongestants help, but people may want to try them (suitable for self-care) Consider prescribing a high-dose nasal corticosteroid for 14days for adults and children aged 12years and over with symptoms for 10 days or more, but being aware that nasal corticosteroids: may improve symptoms but are not likely to affect how long they last could cause systemic effects, particularly in people already taking another corticosteroid may be difficult for people to use correctly -consider providing  HYPERLINK "https://patient.info/treatment-medication/steroids/steroid-nasal-sprays" patient information leaflet on usage For detailed information click on the  HYPERLINK "https://www.nice.org.uk/guidance/ng79/resources/visual-summary-pdf-4656316717" visual summary contained within the NICE hyperlink First Line: self-care see  HYPERLINK "https://www.nhs.uk/conditions/sinusitis-sinus-infection/" NHS ChoicesSecond Line: (delayed antibiotic) phenoxymethylpenicillin (oral) 500mg QDS for 5 days Offer as first choice if systemically very unwell or high risk of complications; Co-amoxiclav 625mg TDS for 5 days Mometasone nasal spray 200mcg BD for 14 days (with or without an oral antibiotic)Second Line: (delayed antibiotic) Doxycycline (oral) 200mg STAT then 100mg OD for a total of 5 days OR Clarithromycin (oral) 500mg BD for 5 days Mometasone nasal spray 200mcg BD for 14 days For 2nd line choice of antibiotic or worsening contact local medical infection team (refer to page 21 for contact details).Second Line: (delayed antibiotic) Phenoxymethylpenicillin (oral) 500mg QDS for 5 days For 2nd line choice of antibiotic or if worsening contact local medical infection team (refer to page 21 for contact details). Mometasone nasal spray 200mcg BD for 14 days if benefit outweighs risk Second Line: (delayed antibiotic) Erythromycin (oral) 250mg 500mg QDS for 5 days For 2nd line choice of antibiotic or if worsening contact local medical infection team (refer to page 21 for contact details). Mometasone nasal spray 200mcg BD for 14 days if benefit outweighs risk. Acute otitis media (AOM)  HYPERLINK "http://cks.nice.org.uk/otitis-media-acute" CKS  HYPERLINK "https://www.nice.org.uk/guidance/ng91" NICE  HYPERLINK "https://www.nice.org.uk/guidance/cg160" NICE: Fever in Under 5s HYPERLINK "http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashx"Treating your infection patient leaflet  HYPERLINK "https://www.nhs.uk/conditions/middle-ear-infection/" NHS Choices Consider no or back up/delayed antibiotics Regular paracetamol or ibuprofen for pain (ensure correct dose for age or weight at the right time and maximum doses for severe pain) AOM resolves in 60% of cases in 24hrs without antibiotics, which only reduce pain at 2 days and does not prevent deafness. Otorrhoea or under 2 years with infection in both ears: no, back-up or immediate antibiotic. Otherwise: no or back-up antibiotic. Systemically very unwell or high risk of complications: immediate antibiotic If systemically unwell, refer to emergency department.First-line: self-care analgesia for pain reliefAmoxicillin (oral) for 5 days 500mg TDS Second Line: (if symptoms worsen on first choice antibiotic taken for at least 2-3 days): Co-amoxiclav 625mg TDS for 5 daysClarithromycin (oral) for 5 days 250 mg BD, increased if necessary in severe infections to 500 mg BDAmoxicillin (oral) 500mg TDS for 5 days Erythromycin (oral) 250mg 500mg QDS for 5 days Acute Otitis Externa (OE)  HYPERLINK "http://cks.nice.org.uk/otitis-externa" CKSIf cellulitis/disease extending outside ear canal, take a swab for culture, start oral flucloxacillin & refer to exclude malignant OE. Malignant OE can be caused by Pseudomonas aeruginosa and therefore may not respond to flucloxacillin. If patient presents with symptoms of longer than 2 weeks, in particular patients with diabetes, refer to exclude malignant OE. First-line: self-care analgesia for pain relief and advice to apply localised heat (e.g. a warm flannel).Second Line: Topical acetic acid 2% spray: 1 spray TDS for 7 days (Available OTC as EarCalm) OR neomycin sulphate with corticosteroid ear drops: 3 drops TDS for 7 days minimum to 14 days maximum. Cure rates similar at 7 days for topical acetic acid or antibiotic +/- steroid. If cellulitis: flucloxacillin (oral) 250mg QDS for 7 days If severe: 500mg QDS for 7 days InfectionCommentsFirst Choice AntibioticsPregnancy and BreastfeedingNo allergyPenicillin allergyNo allergyPenicillin allergyLOWER RESPIRATORY TRACT INFECTIONSCommunity Acquired Pneumonia (treatment in the community) HYPERLINK "https://www.brit-thoracic.org.uk/standards-of-care/guidelines/bts-guidelines-for-the-management-of-community-acquired-pneumonia-in-adults-update-2009/"BTS  HYPERLINK "https://www.nice.org.uk/guidance/cg191" NICE: Pneumonia in AdultsUse CRB65 score in conjunction with clinical judgement to help guide and review: Each parameter scores 1: Confusion (AMTd"8); Respiratory rate >30/min; BP systolic <90mmHg or diastolic d" 60mmHg, Age e"65. Score 3-4: urgent hospital admission Score 1-2: intermediate risk consider hospital assessment Score 0: low risk consider home based care Provide safety net advice and likely duration of symptoms: fever for 1 week, sputum production for up to 4 weeks, cough up to 6 weeks, most symptoms resolve with 3 months and may take up to 6 months to get back to normal. Atypical mycoplasma infection is rare in > 65 years. Failure to improve or worsening within 48 hours, consider hospital treatment or chest X-ray. 'When life threatening infection, GP should administer antibiotics. Benzylpenicillin 1.2gram IV or amoxicillin 1gram orally are preferred agents5. Refer to hospital if CRB65e"3  Refer to hospital if CRB65 e" 1 If CRB65=1,2 & AT HOME, clinically assess need for antibiotic cover for atypicals: Amoxicillin (oral) 500mg TDS AND Clarithromycin (oral) 500mg BD for 7 days depending on severity OR Doxycycline alone (oral) 200mg STAT on day 1 then 100mg OD for a total of 7 days If CRB65=0: Amoxicillin (oral) 500mg TDS for 5 days with safety netting advice; to return for review at within 3 days; continue for a total of 7 days if no improvement or worsening.  If CRB65=1, 2 and at home: Clarithromycin(oral) 500mg BD for 7 days depending on severity OR Doxycycline(oral) 200mg STAT on day 1 then 100mg OD for a total of 7 days If CRB65=0: Clarithromycin (oral) 500mg BD 5 days with safety netting advice; to return for review within 3 days; continue for a total of 7 days if no improvement or worsening. OR Doxycycline (oral)200mg STAT on day 1, then 100mg OD for 4 days; review at 3 days; total 7 days if poor response  If CRB65=0: Amoxicillin(oral) 500mg TDS for 7 days To return for review at 3 days; if not improving or worsening refer to hospital  If CRB65=0: Erythromycin (oral) 250 mg 500mg QDS for 7 days. To return for review at 3 days; if not improving or worsening refer to hospital Acute cough, bronchitis  HYPERLINK "https://cks.nice.org.uk/cough" CKS-cough   HYPERLINK "https://cks.nice.org.uk/chest-infections-adult" CKS-Bronchitis  HYPERLINK "https://www.nice.org.uk/guidance/CG69" NICE: RTI  HYPERLINK "http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashx"Treating your infection patient leafletConsider no or 7 day back up/delayed antibiotic with self-care and safety netting and advise that symptoms can last 3 weeks. Antibiotics are of little benefit if no co-morbidity. Symptom resolution can take up to 3 weeks. Consider immediate antibiotics if >80years of age and ONE of: hospitalisation in past year; taking oral steroids; insulin dependent diabetic; congestive heart failure, serious neurological disorder/stroke OR >65 years with TWO of the above. Consider CRP testing if antibiotic treatment is being considered. No antibiotics if CRP<20mg/L and symptoms for >24 hours; delayed antibiotics if CRP 20-100mg mg/L; immediate antibiotics if >100mg/L. First line: Self Care and safety netting advice, see  HYPERLINK "https://www.nhs.uk/conditions/cough/" NHS ChoicesSecond line: Doxycycline (adults and children over 12 years) (oral)200mg STAT, then 100mg OD (total 5days treatment) Third line: Amoxicillin(oral) 500mg TDS for 5 days Second line: Doxycycline (adults and children over 12 years) (oral)200mg STAT, then 100mg OD (total 5days treatment) OR Clarithromycin (in children < 12 years old) 250mg-500mg BD for 5 daysSecond line: Amoxicillin(oral) 500mg TDS for 5 daysSecond line: Erythromycin(oral) 250mg 500mg QDS for 5 daysAcute exacerbation of COPD  HYPERLINK "https://www.nice.org.uk/guidance/cg101" NICE: COPD in over 16s  HYPERLINK "http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/" GOLD COPD Treat exacerbations promptly with antibiotics if purulent sputum and increased shortness of breath and/or increased sputum volume. Consider risk factors for antibiotic resistance: severe COPD (MRC>3), co-morbidity, frequent exacerbations, antibiotics in the last 3 months Previous microbiology should be reviewed if at risk of resistance.14 Antibiotics should be used to treat exacerbations of COPD associated with a history of more purulent sputum. Patients with exacerbations without more purulent sputum do not need antibiotic therapy unless there is consolidation on a chest radiograph or clinical signs of pneumonia7 - in which case follow treatment guidance for pneumonia. Oral corticosteroids should be considered in patients with a significant increase in breathlessness which interferes with daily activities7.  Rescue Pack (for initial management of exacerbation) Prescribe prednisolone 5mg tablets - Take SIX tablets in the morning for 5 days and Doxycycline 100mg capsules (unless allergic/pregnant/breastfeeding see below for antibiotic choice) - Take TWO capsules on the first day, then 100mg daily for a further 4 days, if no improvement in symptoms or doxycycline allergy refer to  HYPERLINK "https://www.nice.org.uk/guidance/ng114/resources/guide-to-resources-pdf-6602624893" Visual Summary for choice of antibiotics and prescribing considerations If a patient is using two or more packs in a year they need a specialist review. Consider referral to the Integrated Respiratory Team who can be contacted 7 days a week 9am-5pm on 07796 178719 (St Thomas) or 0203 299 6531 (Kings). Single Point of Referral can be accessed via  HYPERLINK "mailto:lamccg.respiratory@nhs.net" lamccg.respiratory@nhs.net (Lambeth)  HYPERLINK "mailto:Souccg.respiratory@nhs.net" Souccg.respiratory@nhs.net (Southwark) For access to the South East London integrated guideline for the management of COPD, click here: HYPERLINK "https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical%20guidelines%20and%20pathways/SEL%20COPD%20guideline%20Apr%202019.pdf"South East London integrated guideline for the management of COPDDoxycycline(oral) 200mg OD for 1 day then 100mg for a further 4 days If at risk of resistance: Co-amoxiclav (oral) 625mg TDS for 5daysDoxycycline (oral) 200mg OD for 1 day then 100mg for a further 4 days OR Clarithromycin (oral) 500mg BD for 5 days If risk factors present, contact microbiology for advice on antibiotic choice in recurrent/resistant casesAmoxicillin (oral) 500mg TDS for 5 days If risk factors present, contact microbiologyErythromycin(oral) 250mg 500mg QDS for 7 days If risk factors present, contact microbiology InfectionCommentsFirst Choice AntibioticsPregnancy and BreastfeedingNo allergyPenicillin allergyNo allergyPenicillin allergyURINARY TRACT INFECTIONSLower UTI in adults (no fever or flank pain)  HYPERLINK "https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis" PHE UTI quick reference guide   HYPERLINK "http://www.sign.ac.uk/sign-88-management-of-suspected-bacterial-urinary-tract-infection-in-adults.html" SIGN   HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-lower-women" CKS women  HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-lower-men" CKS men  HYPERLINK "https://rcgp.org.uk/clinical-and-research/resources/toolkits/target-antibiotic-toolkit.aspx" TARGET Antibiotic Toolkit HYPERLINK "https://www.sapg.scot/media/4653/alternative-management-of-lower-urinary-tract-infection-in-non-pregnant-women.pdf"SAPG UTIWomen treat empirically if HYPERLINK "https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis"e" 2 symptoms Send urine culture if risk of antibiotic resistance. If not pregnant and mild symptoms, watch & wait with back-up antibiotic OR consider immediate antibiotic Advise paracetamol or ibuprofen for pain Men: Consider prostatitis and send pre-treatment Mid-stream urine (MSU OR if symptoms mild/non-specific, use negative dipstick to exclude UTI. Always provide safety net advice. In treatment failure: always perform culture Low risk of resistance: younger women with acute UTI and no risk. Risk factors for increased resistance include: care home resident, recurrent UTI, hospitalisation anywhere >7days within the last 12 months unresolving urinary symptoms, recent travel to a country with increased antimicrobial resistance (outside Northern Europe and Australasia), previous known UTI resistant to trimethoprim, cephalosporins or quinolones ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) If increased resistance risk send culture for susceptibility testing & give safety net advice. >65 years: treat if fever >38C, or 1.5C above base twice in 12 hours, and >1 other symptom  First line for women and men: Nitrofurantoin (oral) 100mg MR twice daily if eGFR over 45ml/min. Use nitrofurantoin 1st line as resistance and community multi-resistant Extended-spectrum Beta-lactamase E. coli are increasing. Nitrofurantoin is contraindicated if eGFR< 45mL/min or if known G6PD deficiency or in acute porphyria. Alternative 1st line agents for women and men: Trimethoprim (oral) 200mg BD (local resistance is high, therefore only recommend if patient has low risk factors for resistance or if sensitivity of this is known). OR For non-pregnant women >16y Pivmecillinam (oral) 400mg STAT then 200mg TDS If eGFR<45ml/min or elderly consider pivmecillinam or fosfomycin (3g stat in women). NOTE: Fosfomycin should only be prescribed on the advice of a microbiologist following culture sensitivity results for the treatment of complicated ESBL producing UTI For men >16y: Second-choice: If no improvement in UTI symptoms on first-choice taken for at least 48 hours or when first-choice not suitable, consider alternative diagnoses and follow recommendations in the NICE guidelines on  HYPERLINK "https://www.nice.org.uk/guidance/ng111" \t "_top" pyelonephritis (acute): antimicrobial prescribing or  HYPERLINK "https://www.nice.org.uk/guidance/ng110" \t "_top" prostatitis (acute): antimicrobial prescribing, basing antibiotic choice on recent culture and susceptibility results.Prompt treatment for seven days to prevent progression to pyelonephritis. Send MSU for culture and review antibiotics already prescribed based on results. Short-term use of nitrofurantoin in pregnancy is unlikely to cause problems to the foetus. Do not prescribe trimethoprim for pregnant women with established folate deficiency, or low dietary folate intake, or those taking folate antagonists (e.g. antiepileptics or proguanil) Treatment duration: Women: 3 days Men: 7 days. Referral to hospital may be indicated in non-responding, severe or recurrent infection or suspicion of underlying UT abnormality  Treat for 7 days: 1st line: Nitrofurantoin (oral) 100mg m/r BD, unless at term 2nd line: Cefalexin (oral) 500mg BD Risk of C.difficileTreat for 7 days: Nitrofurantoin (oral) 100mg m/r BD OR 2nd line: Contact local medical infection team (refer to contact details on page 21) Recurrent UTI in women ( 2 in 6 months or e" 3 proven UTIs/year)  HYPERLINK "https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis" PHE UTI diagnosis guide for primary care  HYPERLINK "http://www.rcgp.org.uk/TARGETantibiotics/" TARGET UTI Consider STI screen and Urology referral where necessary. First line: Advise simple measures, including hydration & ibuprofen for symptom relief. Cranberry products, which can be purchased from pharmacies and health food stores, work for some women, but good evidence is lacking. For postmenopausal women, if no improvement, consider vaginal oestrogen (review with 12 months). Contact local medical infection team (refer to contact details on page 21) for advice on treating recurrent UTIs in pregnant, breastfeeding women and women trying to conceive. Second line: Standby: for those with recurrent UTIs consider a course at home to start as soon as symptoms occur. Base choice on past sensitivity. ORPost-coital (off label) take STAT Third line: Prophylaxis once daily at night and review at 3 months. First line choice (if eGFRe"45ml/min): Nitrofurantoin M/R 100mg Second line choice: Ciprofloxacin (oral) 500mg If recent culture sensitive: Trimethoprim (oral) 100mgRecurrent UTI in men Refer to hospitalLower UTI in children HYPERLINK "https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis"PHE UTI  HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-children" CKS  HYPERLINK "https://www.nice.org.uk/guidance/cg54?unlid=9336988692016286120" NICE: UTI in under 16sUrgently refer children < 3 months old for assessment If e" 3 months old: If nitrate positive and fresh sample, start antibiotics and send for microscopy, culture and sensitivity (MC+S). If leucocyte only positive, may be indicative of infection outside urinary tract, send MSU for MC+S, initiate antibiotics if there is good clinical evidence of UTI. If nitrate and leucocyte negative, consider another cause for illness. Imaging: only refer if child <6 months, or recurrent or atypical UTI See HYPERLINK "https://bnfc.nice.org.uk/"BNF-C for doses First Line: Trimethoprim (oral) OR if eGFRe"45ml/min Nitrofurantoin (oral) If susceptible, amoxicillin (oral) Second line: Cefalexin(oral) 3 days treatmentSee HYPERLINK "https://bnfc.nice.org.uk/"BNF-C for doses Trimethoprim(oral) OR Nitrofurantoin(oral) For 2nd line choice of antibiotic contact local trust medical infection team (see contact details on page 20). 3 days treatment Upper UTI in children HYPERLINK "https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis"PHE UTI  HYPERLINK "http://cks.nice.org.uk/urinary-tract-infection-children" CKS  HYPERLINK "https://www.nice.org.uk/guidance/cg54?unlid=9336988692016286120" NICE: UTI in under 16s Refer to paediatrics to obtain a urine sample for culture; assess signs of systemic infection , consider systemic antimicrobialsCatheter associated UTIAntibiotic treatment is not routinely needed for asymptomatic bacteriuria in people with a urinary catheter. Consider removing or, if not possible, changing the catheter if it has been in place for more than 7 days. But do not delay antibiotic treatment. Advise paracetamol for pain. Advise drinking enough fluids to avoid dehydration. Offer an antibiotic for a symptomatic infection. When prescribing antibiotics, take account of severity of symptoms, risk of complications, previous urine culture and susceptibility results, previous antibiotic use which may have led to resistant bacteria and local antimicrobial resistance data. Do not routinely offer antibiotic prophylaxis to people with a short-term or long-term catheter. KCH and GSTFT (Including community services) launched My Catheter Passport to improve the care for people with catheters. You can view My Catheter PassportHYPERLINK "https://www.guysandstthomas.nhs.uk/resources/patient-information/urology/bladder/my-catheter-passport.pdf" \t "_blank"here If no upper UTI symptoms First line: Nitrofurantoin (if eGFRe"45ml/min) 100mg M/R 100mg BD OR Trimethoprim (if low risk of resistance) 200mg BD OR Amoxicillin (only if culture results available and susceptible) 500mg TDS Second line Pivmecillinam 400mg STAT then 200mg TDS 7 days treatmentIf no upper UTI symptoms First line: Nitrofurantoin (if eGFRe"45ml/min) 100mg M/R 100mg BD OR Trimethoprim (if low risk of resistance) 200mg BD 7 days treatment First line: Cefalexin 500mg BD or TDS (up to 1g-1.5g TDS or QDS for severe infections) 7-10 days treatment Second line: Seek advice from the local Microbiologist  Contact local medical infection team (refer to contact details on page 21) If upper UTI symptoms present Cefalexin 500mg BD or TDS (up to 1g-1.5g TDS or QDS for severe infections) OR Co-amoxiclav (only if culture results available and susceptible) 625mg TDS 7-10 days treatment OR Trimethoprim (only if culture results available and susceptible) 200mg BD 14 days treatment OR Ciprofloxacin (oral) 500mg BD ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) 7 days treatment If upper UTI symptoms present Trimethoprim (only if culture results available and susceptible) 200mg BD 14 days treatment OR Ciprofloxacin (oral) 500mg BD ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) 7 days treatmentAcute prostatitis  HYPERLINK "https://www.bashh.org/guidelines" BASHH  HYPERLINK "http://cks.nice.org.uk/prostatitis-acute" CKSAdvise paracetamol (+/- low-dose weak opioid) for pain, or ibuprofen if preferred and suitable. Offer antibiotic. Review antibiotic treatment after 14 days and either stop antibiotics or continue for a further 14 days if needed (based on assessment of history, symptoms, clinical examination, urine and blood tests). Send MSU for culture and start antibiotics. Consider STI screen and urology referral where necessary. 4 week course may prevent chronic prostatitis Quinolones ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) achieve higher prostate levelsTreatment duration: 14 days then review Frist line (guided susceptibilities when available: Ciprofloxacin (oral) 500mg BD ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) or ofloxacin 200mg BD ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) or trimethoprim (oral) 200mg BD (if unable to take quinolone Second line (after discussion with specialist) 14 days then review: Levofloxacin 500mg OD ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) OR co-trimoxazole 960mg BD Not applicable Acute pyelonephritis  HYPERLINK "http://cks.nice.org.uk/pyelonephritis-acute" CKS Advise paracetamol (+/- low-dose weak opioid) for pain, or ibuprofen if preferred and suitable. If admission not needed, send MSU for culture & susceptibility for people aged e"16 years and start empirical antibiotics. Review MSU result once available and adjust treatment appropriately if necessary. Arrange if there is any clinical deterioration or the person does not respond to treatment within 24 hours. If extended-spectrum beta-lactamases (ESBL) risk and with microbiology advice consider intravenous (IV) antibiotic via the Outpatient Parenteral Antimicrobial Therapy (OPAT) service. This service is managed by the acute trust and GPs would not be expected to prescribe intravenous antibiotics. For children: Ensure sample is taken and referral is made to paediatrics Cefalexin (oral) for 7 days e"16 years: 500mg BD or TDS For severe infections: Up to 1-1.5g TDS - QDS OR Co-amoxiclav (oral) for 7 days e"16 years: 625mg TDS OR if MSU results show susceptibility consider switch to: Trimethoprim (oral) 200mg BD for 14 days OR Ciprofloxacin ( HYPERLINK "https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects" consider safety issues) 500mg BD for 7 days Refer to hospital if 2nd line agent required If susceptible, Trimethoprim (oral) 200mg BD for 14 days OR Ciprofloxacin (oral) 500mg BD for 7 days Refer to hospital if 2nd line agent required. Cefalexin (oral) 500mg BD-TDS (upto 1-1.5g TDS-QDS for severe infections 7-10 days treatment Contact local medical infection team for advice(see contact details on page 21)  InfectionCommentsFirst Choice AntibioticsPregnancy and BreastfeedingNo allergyPenicillin allergyNo allergyPenicillin allergySKIN INFECTIONSRefer to local infection department for all patients with known or suspected MRSA where oral antibiotics are requiredImpetigo  HYPERLINK "http://cks.nice.org.uk/impetigo" CKSA systematic review indicates topical and oral treatment produces similar results. Reserve topical antibiotics for very localised lesions to reduce the risk of resistance. Treatment for 7 days is usually adequate; max. duration of topical treatment 10 days. Reserve mupirocin for MRSA For extensive, severe, or bullous impetigo, use oral antibiotics for 7 days.Flucloxacillin oral) 250-500mg QDS for 7 days Topical Fusidic acid 2% TDS (thinly) for 5days Mupirocin TDS for 5 days (if MRSA)Clarithromycin (oral) 250mg 500mg BD for 7 days Flucloxacillin (oral) 250-500mg QDS for 7 days Erythromycin (oral) 250mg 500mg QDS for 7 daysCellulitis and Erysipelas  HYPERLINK "http://cks.nice.org.uk/cellulitis-acute" CKS  HYPERLINK "https://www.lymphoedema.org/images/pdf/CellulitisConsensus.pdf" British Lymphology SocietyIf river or sea water exposure, discuss with microbiologist Class I: patient afebrile and healthy other than cellulitis, use oral flucloxacillin alone. If river or sea water exposure: seek advice. Class II febrile & ill, or unstable comorbidity, admit for intravenous treatment, or use OPAT (if available). Class III toxic appearance: admit. Deep pain may indicate severe streptococcal sepsis and will require IV therapy. Admit patients urgently in such circumstances for early surgical review. Do not prescribe topical antibiotics. There is no published evidence to support their use, and widespread use is likely to increase antibiotic resistance. Erysipelas: often facial and unilateral. Use flucloxacillin for non-facial erysipelas. Arrange a review after 48 hours by telephone or face-to-face, depending on clinical judgement.Non facial cellulitis/erysipelas Flucloxacillin oral) 500mg QDS for 7 days If unresolving, Clindamycin oral) 300-450mg QDS for 7 days Facial cellulitis/erysipelas (non dental): Co-amoxiclav (oral) 625mg TDS for 7days   Clarithromycin oral) 500mg BD for 7days If on statins: Doxycycline oral) 200mg stat on day 1, then 100mg daily for 6 days OR Clindamycin oral) 300mg-450mg QDS for 7days Stop clindamycin if diarrhoea occurs  Flucloxacillin oral) 500mg QDS for 7days  Erythromycin oral) 250mg 500mg QDS for 7days be particularly alert to deteriorating disease, carry out an early reviewMastitis  HYPERLINK "https://cks.nice.org.uk/mastitis-and-breast-abscess" CKSS. aureus is the most common infecting pathogen. Suspect if woman has: a painful breast; fever and/or general malaise; a tender, red breast. Breastfeeding: oral antibiotics are appropriate, where indicated. Women should continue feeding, including from the affected breast Treat all non-lactating women with oral antibiotics; consider 24-48 hours of effective breast milk removal by expressing milk/breastfeeding from affected breast before starting antibiotics for lactating women. If a breast abscess is suspected, the woman should be referred urgently to a general surgeon for confirmation of the diagnosis and management.Flucloxacillin 500mg QDS for 10-14 days Erythromycin 250-500mg QDS for 10-14 days OR Clarithromycin 500mg BD for 10-14 days Flucloxacillin 500mg QDS for 10-14 days days Erythromycin 250-500mg QDS for 10-14 days Diabetic foot infectionsRefer for specialist (e.g. microbiologist, diabetes foot specialist) opinion unless mild, superficial wound margins. If diagnosis of mild cellulitis is suspected, treat as above. Check microbiology results in those who may have been previously treated. Refer MRSA and treatment failure casesAcne HYPERLINK "https://cks.nice.org.uk/acne-vulgaris"CKS Mild (open and closed comedones) HYPERLINK \l "Acne1"  or moderate (inflammatory lesions): First-line: self-care (wash with mild soap; do not scrub; avoid make-up). Second-line: topical retinoid or benzoyl peroxide. Third-line: add topical antibiotic, or consider addition of oral antibiotic. Severe (nodules and cysts): add oral antibiotic (for 3 months max) and refer to a dermatologist. First-line: Self-care  HYPERLINK "https://www.nhs.uk/conditions/Acne/" NHS ChoicesSecond-line: topical retinoid thinly OD OR over the counter (OTC) benzoyl peroxide 5% gel OD-BD (especially if papules and pustules are present) for 6-8 weeks Third-line: topical clindamycin HYPERLINK \l "Acne3"  1% cream, thinly BD for 12 weeks Fourth- line:If treatment failure/severe: oral tetracycline 500mg BD OR oral doxycycline 100mg OD for 6-12 weeks Lymecycline 408mg OD should ONLY be considered in patients experiencing photosensitivity/ADRs/contraindication/intolerance/inefficacy with doxycycline.Erythromycin (oral) 500mg BD for 6-12 weeks Eczema  HYPERLINK "http://cks.nice.org.uk/eczema-atopic" CKSIf no visible signs of infection use of antibiotics (alone or with steroids) encourages resistance and does not improve healing. In eczema with visible signs of infection, use treatment as in impetigo (see page 12). Human or animal bites  HYPERLINK "http://cks.nice.org.uk/bites-human-and-animal" CKSEnsure thorough cleaning of wound and check tetanus status. For further information and advice on tetanus schedule refer to Immunisation against Infectious Disease( HYPERLINK "https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book" The Green Book): Assess rabies risk. For advice on rabies prophylaxis, contact  HYPERLINK "http://legacytools.hpa.org.uk/AboutTheHPA/WhatTheAgencyDoes/LocalServices/SouthEastLondonHPT/" South East London Health Protection Team (HPT). Surgical toilet most important. Contact the South London HPT on 0344 326 2052 or via HYPERLINK "C:\\Users\\NADATIA\\AppData\\Local\\Microsoft\\Windows\\Temporary Internet Files\\Content.Outlook\\K2AJ3201\\phe.slhpt@nhs.net"phe.slhpt@nhs.net; HYPERLINK "C:\\Users\\NADATIA\\AppData\\Local\\Microsoft\\Windows\\Temporary Internet Files\\Content.Outlook\\K2AJ3201\\slhpt.oncall@phe.gov.uk"slhpt.oncall@phe.gov.uk. Human bites: Assess HIV/hepatitis B/hepatitis C risk. Thorough irrigation. Antibiotic prophylaxis is recommended. Animal bites: Cat bite: always give antibiotic prophylaxis, other animal give antibiotic prophylaxis if puncture wound; bite involving hand, foot, face, joint, tendon, ligament; immunocompromised, diabetics, elderly, asplenic, cirrhotic, presence of prosthetic valve or prosthetic joint Review at 24 and 48 hours. People with severely infected wounds or who are systemically unwell may require referral to A&E for IV antibiotics. First line animal or human prophylaxis and treatment: Co-amoxiclav 625mg TDS for 7 days Children with bites should also be treated with: Co-amoxiclav. See  HYPERLINK "https://bnfc.nice.org.uk/" BNF-C for doses. Seek advice from the local Microbiologist if necessary (see contact details on page 21).First line prophylaxis or treatment for: Animal bite: Metronidazole 400 mg TDS PLUS doxycycline 100mg BD for 7 days Human bite: Metronidazole 400 mg TDS PLUS Clarithromycin 250500mg BD for 7 days Animal or human bites in children under 12 years: Metronidazole AND clarithromycin. See  HYPERLINK "https://bnfc.nice.org.uk/" BNF-C for doses. Seek advice from the local Microbiologist if necessary (see contact details on page 20). Animal or human prophylaxis/treatment: Co-amoxiclav 625mg TDS for 7 days The use of a combination of co-amoxiclav is NOT recommended for women with Preterm Prelabour Rupture of Membranes or 4 weeks before term. If pregnancy and rash after penicillin, refer to ambulatory. Varicella zoster/ chickenpox  HYPERLINK "https://cks.nice.org.uk/chickenpox" CKS  Herpes zoster/ shingles HYPERLINK "https://cks.nice.org.uk/shingles"CKS Pregnant/immunocompromised/ neonate: seek urgent specialist advice. Chickenpox: consider aciclovir if: onset of rash > 14 years of age; severe pain; dense/oral rash; taking steroids; smoker. Give paracetamol for pain relief. Shingles: treat if >50 years (Postherpetic neuralgia rare if, <50 years) and within 72 hours of rash, or if 1 of the following: active ophthalmic; Ramsey Hunt, eczema, non-truncal involvement, moderate/severe pain or rash Shingles treatment if not within 72 hours; consider starting antiviral drug up to 1 week after rash onset, if high risk of severe shingles or continued vesicle formation, older age, immunocompromised or severe painFirst Line: Aciclovir 800mg, 5 TDS for 7 days Second line for shingles if poor compliance: Valaciclovir 1g TDS for 7 daysSeek urgent specialist adviceTick bites (Lyme disease) HYPERLINK "https://cks.nice.org.uk/lyme-disease"CKS Prophylaxis: Not routinely recommended. If immunocompromised, consider prophylactic doxycycline. High-risk areas include grassy and wooded areas in southern England and the Scottish Highlands. Only give prophylaxis within 72 hours of tick removal. Give safety net advice about erythema migrans and other possible symptoms that may occur within 1 month of tick removal.Prophylaxis: Doxycycline 200mg STAT Treatment Doxycycline 100mg BD for 21 days First alternative: Amoxicillin 1g TDS for 21 daysProphylaxis: Doxycycline 200mg STAT Treatment Doxycycline 100mg BD for 21 days Amoxicillin 1g TDS for 21 daysContact local medical infection team for advice (see contact details on page 21)  InfectionCommentsAntibiotic treatment SEXUALLY TRANSMITTED INFECTIONS (STIs): For guidance, refer to HYPERLINK "https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/lambeth-borough-prescribing-committee/Lambeth%20Borough%20Prescribing%20Committee/Clinical%20Guidelines/Sexually%20Transmitted%20Infections%20quick%20reference%20treatment%20guideline%202019.pdf"Southwark and Lambeth STI Management in Primary Care GASTROINTESTINAL INFECTIONSInfectious diarrhoea  HYPERLINK "http://cks.nice.org.uk/gastroenteritis" CKS Refer previously healthy children with acute painful or bloody diarrhoea to exclude E. coli 0157 infection. Normal feeding should be restarted as soon as possible; there is no evidence that fasting will have any benefit. Fluid replacement is essential. Travel history should be reported if stool sample sent.  Antibiotic therapy usually not indicated unless systemically unwell as it only reduces diarrhoea by 1-2 days and can cause resistance. Initiate treatment, on advice of Microbiologist (see contact details on page 20). If systemically unwell and campylobacter suspected (e.g. undercooked meat and abdominal pain), consider clarithromycin 250500mg BD for 57 days if treated early (within 3 days). If giardia is confirmed or suspected tinidazole 2g single dose is the treatment of choice Notify suspected cases of food poisoning to, and seek advice on exclusion of patients from,  HYPERLINK "http://legacytools.hpa.org.uk/AboutTheHPA/WhatTheAgencyDoes/LocalServices/SouthEastLondonHPT/" South London HPT on 0344 326 2052, or email phe.slhpt@nhs.net ; slhpt.oncall@phe.gov.uk . Send stool samples in these cases.Clostridium difficile Stop unnecessary antibiotics and/or PPIs to re-establish normal flora. Stop any antidiarrhoeal agents in patients who are proven CD toxin positive. Clostridium difficile (CD) has been identified as a causative organism in pseudomembranous colitis/antibiotic-associated diarrhoea. Fluids and electrolytes should be replaced.  Some patients with recurrent C. difficile infections (CDI) may continue their treatment in a primary care setting, due to long-duration and/or tapering courses of vancomycin and attempts to avoid long hospital stays. 1st episode: Oral metronidazole 400mg TDS for 10-14 days 2nd episode/Severe CDI/ type 027: Oral vancomycin 125mg QDS for 10-14 days If severe symptoms or signs (see below) should treat with oral vancomycin, review progress closely and/or consider hospital referral Severe if T > 38.50C; WCC > 15 x109/L, rising creatinine (> 50% increase above baseline) or signs/symptoms of severe colitis (abdominal or radiological). Fidaxomicin (200mg PO BD for 10 days)- Treatment can be initiated in primary care after a recommendation from a Consultant Microbiologist. Restricted to treatment of laboratory-confirmed clostridium difficile infection (CDI) in the following groups: Recurrence following vancomycin treatment Patients who require ongoing concomitant antibiotic treatment Patients who are immunocompromised and at risk of further recurrence Subsequent recurrences and all cases of severe CDI will require admission. If the patient is well enough to avoid admission to hospital, but has diarrhoea and there is a suspicion of CDI, for the first and second episodes, send a stool sample, rehydrate and consider treatment as above. MENINGITISSuspected meningococcal disease  HYPERLINK "https://www.gov.uk/government/collections/meningococcal-disease-guidance-data-and-analysis" PHE Transfer all patients to hospital immediately. Keep supply of benzylpenicillin and check expiry dates.   If time before hospital admission, and non-blanching rash, administer benzylpenicillin prior to admission, unless history of true anaphylaxis reaction to previous penicillin; Ideally administer IV bolus but IM if a vein cannot be found. Adults and children: 10 yr and over: 1200 mg (1.2grams) Children 1 - 9 yr: 600 mg Children <1 yr: 300 mg Past history of allergic responses other than anaphylaxis, such as a rash is not a contraindication to an urgent penicillin injection in this situation. No alternative antibiotic is indicated in patients with anaphylactic reactions to penicillin. Prevention of secondary case of meningitis (prophylaxis): prescribe only on advice of South London HPT: on 0344 326 2052 or via phe.slhpt@nhs.net;  HYPERLINK "mailto:slhpt.oncall@phe.gov.uk" slhpt.oncall@phe.gov.uk.METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)MRSA infections HYPERLINK "https://cks.nice.org.uk/mrsa-in-primary-care" \l "!diagnosis"CKS  For support in prophylaxis and treatment of MRSA infections contact the local Medical Infection team (refer to page 21 for contact details). For advice on infection control, contact the local Infection Prevention and Control Team (IPCT) (refer to page 21 for contact details). Severe MRSA infections would be better treated in secondary care, on an individual case basis, working closely with the IPCT.EYE CONDITIONS Conjunctivitis  HYPERLINK "https://www.nhs.uk/conditions/conjunctivitis/" NHS Choices  HYPERLINK "https://cks.nice.org.uk/conjunctivitis-infective" CKS (Infective)  HYPERLINK "https://cks.nice.org.uk/conjunctivitis-allergic" CKS (Allergic) Treat only if severe, as most cases are viral or self-limiting especially in children. Bacterial conjunctivitis: usually unilateral and also self-limiting. It is characterised by red eye with mucopurulent, not watery discharge. 65% and 74% resolve on placebo by days 5 and 7. First line: Self-care and OTC lubricant eye drops. Children rarely require treatment or exclusion ( HYPERLINK "https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2017/09/spotty-book-2018.pdf" PHE) Bathe/clean eyelids with cotton wool dipped in sterile saline or boiled (cooled) water, to remove crusting HYPERLINK \l "Conjunctivitis1" Second line: Chloramphenicol 0.5% eye drops (available OTC to patients aged 2 years and above) 2 hourly for 2 days, then reduce frequency to 3-4 times a day OR 1% ointment (available OTC to patients aged 2 years and above) 3-4 times daily,or just at night if using eye drops Third line (as less gram-negative activity): Topical fusidic acid 1% gel BD Treatment should continue for 48 hours after resolution Blepharitis  HYPERLINK "https://cks.nice.org.uk/blepharitis" CKS (Blepharitis)   HYPERLINK "https://www.nhs.uk/conditions/blepharitis/" NHS Choices First line: Self Care-Lid hygiene for symptom control, including: warm compresses; lid massage and scrubs; gentle washing; avoiding cosmetics. Second line: topical antibiotics if hygiene measures are ineffective after 2 weeks. Signs of Meibomian gland dysfunction, or acne rosacea: consider oral antibiotics. First line: Self-careSecond line: Topical chloramphenicol 1% ointment (available OTC only patients aged 2 years and above) BD 6 week trial Third line (excluding pregnancy and breastfeeding): Oral oxytetracycline 500mg BD 4 weeks (initial) then 250mg BD 8 weeks (maintance) OR Oral doxycycline 100mg OD 4 weeks (initial) then 50mg OD 8 weeks (maintance) DENTAL INFECTIONS GPs should not be involved in prescribing antibiotics for dental treatment. Patients should be directed to their regular dentist or if this is not possible 111. Most dental conditions require dental input rather than antibiotics. Advise regular analgesia until a dentist can be seen. Also refer to: NHS choices topic on  HYPERLINK "https://www.nhs.uk/conditions/Dental-abscess/" Dental Abscess British Dental Association  HYPERLINK "https://bda.org/dentists/advice/Documents/NHS%20patient%20information%20leaflet%20on%20antibiotics.pdf" Patient Information Leaflet Contact Details Guys and St Thomas NHS Foundation TrustMedical Infection team: During working hours: (Monday Friday, 9am 5pm) Tel: 0207 188 3100 or call 0207 188 7188 (switchboard) Out of hours: Call switchboard on 0207 188 7188 and ask to speak to the Microbiology Registrar on call. Infection Prevention and Control Team(IPCT) Tel: 020 7188 3153 Email: gst-tr.infectiousdiseases@nhs.netKings College Hospital NHS Foundation TrustMedical Infection team: During working hours: (Monday Friday, 9am 5pm) Tel. 020 3299 9000 followed by extensions:34360/34358/34356 Out of hours: Call switchboard on 020 3299 9000 and ask to speak to the Microbiology Registrar on call.  #'-ILMNOVWX¹­zrz`N:&h*B*CJ0aJph hAoh>*B*CJ0aJphhU>*CJ0aJhAoh>*CJ0aJh>3>*CJ0aJhAohqM>*CJ0aJhAohAo>*CJ0aJh/h/nH tH h/nH tH hCR->*CJ0aJhx>*CJ0aJ     OPQRSTUVWX $a$gdAogdAogd^tgd/$a$gd/  raO=#hAchAoCJOJQJ\^JaJ#h!VhAo5CJOJQJ^JaJ *hrx5CJOJQJ^JaJ&h*OJQJhh ]hW5OJQJhiJ5OJQJh/5CJOJQJaJhAoCJOJQJ\^JaJh 2CJOJQJ\^JaJ#hAchAoCJOJQJ\^JaJh ]CJOJQJ\^JaJ'h"h ]0JCJOJQJ\^JaJ,jh"h ]CJOJQJU\^JaJ#h"h ]CJOJQJ\^JaJ   D E F G _ w'' $h^ha$gd2 $ & Fa$gd2$a$gd73gd 4h^hgd3 & Fgd3 & FgdW  ~= z9!v%gdW$a$gd3$a$gdAoQ   & B C D E F G ^ _ ͼޫͼ~p_N@2h ]h5m5OJQJ^Jh ]hW5OJQJ^J h^th 4CJ OJQJ^JaJ h3h3CJOJQJ^JaJh3CJOJQJ^JaJhAoCJOJQJ^JaJ hAchCJOJQJ^JaJhj^CJOJQJ^JaJ hAch9(CJOJQJ^JaJ hDhqMCJOJQJ^JaJ hDhWCJOJQJ^JaJ hAchWCJOJQJ^JaJ hAch;u>CJOJQJ^JaJ_ w&'()fgh"ͼͫmZI8I hAch=CJOJQJ^JaJ hAch$CJOJQJ^JaJ$h"h=0JCJOJQJ^JaJ/jh"hJiPCJOJQJU^JaJ h"hJiPCJOJQJ^JaJ)jh"hJiPCJOJQJU^JaJ h"h=CJOJQJ^JaJ h"h>uCJOJQJ^JaJ h"hCJOJQJ^JaJ h"hCJOJQJ^JaJ h"hWCJOJQJ^JaJ"02BMYZ%&'qпЮs`O> hAchiCJOJQJ^JaJ hAchWCJOJQJ^JaJ$hAch\|80JCJOJQJ^JaJ/jhAchJiPCJOJQJU^JaJhJiPCJOJQJ^JaJ)jhAch\|8CJOJQJU^JaJ hAch\|8CJOJQJ^JaJ hAch(fMCJOJQJ^JaJ hAch$CJOJQJ^JaJh(fMCJOJQJ^JaJ h"h(fMCJOJQJ^JaJqw%()νwdVE4 hYhCJOJQJ^JaJ hYhmOCJOJQJ^JaJhCJOJQJ^JaJ$h`Ph`P0JCJOJQJ^JaJ)jh`PCJOJQJU^JaJ#jh`PCJOJQJU^JaJh`PCJOJQJ^JaJ hAchCJOJQJ^JaJ hAchWCJOJQJ^JaJhmOCJOJQJ^JaJ hAchiCJOJQJ^JaJ#hAchi5CJOJQJ^JaJ'(Sk%EL' $ a$gdG gdG$a$gd2$ & F  ~= z9!v%a$gd2 $ & Fa$gd2)BSTayͼxfO=#h(hCUD5CJOJQJ^JaJ,h(h45B*CJOJQJ^JaJph#jhwhq}5UmHnHu hYh 2CJOJQJ^JaJ hYhCJOJQJ^JaJ hYh CJOJQJ^JaJ hYh(fMCJOJQJ^JaJ hYhWCJOJQJ^JaJ hYhCJOJQJ^JaJ hYhYCJOJQJ^JaJ hYh_"CJOJQJ^JaJy}~jkɲɡxl[J9[J hAch CJOJQJ^JaJ hAchd&CJOJQJ^JaJ hAchWCJOJQJ^JaJh`Ch!OJQJhh`ChqMOJQJhh`ChWOJQJh hCUDhCUDCJOJQJ^JaJ hAch4CJOJQJ^JaJ,h(h45B*CJOJQJ^JaJph3f#h(h45CJOJQJ^JaJ#h(hCUD5CJOJQJ^JaJ#hYhCUD5CJOJQJ^JaJ$ "'5L޻޻Ёp_Q_Q_Q_Q@ h`ChWCJOJQJ^JaJh`CCJOJQJ^JaJ h`Ch(fMCJOJQJ^JaJ hAcheCJOJQJ^JaJ&hAchW6CJOJQJ]^JaJ)hAchWB*CJOJQJ^JaJph3f hAchsRCJOJQJ^JaJ)hAchWB*CJOJQJ^JaJphhCJOJQJ^JaJ hAchWCJOJQJ^JaJ hAchCJOJQJ^JaJLXYZEFTmy{JKƮwfffTB#h 2hA5CJOJQJ^JaJ#h 2h{5CJOJQJ^JaJ hAch9;CJOJQJ^JaJ hAchKCJOJQJ^JaJ hAchWCJOJQJ^JaJ)hAchWB*CJOJQJ^JaJph3f.jhq}CJOJQJU^JaJmHnHu hAch{CJOJQJ^JaJ h`ChV5 h`ChV5CJOJQJ^JaJ h`ChWCJOJQJ^JaJKL )+7XZhlw,8ܲܡܲܲܲܲܲ{ܲܲfU h`Ch 2UCJOJQJ^JaJ)h"hvB* CJOJQJ^JaJphP h`ChV5CJOJQJ^JaJ)h`Ch73B* CJOJQJ^JaJphP h`ChmOCJOJQJ^JaJ)h`ChvB* CJOJQJ^JaJphP)h`ChvB*CJOJQJ^JaJph h`ChvCJOJQJ^JaJ#h 2h85CJOJQJ^JaJ&'TW`hiy}۸t_N6_/jh`ChHwCJOJQJU^JaJ h`ChHwCJOJQJ^JaJ)jh`ChCJOJQJU^JaJ h`ChCJOJQJ^JaJ h`Ch#CJOJQJ^JaJ h`ChmOCJOJQJ^JaJ h`ChCJOJQJ^JaJ h`Cht=CJOJQJ^JaJ#h`ChSE5CJOJQJ^JaJ#h`Ch@5CJOJQJ^JaJ#h`ChFs85CJOJQJ^JaJBCdefǶvePe8P/jh`Ch9!CJOJQJU^JaJ)jh`Ch9!CJOJQJU^JaJ h`Ch9!CJOJQJ^JaJ$h`Ch#0JCJOJQJ^JaJ/jh`Ch#CJOJQJU^JaJ)jh`Ch#CJOJQJU^JaJ h`Ch#CJOJQJ^JaJ h`ChCJOJQJ^JaJ)jh`ChCJOJQJU^JaJ$h`Ch0JCJOJQJ^JaJfHǹvhVGVG5V5#hhG>*CJOJQJ^JaJh3>*CJOJQJ^JaJ#hhw>*CJOJQJ^JaJh}Kh ]5OJQJ^Jh ]5OJQJ^JhG5OJQJ^JhwhG5OJQJ^J hG5>*CJOJQJ^JaJh'|9CJOJQJ^JaJhAcCJOJQJ^JaJ h`Ch9!CJOJQJ^JaJ)jh`Ch9!CJOJQJU^JaJ$h`Ch9!0JCJOJQJ^JaJ ! 9 ^ !""###$gd}K$a$gd'|9 & Fgd(gd ^gd3 & Fgd3 ^gd3 gdG  ! 8 9 ] ^ !(!)!*!!ۼxxxc)jhh(CJOJQJU^JaJ hh}KCJOJQJ^JaJ hh'|9CJOJQJ^JaJ hh(CJOJQJ^JaJ h3hGCJOJQJ^JaJh3CJOJQJ^JaJ hh3CJOJQJ^JaJ hhGCJOJQJ^JaJ&hh}K5>*CJOJQJ^JaJ"!!!!!!" """""""""ҿҮp]L>- hh#48CJOJQJ^JaJh3CJOJQJ^JaJ hh'|9CJOJQJ^JaJ$hh}K0JCJOJQJ^JaJ/jhh}KCJOJQJU^JaJ)jhh}KCJOJQJU^JaJ hh}KCJOJQJ^JaJ hh(CJOJQJ^JaJ$hh(0JCJOJQJ^JaJ)jhh(CJOJQJU^JaJ/jhh(CJOJQJU^JaJ"""""""""########p## $ $ ${$ٖقq`qOq:q)jhh6yPCJOJQJU^JaJ hh+HCJOJQJ^JaJ hh}KCJOJQJ^JaJ hh6yPCJOJQJ^JaJ& *hhG5CJOJQJ^JaJ/j hh#48CJOJQJU^JaJ$hh#480JCJOJQJ^JaJ/j hh#48CJOJQJU^JaJ hh#48CJOJQJ^JaJ)jhh#48CJOJQJU^JaJ{$|$}$$$$$$$$$$$$ҿҮ|k]L5##hA%ht-5CJOJQJ^JaJ,jhA%ht-5CJOJQJU^JaJ hA%hCJOJQJ^JaJh'|9CJOJQJ^JaJ h'|9h'|9CJOJQJ^JaJ#h'|9h'|95CJOJQJ^JaJhuw5CJOJQJ^JaJ hh(CJOJQJ^JaJ hh6yPCJOJQJ^JaJ$hh6yP0JCJOJQJ^JaJ)jhh6yPCJOJQJU^JaJ/j hh6yPCJOJQJU^JaJ $$$$I%J%K%%%%%)&wwwg & F d$Ifgd+ & F d$Ifgd. dkd3 $$IflO0p#U=# tj>644 lapyt-# d$Ifgd. $a$gd'|9 $$$$$$$#%$%%%G%H%I%J%K%L%ϻϩfTC.)jhA%hRCJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ# *hA%h'|9CJOJQJ^JaJ2j hA%h+5CJOJQJU^JaJ#hA%h+5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ#hA%h'|95CJOJQJ^JaJ'hA%h'|90J5CJOJQJ^JaJ,jhA%ht-5CJOJQJU^JaJ2j hA%ht-5CJOJQJU^JaJL%m%n%o%%%%%%%%%%%%¯žx`M<')jhA%he9CJOJQJU^JaJ hA%h@CJOJQJ^JaJ$hA%h@0JCJOJQJ^JaJ/j)hA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ$hA%h'|90JCJOJQJ^JaJ)jhA%hRCJOJQJU^JaJ/j hA%hRCJOJQJU^JaJ hA%hRCJOJQJ^JaJ%%%%%%%%% & & &&&'&(&)&*&P&¯x`M:xx$hA%h+0JCJOJQJ^JaJ$hA%h'|90JCJOJQJ^JaJ/jhA%h+CJOJQJU^JaJ hA%h+CJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ$hA%he90JCJOJQJ^JaJ)jhA%he9CJOJQJU^JaJ/jhA%he9CJOJQJU^JaJ hA%he9CJOJQJ^JaJP&Q&R&i&j&k&l&m&n&&&&&&&&&ҿҮw_L; hA%h+CJOJQJ^JaJ$hA%h'|90JCJOJQJ^JaJ/jhA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%h'|9CJOJQJ^JaJ$hA%h+0JCJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ/jhA%h+CJOJQJU^JaJ)&k&l&m&&&^RBR & F d$Ifgd. d$Ifgd. kd;$$IflO\~p#%U="a tj>644 lap(yt-# & F $Ifgd+&&&&&&&&&''''''' '!'E'F'G'ҿҮw_Lw4/jhA%ht-CJOJQJU^JaJ$hA%h'|90JCJOJQJ^JaJ/jyhA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%h'|9CJOJQJ^JaJ$hA%h+0JCJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ/jihA%h+CJOJQJU^JaJ&&&&''[O?O & F d$Ifgd. d$Ifgd. kd$$IflO\~p#%U="a tj>644 lap(yt-# & F d$Ifgd+''' ']'^'[O?O & F d$Ifgd. d$Ifgd. kd$$IflO\~p#%U="a tj>644 lap(yt-#d$If^gd+G'['\'_'`'c'd'e'{'|'}'''''ǶǶs_M;#hA%hA%5CJOJQJ^JaJ#hA%h'|95CJOJQJ^JaJ'hA%h'|90J5CJOJQJ^JaJ2jZhA%h65CJOJQJU^JaJ#hA%h65CJOJQJ^JaJ,jhA%h65CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%h'|9CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ$hA%h'|90JCJOJQJ^JaJ^'_'`'a'b'c'[OOC d$Ifgd6[ d$Ifgd. kd($$IflO\~p#%U="a tj>644 lap(yt-#d$If^gd. c'd'''ww d$Ifgd. |kd$$IflOF~p#U=" tj>6    44 lapyt-#'''''''''''''.(0(4(׽闅t_N_;_t$hA%he90JCJOJQJ^JaJ hA%he9CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ# *hA%h'|9CJOJQJ^JaJ#hA%h'|95CJOJQJ^JaJ'hA%h'|90J5CJOJQJ^JaJ2jhA%h+5CJOJQJU^JaJ#hA%h+5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ'''2(4(~(o & Fd$Ifgd6[ & Fd$Ifgd. d$Ifgd. dkdD$$Ifl>0p#U=# tj>644 lapyt-#4(6(f(h(j(z(|(~((((((( )")$)&)l)ꝌwfNw;wwf$hA%h'|90JCJOJQJ^JaJ/jhA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%h'|9CJOJQJ^JaJ$hA%h6[0JCJOJQJ^JaJ/jhA%h6[CJOJQJU^JaJ hA%h6[CJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ~((($))) *0*k_OO_?? & Fd$Ifgd.  & Fd$Ifgd. d$Ifgd. kd,$$IflO\~p#%U="a tj>644 lap(yt-#l)n)p)))))))))))**ҿқudLu9&u$hA%hM340JCJOJQJ^JaJ$hA%h'|90JCJOJQJ^JaJ/jhA%h+CJOJQJU^JaJ hA%h+CJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ hA%h@CJOJQJ^JaJ$hA%h@0JCJOJQJ^JaJ$hA%hw0JCJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ/jZhA%ht-CJOJQJU^JaJ* * *$*%*&*.*/*0*1*2*3*W*X*Y*n*o*ɱڞڍ|gV>g+g$hA%h'|90JCJOJQJ^JaJ/jnhA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%hM34CJOJQJ^JaJ$hA%hM340JCJOJQJ^JaJ/jVhA%h+CJOJQJU^JaJ hA%h+CJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ0*1*2*p*q**k_O_? & Fd$Ifgd.  & Fd$Ifgd. d$Ifgd. kd$$IflO\~p#%U="a tj>644 lap(yt-#o*q*r***************ɱڞ|gV>g+g$hA%h.0JCJOJQJ^JaJ/jhA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%h.CJOJQJ^JaJ hA%hW:CJOJQJ^JaJ$hA%hT0JCJOJQJ^JaJ/jhA%hTCJOJQJU^JaJ hA%hTCJOJQJ^JaJ)jhA%hTCJOJQJU^JaJ hA%h'|9CJOJQJ^JaJ***** +k_O_? & Fd$Ifgd} & Fd$Ifgd. d$Ifgd. kdp$$IflO\~p#%U="a tj>644 lap(yt-#***+++ + + + +++1+2+3+D+E+G+H+`+ɱڞxgOx644 lap(yt-#`+a+b+h+i+j+k+l+m+++++++++ҿҮw_L; hA%hTCJOJQJ^JaJ$hA%h.0JCJOJQJ^JaJ/jChA%ht-CJOJQJU^JaJ hA%ht-CJOJQJ^JaJ)jhA%ht-CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%h.CJOJQJ^JaJ$hA%hT0JCJOJQJ^JaJ)jhA%hTCJOJQJU^JaJ/j/hA%hTCJOJQJU^JaJj+k+l++++E,,k_O_??? & Fd$Ifgd} & Fd$Ifgd. d$Ifgd. kd$$IflO\~p#%U="a tj>644 lap(yt-#+++++++ , , ,C,D,E,F,l,m,n,,,,,ҿҮp]E]4 hA%hW:CJOJQJ^JaJ/j hA%h CJOJQJU^JaJ$hA%h 0JCJOJQJ^JaJ/jO hA%h CJOJQJU^JaJ hA%h CJOJQJ^JaJ)jhA%h CJOJQJU^JaJ hA%h.CJOJQJ^JaJ$hA%hT0JCJOJQJ^JaJ)jhA%hTCJOJQJU^JaJ/jhA%hTCJOJQJU^JaJ,,,,,,k_O_?d$If^gdTd$If^gd. d$Ifgd. kd[!$$IflO\~p#%U="a tj>644 lap(yt-#,,,,,,,,,,,---ǵLJu`O7`/j<#hA%h+CJOJQJU^JaJ hA%h+CJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ#hA%h.5CJOJQJ^JaJ'hA%h.0J5CJOJQJ^JaJ2j"hA%h+5CJOJQJU^JaJ#hA%h+5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ hA%hW:CJOJQJ^JaJ hA%h.CJOJQJ^JaJ ,,,.---k_OOC d$Ifgd. & F"d$IfgdHw d$IfgdHwkd"$$IflO\~p#%U="a tj>644 lap(yt-#-,---.-/-U-V-W---------ض،zcQ7c2jP$hA%h+5CJOJQJU^JaJ#hA%h+5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ#hA%h35CJOJQJ^JaJ#hA%hHw5CJOJQJ^JaJ/j#hA%h+CJOJQJU^JaJ hA%h+CJOJQJ^JaJ hA%hHwCJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ$hA%hHw0JCJOJQJ^JaJ-------......./.0.;.<.>.­q`H5`$hA%hHw0JCJOJQJ^JaJ/jJ%hA%h+CJOJQJU^JaJ hA%hHwCJOJQJ^JaJ$hA%hw0JCJOJQJ^JaJ/j$hA%h+CJOJQJU^JaJ hA%h+CJOJQJ^JaJ)jhA%h+CJOJQJU^JaJ#hA%h.5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ'hA%h:k0J5CJOJQJ^JaJ-.>.?.@.A.{.sg d$IfgdCR- d$IfgdHw d$Ifgd. dkd%$$Ifl$0p#U=# tj>644 lapyt-# & Fd$IfgdHw>.?.A.C.D.f.g.h.y.z.{.|.~............ʳsaʳGsa2jH'hA%h+5CJOJQJU^JaJ#hA%h.5CJOJQJ^JaJ'hA%hS0J5CJOJQJ^JaJ2j8&hA%h+5CJOJQJU^JaJ#hA%h+5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ#hA%h35CJOJQJ^JaJ hA%h.CJOJQJ^JaJ# *hA%h.CJOJQJ^JaJ{.|.}.~..wg[ d$Ifgd}d$If^gd. d$Ifgd. |kd&$$IflOF~p#U=" tj>6    44 lapyt-#.. /C/wk d$Ifgd. d$IfgdA%|kd'$$IflOF~p#U=" tj>6    44 lapyt-#... / / ///0/1/2/A/B/C/D/F/ϻϩυkϻZH7 hhSCJOJQJ^JaJ# *hhSCJOJQJ^JaJ hA%hSCJOJQJ^JaJ2j(hA%h+5CJOJQJU^JaJ#hA%h+5CJOJQJ^JaJ#hA%h35CJOJQJ^JaJ#hA%hS5CJOJQJ^JaJ'hA%hS0J5CJOJQJ^JaJ,jhA%h+5CJOJQJU^JaJ2jr(hA%h+5CJOJQJU^JaJC/D/E/F/G/H/ssd$If^gdCR- d$Ifgd. d$Ifgd. dkdZ)$$IflF0p#U=# tj>644 lapyt-#F/G/H/I/R/S/s/t/u//////////////00нvovhvaSHh5OJQJaJh^}h5OJQJaJ hChM hCh" hChM[&hM5CJOJQJ\aJ hM5CJOJQJ\^JaJ&ha>hM5CJOJQJ\^JaJ%ha>h=(.5CJOJQJ\aJh%ha>hM5CJOJQJ\aJh hhSCJOJQJ^JaJ hhCJOJQJ^JaJhSCJOJQJ^JaJH/I/S/\/u//i]]L$ = P $Ifa$gdyA $$Ifa$gdyA$  ~= z9!v%$Ifa$gd=|kd)$$Ifl_F~p#U=" tj>6    44 lapyt-#///0$  ~= z9!v%$Ifa$gdyAkd\*$$Ifl44\,0,=@ `(0j>64 lap(yt-#/////////0g[ $$Ifa$gdrkd /$$Ifl=h>  0j>64 lap yt-# $IfgdO;Ff, $$Ifa$gda> $$Ifa$gdyA 00i0j000000111111111V2W222=3>3 $Ifgd=(. $IfgdgOB $Ifgd^& $$Ifa$gdg $$Ifa$gd- $$Ifa$gd $IfgdP>00 0b0c0d0g0h0i0j0k000000000ՏjYMA1jhOCJOJQJUaJh5CJOJQJaJhCJOJQJaJ hHth0JCJOJQJaJ+j0hHthCJOJQJUaJhHthCJOJQJaJ%jhHthCJOJQJUaJh^}hCJOJQJaJ h h 0JCJOJQJaJ%j/h CJOJQJUaJh CJOJQJaJjh CJOJQJUaJh^}h 5OJQJaJ00000000#1$1%1.1/111211111111ѱwkUwIAhCJaJhCJOJQJaJ+js3hHth&yCJOJQJUaJh&yCJOJQJaJ hHth0JCJOJQJaJ+j2hHthCJOJQJUaJ%jhHthCJOJQJUaJhHthCJOJQJaJ hOh50JCJOJQJaJjhOCJOJQJUaJ%j1hOCJOJQJUaJhOCJOJQJaJ111111T2V2W2[2d2e2f22222222222223=3>3H3f3j3̹yjj\h CJOJQJ^JaJhC5CJOJQJ^JaJh5CJOJQJ^JaJ#hh5CJOJQJ^JaJ hhCJOJQJ^JaJhCCJOJQJ^JaJ$hh@CJOJQJ^JaJ'hh5@CJOJQJ^JaJ!hC5@CJOJQJ^JaJh^}hwj5OJQJaJj333333333444444 5 55D5E5F5h5k5l5Ͻެޛެލލn`RA hhCCJOJQJ^JaJhCJOJQJ^JaJhe7CJOJQJ^JaJ hP>hqCJOJQJ^JaJhCJOJQJ^JaJhCCJOJQJ^JaJ hh5CJOJQJ^JaJ hhCJOJQJ^JaJ#hh5CJOJQJ^JaJhC5CJOJQJ^JaJ hhCJOJQJ^JaJ h h CJOJQJ^JaJ>3334444 55E5F5h5i5j5k5l5x55 $$Ifa$gdg $$Ifa$gd $Ifgdq $IfgdO $Ifgd=(.l5x5555555555555555˸ocTM>*& *hlh7CJOJQJ^JaJh^&hCJOJQJaJ hChhghCJOJQJaJhgCJOJQJaJ hhg0JCJOJQJaJ+j4hhgCJOJQJUaJhhgCJOJQJaJ%jhhgCJOJQJUaJ%hhgB*CJOJQJaJphhcOCJOJQJaJ%hhB*CJOJQJaJph)hhB*CJOJQJ^JaJph5555516OC:11 $Ifgd= $Ifgd=(. $$Ifa$gd-kdi5$$Ifl4F,0=`! 0j>6    4 lapyt-#556/6162636I6J6P6a6b66666666оm\N=N=/hCJOJQJ^JaJ hhCJOJQJ^JaJhP>CJOJQJ^JaJ hh5CJOJQJ^JaJ)hhTxB*CJOJQJ^JaJph#hB*CJOJQJ^JaJph)hhB*CJOJQJ^JaJph)h"@hB*CJOJQJ^JaJph#hB*CJOJQJ^JaJph h ]/hCJOJQJ^JaJhuwCJOJQJ^JaJ hhCJOJQJ^JaJ1626}66666&7[7i77777.8<8s8t888 $IfgdR $Ifgd ]/ $Ifgd=6666666666 777/7E7Y7î؝wbM<+< hhCJOJQJ^JaJ hhCJOJQJ^JaJ)hhTxB*CJOJQJ^JaJph)hhB*CJOJQJ^JaJph3f)hhXB*CJOJQJ^JaJph hhXCJOJQJ^JaJ hhRCJOJQJ^JaJ)hh6B*CJOJQJ^JaJph)hhI@zB*CJOJQJ^JaJph)hhB*CJOJQJ^JaJph#h_?)h5CJOJQJ^JaJY7[7i7777777777788-8ɴxfQ@/ hq]hCJOJQJ^JaJ hq]hJTCJOJQJ^JaJ)hq]hRB*CJOJQJ^JaJph#hY.<B*CJOJQJ^JaJph#hq]h5CJOJQJ^JaJ)hY.<hB*CJOJQJ^JaJph)hY.<hXB*CJOJQJ^JaJph)hq]hB*CJOJQJ^JaJph hq]hRCJOJQJ^JaJ)hq]hRB*CJOJQJ^JaJph hhCJOJQJ^JaJ-8.8<8d8r8s8t888888888Ƕ{fUC<.hq]h?5OJQJaJ hCh#h_?)h5CJOJQJ^JaJ h_?)hCJOJQJ^JaJ)hq]hTxB*CJOJQJ^JaJph)hq]h5B*CJOJQJ^JaJph3f)hq]h5B*CJOJQJ^JaJph hq]hCJOJQJ^JaJ hq]h5CJOJQJ^JaJ hq]hRCJOJQJ^JaJ)hq]hRB*CJOJQJ^JaJph#h_?)hR5CJOJQJ^JaJ88kdn6$$Ifl4Gֈ,0$,Z5= 0j>64 lap<yt-#8881929::8:9:::;:gwkd8$$Ifl40,0`0j>6!4 laytC $Ifgd^& $$Ifa$gd $$Ifa$gd 8888999/9091929C999:ĮӝӋzfSC0$hP>h?@CJOJQJ^JaJh?@CJOJQJ^JaJ$hq]h?@CJOJQJ^JaJ'hq]h?5@CJOJQJ^JaJ!hC5@CJOJQJ^JaJ" *hq]h?5CJOJQJaJ hq]h?0JCJOJQJaJ+j7hq]h?CJOJQJUaJhq]h?CJOJQJaJ%jhq]h?CJOJQJUaJh^}h?5OJQJaJh?5OJQJaJ:::#:$:7:8:9:::;:@:A:H:_:g:ɮr]H3H)hq]h&yB*CJOJQJ^JaJph)hq]h&yB*CJOJQJ^JaJph)hq]hHB*CJOJQJ^JaJph#hHB*CJOJQJ^JaJph* *h~{h&y5@CJOJQJ^JaJh h&yOJQJaJ hCh?'h3h?5@CJOJQJ^JaJ hq]h?'hq]h?5@CJOJQJ^JaJ!hC5@CJOJQJ^JaJ!h?5@CJOJQJ^JaJ;:H::::::;;W; $Ifgd3 $Ifgd/ $Ifgd $Ifgd= g:}:~::::::::::::::::Ͻ{i{T?-#h7~NB*CJOJQJ^JaJph)hq]h&yB*CJOJQJ^JaJph)h_?)h&yB*CJOJQJ^JaJph3f#hq]B*CJOJQJ^JaJph3f)hq]h&yB*CJOJQJ^JaJph3f)hq]h&yB*CJOJQJ^JaJph/hq]hHhHB*CJOJQJ^JaJph#hHB*CJOJQJ^JaJph h h&yCJOJQJ^JaJh&y5CJOJQJ^JaJ hq]h&yCJOJQJ^JaJ:;;;;;;";7;K;V;W;X;b;c;;Ȱxg`UC5hq0JCJOJQJaJ#jhq0JCJOJQJUaJhq5OJQJaJ hCh&y h3h&yCJOJQJ^JaJhCJOJQJ^JaJ)hq]h&yB*CJOJQJ^JaJph3f)hq]h&yB*CJOJQJ^JaJph/hq]hHhHB*CJOJQJ^JaJph#hHB*CJOJQJ^JaJph)h_?)h&yB*CJOJQJ^JaJph hq]h&yCJOJQJ^JaJW;X;b;;<<00' $Ifgd $$Ifa$gdkdj9$$Ifl4ֈ,0$,Z5= 0j>64 layt-#;;;;;;;;[<\<]<s<t<<<<ز{dO:3 hChq)hhqB*CJOJQJ^JaJph(hP>hq0J@CJOJQJ^JaJ-j;hq@CJOJQJU^JaJhq@CJOJQJ^JaJ'jhq@CJOJQJU^JaJ$hP>hq@CJOJQJ^JaJ(hhq>*B*CJOJQJaJph hP>hq0JCJOJQJaJ#jhq0JCJOJQJUaJ)jF:hq0JCJOJQJUaJ<<<<<<====oooooocW $$Ifa$gd? $$Ifa$gd|N$  ~= z9!v%$Ifa$gdgOBukd<$$IflH0,=80j>64 layt <<<<<<<<<<<<=======n=o=p=˺˒˺˺y˒˺fWAf+j3?hq]hCJOJQJUaJhq]hCJOJQJaJ%jhq]hCJOJQJUaJ0jh>hq]hB*CJOJQJUphhq]h0JCJOJQJ0j=hq]hB*CJOJQJUph!hq]hB*CJOJQJph*jhq]hB*CJOJQJUphh(5B*OJQJph hHth5B*OJQJphp=====!>4>G>W>a>d>m>v>>??Z????? @g@˷}mYF$hqhq@CJOJQJ^JaJ'hq]h7@CJOJQJ^JaJhj5@CJOJQJ^JaJ$hq]h2@CJOJQJ^JaJ'hq]h25@CJOJQJ^JaJ$hq]h@CJOJQJ^JaJ'hq]h5@CJOJQJ^JaJ hHth5B*OJQJph%jhq]hCJOJQJUaJ hq]h0JCJOJQJaJ=">>A??AAAABBZCC $$Ifa$gd $Ifgd? $If^gdP> & F$Ifgdm & F$Ifgd_! $Ifgd_! $Ifgdm g@@@@@@B"B#BxByBzBBBBBܲܞw^H7!h@CJOJQJ]^JaJ+h?h?0J@CJOJQJ]^JaJ0jJ@h?@CJOJQJU]^JaJ!h?@CJOJQJ]^JaJ*jh?@CJOJQJU]^JaJ'hs]h@CJOJQJ]^JaJ*hs]h@CJH*OJQJ]^JaJ'hs]hi@CJOJQJ]^JaJ'hs]h@CJOJQJ]^JaJhq@CJOJQJ^JaJBBBB#C$C%C3C4CXCYCZCfCpCtCıĄo[I;&)hq]h+B*CJOJQJ^JaJphhcOCJOJQJ^JaJ#hq]B*CJOJQJ^JaJph'h3hr*@CJOJQJ]^JaJ)h?0JCJOJQJ^JaJhnH tH $h?h?@CJOJQJ^JaJ3jcAh?hl@CJOJQJU^JaJ$h?hl@CJOJQJ^JaJ-jh?hl@CJOJQJU^JaJ$h?hr*@CJOJQJ^JaJ!hr*@CJOJQJ]^JaJtCuCCCCCCCCCCCCCCDѴ挅u`QBQB/%h2hB*CJOJQJaJphh2hCJOJQJaJh2hoCJOJQJaJ)h_?)hB*CJOJQJ^JaJphhHthCJOJQJaJh hCh)hRhB*CJOJQJ^JaJph$hq]h+0JCJOJQJ^JaJ8jBhq]h+B*CJOJQJU^JaJph)hq]h+B*CJOJQJ^JaJph2jhq]h+B*CJOJQJU^JaJphCCCCO5, $Ifgdm$  ~= z9!v%$Ifa$gdgOBkdC$$Ifl4F,0=`! 0j>6    4 lapyt-#DD$D%D'D/DWDwDxDyDDDDDDDDDDۿrbSGS8h&hCJOJQJaJh2CJOJQJaJh2hCJOJQJaJh2h5CJOJQJaJh2h)CJOJQJaJ%h2hB*CJOJQJaJphh B*CJOJQJaJphh CJOJQJaJh h CJOJQJaJhj5CJOJQJaJh2hCJH*OJQJaJh2hCJOJQJaJ)h2hB*CJOJQJ^JaJphC%D&D'DDDDESEVEEEEE-FOFFFGMG $Ifgdo $Ifgd7s $Ifgd-# $$Ifa$gdKG $Ifgdj $Ifgd2 $Ifgdo $Ifgd/ DEEE#E?EKERESEVEeEmEEEEEEDzyDzj\K: hs]h"CJOJQJ^JaJ hs]hoCJOJQJ^JaJhCJOJQJ^JaJh2hCJOJQJaJ,h2h6B* CJOJQJ^JaJphP h2hCJOJQJ^JaJ h2hCJOJQJ^JaJ)h2hB*CJOJQJ^JaJph)h2hB* CJOJQJ^JaJphP)h_?)hB*CJOJQJ^JaJph3fh2hoCJOJQJaJEEEEEEEEFFFF*F,F-FNF˹˨xj\xK<h2h"CJOJQJaJ h"hoCJOJQJ^JaJh-#CJOJQJ^JaJhCJOJQJ^JaJ hs]hpCJOJQJ^JaJh}jCJOJQJ^JaJ hs]hoCJOJQJ^JaJ hs]h"CJOJQJ^JaJ#hs]hs]CJH*OJQJ^JaJ hs]hs]CJOJQJ^JaJ hs]h)CJOJQJ^JaJ#hs]hoCJH*OJQJ^JaJNFOFPFfFgFhFnFoF~FFFFFòveVD3 hs]hR)CJOJQJ^JaJ#h7shR)CJH*OJQJ^JaJh5CJOJQJ^JaJ hs]hCJOJQJ^JaJ#hB*CJOJQJ^JaJph)hs]hB*CJOJQJ^JaJph)hTxhB*CJOJQJ^JaJph h7shCJOJQJ^JaJ)h7shB*CJOJQJ^JaJph#h2B*CJOJQJ^JaJph)h"hB*CJOJQJ^JaJph3f FFFFFFFFFFFFFGGG1G2GKGLGܽܯ|n`|QAQ4ho5CJOJQJaJhs]ho5CJOJQJaJhs]hoCJOJQJaJhn)CJOJQJ^JaJh-#CJOJQJ^JaJ hs]hs]CJOJQJ^JaJ hs]hpCJOJQJ^JaJ hs]hTCJOJQJ^JaJh}jCJOJQJ^JaJhGCJOJQJ^JaJ hs]h)CJOJQJ^JaJ hs]hR)CJOJQJ^JaJ#hs]hR)CJH*OJQJ^JaJLGMGNGoG|GGGGGGGGGGGGҽn]L;-;hGCJOJQJ^JaJ hs]h"CJOJQJ^JaJ hs]h2CJOJQJ^JaJ hs]h)CJOJQJ^JaJ#hs]hCJH*OJQJ^JaJ,hs]h5B*CJOJQJ^JaJph hs]hCJOJQJ^JaJ)hs]hB*CJOJQJ^JaJph)hs]hB*CJOJQJ^JaJph3fhs]h"CJOJQJaJ h_?)hCJOJQJ^JaJhoCJOJQJ^JaJMGNGpGGG#HlHmH $Ifgd" $Ifgd^& $Ifgdj $Ifgd/_GGH H"H#HOHPHiHjHkHlHmHnHHHHŴ|n\UE8Eh^m5OJQJaJhhHth^m5OJQJaJh hCh#h_?)ho>*CJOJQJ^JaJh"CJOJQJ^JaJh"5CJOJQJaJhs]CJOJQJaJhs]h"5CJOJQJaJhs]h"CJOJQJaJ h"hCJOJQJ^JaJ hs]hs]CJOJQJ^JaJh-#CJOJQJ^JaJhCJOJQJ^JaJh}jCJOJQJ^JaJmHnHH<"$  ~= z9!v%$Ifa$gdCkdD$$Ifl4ֈ,0$,Z5= 0j>64 layt-#HHHHHIIWIXIII)JTJUJWKKK(L)L $Ifgd" $IfgdY $Ifgd= $$Ifa$gdC $$Ifa$gdP& $$Ifa$gd$  ~= z9!v%$Ifa$gdHHHHHHHHHHHHHIIIIIIIUIVIXIYIIIIIIIIJJJӱ|kXI3X+jIhs]h^mCJOJQJUaJhs]h^mCJOJQJaJ%jhs]h^mCJOJQJUaJ hHth^m0JCJOJQJaJ+jGhHth^mCJOJQJUaJh^mCJOJQJaJ%jhHth^mCJOJQJUaJhHth^mCJOJQJaJh#hHth^m0JCJOJQJaJh(jhHth^mCJOJQJUaJh.jGhHth^mCJOJQJUaJhJ&J'J(J)J@JSJTJUJJJJJWKKu^uM<*#h=hr*5CJOJQJ^JaJ h3h^mCJOJQJ^JaJ h3h_CJOJQJ^JaJ,h1h_5B*CJOJQJ^JaJph,h1hq5B*CJOJQJ^JaJph h_?)h^mCJOJQJ^JaJ#h_?)h^m5CJOJQJ^JaJ#hezh^m5CJOJQJ^JaJhChCJOJQJaJh^mCJOJQJaJ%jhs]h^mCJOJQJUaJ hs]h^m0JCJOJQJaJKKKKKKL'L)L,LBLaLbLcLoLyLLLLL}o}^WGhHth(CJOJQJaJh hCh^m hq0yh^mCJOJQJ^JaJh^mCJOJQJ^JaJ h3h^mCJOJQJ^JaJ#hezh$5CJOJQJ^JaJhq5CJOJQJ^JaJ#hqhq5CJOJQJ^JaJhqCJOJQJ^JaJ#h=hr*5CJOJQJ^JaJhr*CJOJQJ^JaJ h=hr*CJOJQJ^JaJ)L*L+L,LcLLL6kdI$$Ifl4!F,0=`! 0j>6    4 lapyt-#$$If^a$gd$ $IfgdP>LLLLLLLL?MbMcMMMMMMMM $$1$Ifa$gd3 $1$Ifgd3 $Ifgd_ $Ifgdq6 $IfgdLF $Ifgd_ & F=$If^=gd3$  ~= z9!v%$Ifa$gdLLLLLLLLLLLLLLM̦̽p^I7I#hHB*CJOJQJ^JaJph)h1thr*B*CJOJQJ^JaJph#hr*B*CJOJQJ^JaJph#h(B*CJOJQJ^JaJph)hs]h(B*CJOJQJ^JaJphhs]hB*CJaJphh(B*CJaJphhs]h(CJaJhs]h(B*CJaJphhs]h(B*CJaJphhs]h(B*CJaJph)hLFh(B*CJOJQJ^JaJphMM)M>M?MNMUMVMWMbMcMMMM;teP>*&h37h(57CJOJQJ^JaJ"hq6CJOJQJ^JaJmHsH(hs]h(CJOJQJ^JaJmHsHh>*CJOJQJ^JaJ hs]h(CJOJQJ^JaJhs]h(CJOJQJaJ)hs]h(B*CJOJQJ^JaJph)hs]h(B*CJOJQJ^JaJph3fhq6h(CJOJQJaJh2hr*CJOJQJaJ%h2hr*B*CJOJQJaJphhr*B*CJOJQJaJph MMMMMMMMMMMMMƵtfU@+)hs]h(B*CJOJQJ^JaJph)hs]h(B*CJOJQJ^JaJph3f hq6h1tCJOJQJ^JaJh1tCJOJQJ^JaJh(CJOJQJ^JaJ hq6hq6CJOJQJ^JaJ hq657CJOJQJ^JaJ hah(CJOJQJ^JaJ h3h(CJOJQJ^JaJh3h(CJOJQJaJ)h3h(B*CJOJQJ^JaJph)h3h(B*CJOJQJ^JaJph MMMMMMMMMMMMNNNNNNNNNNN N!N"N#N $Ifgd1t $1$Ifgd1t $Ifgdq6MNNNNN$N%N&N;NANBNuNvNwNzN{N|NͿͪueMu;ue#hHth^m0JCJOJQJaJh.jKhHth^mCJOJQJUaJhhHth^mCJOJQJaJh(jhHth^mCJOJQJUaJhhHth^m5OJQJaJhhh^m5OJQJaJh hCh(h(CJOJQJ^JaJh1tCJOJQJ^JaJ h1th1tCJOJQJ^JaJ h1t57CJOJQJ^JaJ hs]h(CJOJQJ^JaJ#N$N%N&N3kdK$$Ifl46ֈ,0$,Z5= 0j>64 layt-# $Ifgd1t&N@NAN|NjOkOOVP$$If^a$gd $IfgdR$@$  ~= z9!v%$Ifa$gdHt$  ~= z9!v%$Ifa$gd  ~= z9!v%$IfgdC|N!O7OhOkOOOOOPUPVPWPXPYPPPQQQQͽﬡq_J9 hq6h^mCJOJQJ^JaJ)h@h^mB*CJOJQJ^JaJph#h3h^m5CJOJQJ^JaJh3h^mB*CJaJph hh^mCJOJQJ^JaJhh^m5OJQJaJhh$Nh^mmHsH hq0yh^mCJOJQJ^JaJ *h%h^m0J OJQJ^Jh^mCJOJQJ^JaJ&hP>h^m6CJOJQJ]^JaJ h3h^mCJOJQJ^JaJVPWPXPYPO5, $IfgdR$@$  ~= z9!v%$Ifa$gdkdL$$Ifl4F,0=`! 0j>6    4 lapyt-#YPgPP!QrQQQQQGkdM$$Ifl4\,0,= @0j>64 layt-# $IfgdY $Ifgdq0y $Ifgdq0yQQQQQQQQQQRRRRR&R'R9R:RXRYReR{R|R}RRʿxqxqbSxqEha}h5OJQJaJh=5CJOJQJ\aJh5CJOJQJ\aJ hCh8Qh8Q5CJOJQJ\aJ h8Q5CJOJQJ\^JaJ&ha>h8Q5CJOJQJ\^JaJ%ha>h8Q5CJOJQJ\aJhhwu$hmHsHh4-mHsHh4-CJaJmHsHh$Nh^mmHsH+h^mB*CJOJQJ^JaJmHphsHQQQQQQR$ = P $Ifa$gdyA $$Ifa$gdyA$  ~= z9!v%$Ifa$gdyAgd4- ;6gd*RRR2$  ~= z9!v%$Ifa$gdyAkdN$$Ifl44}\rl+x<z, `(0=4 lap(RR'R:RERXRYR|R}RRu[$  ~= z9!v%$Ifa$gd MpkdS$$Ifl}rx<=  0=4 lap $Ifgd8QFfQ $$Ifa$gdyA RRbScSS>TTULUU V VVV!W&X $IfgdK(9 $Ifgd&v $Ifgd \ $IfgdM $IfgdC[ $$Ifa$gd M$  ~= z9!v%$Ifa$gd M  ~= z9!v%$IfgdfRRR[S\S]S`SaScSdSSSSSSSSS>T@TdTfTҼޫޜyhZI7I7I7#h3h5CJOJQJ^JaJ h3hCJOJQJ^JaJha}h5OJQJaJ hOh0JCJOJQJaJ%jlUhOCJOJQJUaJjhOCJOJQJUaJhHthCJOJQJaJ hHth0JCJOJQJaJ+jShHthOCJOJQJUaJhOCJOJQJaJ%jhHthCJOJQJUaJhHth5OJQJaJfTTTTTUULU`UUU VV W!W}W~WWWWWWWW X"X$X&X(X`XϾwfWh(5CJOJQJ^JaJ h_?)hCJOJQJ^JaJhCJH*OJQJ^JaJ)hhhB*CJOJQJ^JaJph#hhh5CJOJQJ^JaJ hhhCJOJQJ^JaJ hK(9hCJOJQJ^JaJhCJOJQJ^JaJ#h3h5CJOJQJ^JaJ h3hCJOJQJ^JaJ&X(XbXdXfXXXJkdCV$$Ifl4\rl+x<z,0=4 la $$1$Ifa$gd $$Ifa$gd`XbXdXfXXXXXXXXXVYnYzY|YϽs`K`8)8hhCJOJQJaJ%hhB*CJOJQJaJph(hh5B*CJOJQJaJph%hhB*CJOJQJaJphhC[B*CJOJQJaJph hjhCJOJQJ^JaJha? hCJOJQJaJh hCh#hh5CJOJQJ^JaJ#h_?)h5CJOJQJ^JaJh(5CJOJQJ^JaJ#hh(5CJOJQJ^JaJh5CJOJQJ^JaJXXXXXVYYZZiZjZwZ%[&['[B[[[[[ $Ifgd[b $Ifgd $Ifgd $IfgdI(- $IfgdI(- $IfgdK(9$  ~= z9!v%$Ifa$gd M|YYYYYZZZZ Z%Z&Z-ZbZcZlZwZZZZZZZ"[$[%[񼫖񫈫saRA h[bhCJOJQJ^JaJh7CJOJQJ^JaJ#hh7CJOJQJ^JaJ)hhB*CJOJQJ^JaJphhCJOJQJ^JaJ)hhB*CJOJQJ^JaJph3f hhCJOJQJ^JaJ#hh5CJOJQJ^JaJ%hhB*CJOJQJaJph3fhh5CJOJQJaJhhCJOJQJaJ%['[*[5[B[P[V[f[g[k[[[[[[[[[[[[[[\\\\\\\]ẫẫẫϺzhV#h~B*CJOJQJ^JaJph3f#h(B*CJOJQJ^JaJph3fhCJOJQJ^JaJ&hh5CJOJQJ\^JaJh7CJOJQJ^JaJhhCJOJQJaJ)hhB*CJOJQJ^JaJph3f#hh5CJOJQJ^JaJ hhCJOJQJ^JaJhC[CJOJQJ^JaJ[[[\\\\\]]]]]]9]]]]]]]] $Ifgd[b $$Ifa$gdkI $Ifgd[b $Ifgd[b $Ifgd" $Ifgdf]]]]]]]"]8]9]N]P]]]]]]]˹r`rRrAr hhCJOJQJ^JaJhn)CJOJQJ^JaJ#h"h7CJOJQJ^JaJ h"hCJOJQJ^JaJh"hCJOJQJaJ)h"hB*CJOJQJ^JaJph#h"h5CJOJQJ^JaJ#h_?)h5CJOJQJ^JaJ h_?)hCJOJQJ^JaJhC[CJOJQJ^JaJ)h[bh~B*CJOJQJ^JaJph3f]]]]]]]] ^!^"^#^<^=^h^i^j^ɸvoaSI8S!jWh>eCJOJQJUh>eCJOJQJjh>eCJOJQJUhHthov5CJOJQJ hCh h_?)hCJOJQJ^JaJ hhCJOJQJ^JaJhn)CJOJQJ^JaJ#h"h"7CJOJQJ^JaJ h"hCJOJQJ^JaJh"hCJOJQJaJ#h"B*CJOJQJ^JaJph3f)h"hB*CJOJQJ^JaJph3f]!^"^#^)kdV$$Ifl4ֈrl#+4x<z ppp0=4 la $$Ifa$gdkI $Ifgdov#^;^<^t^v^^^_ __`:`e`Va bb $$Ifa$gdC[ $IfgdT $Ifgd8 $IfgdyA $IfgdOm $$Ifa$gdC[ $Ifgdf $$Ifa$gd Mj^m^s^t^u^v^w^^^^^^^^^^^^___ _ _\_paʄNBhovCJOJQJaJ%jhHthovCJOJQJUaJhHthov0JCJOJQJ'jqYhHthovCJOJQJUhHthovCJOJQJ!jhHthovCJOJQJUhHthlCJOJQJ!jXh>eCJOJQJUh>eCJOJQJhovCJOJQJjh>eCJOJQJUh>eh>e0JCJOJQJh>ehov0JCJOJQJ\_]_^_____``U`[`e`````ֶ{j\jK9K( h&h37CJOJQJ^JaJ#hP>h&5CJOJQJ^JaJ h&h&CJOJQJ^JaJhcOCJOJQJ^JaJ hHthovCJOJQJ^JaJ$hHthov@CJOJQJ^JaJ'h"hov5@CJOJQJ^JaJ'hHthov5@CJOJQJ^JaJhwjhovCJOJQJaJ hHthov0JCJOJQJaJ%jhHthovCJOJQJUaJ+jFZhHthovCJOJQJUaJ`2a4aDaGaUaVaaaaabb b-b1b2bPbVbϾt]tF/,h"h9"5B*CJOJQJ^JaJph,h"hov5B*CJOJQJ^JaJph,h"h(5B*CJOJQJ^JaJph,h"h"5B*CJOJQJ^JaJph hC[h"CJOJQJ^JaJ hnPhovCJOJQJ^JaJ h"h"CJOJQJ^JaJ h"hovCJOJQJ^JaJh&CJOJQJ^JaJ#hP>h&5CJOJQJ^JaJ h&h&CJOJQJ^JaJVbWbbbbbbbbbbbbbb짠}hVA0 h"h $CJOJQJ^JaJ)h"h $B*CJOJQJ^JaJph3f#hovB*CJOJQJ^JaJph)h1hovB*CJOJQJ^JaJph#h/_hov7CJOJQJ^JaJ hHthovCJOJQJ^JaJ hChovhC[hC[CJOJQJaJ h"h9"0JCJOJQJaJ+j][h"h9"CJOJQJUaJh"h9"CJOJQJaJ%jh"h9"CJOJQJUaJbbbbbcQH?6- $Ifgd $ $Ifgdf $IfgdT $Ifgdfkd0\$$Ifl4Frlx<z` ! 0=    4 lapbbbccc!c"c-c3cIcKcLcZcecrdO:%)h"h B*CJOJQJ^JaJph3f)h"hovB*CJOJQJ^JaJph)h_?)hovB*CJOJQJ^JaJphhovCJOJQJ^JaJ h"hovCJOJQJ^JaJ%h"hovB*CJOJQJaJph)h"hovB*CJOJQJ^JaJph)h1h $B*CJOJQJ^JaJph#h $B*CJOJQJ^JaJph h"h $CJOJQJ^JaJh"h $CJOJQJaJh $CJOJQJ^JaJcc"cJcKcLcZcccddEdSdd $Ifgdjq $Ifgdf $Ifgdeh $Ifgd $Ifgdeh $Ifgd $ $Ifgdf ecfccccccccccddd(d.d᫖wfQ<-h"hovCJOJQJaJ)h"hovB*CJOJQJ^JaJph)h"hovB*CJOJQJ^JaJph h"hHCJOJQJ^JaJh<CJOJQJ^JaJ h<hHCJOJQJ^JaJ)h<hHB*CJOJQJ^JaJph3f)h<h<B*CJOJQJ^JaJph3f#h h 5CJOJQJ^JaJh"h CJOJQJaJh CJOJQJ^JaJ h"h CJOJQJ^JaJ.dEdSd_dedddddddddddddŶﯟqbLq;qb hHh]0JCJOJQJaJ+j.^hHh]CJOJQJUaJhHh]CJOJQJaJ%jhHh]CJOJQJUaJh]5CJOJQJhh#W5CJOJQJaJhh>e5CJOJQJaJ hChovh"hovCJOJQJaJ)h"hovB*CJOJQJ^JaJph3f)h"hovB*CJOJQJ^JaJph h"hovCJOJQJ^JaJddkd']$$Ifl4ֈrl#+4x<z ppp0=4 lap<ddddd]eeeofffgh hhhhh $IfgdQ $$Ifa$gdI15 $Ifgd& $Ifgd] $Ifgd@m $Ifgd; $$Ifa$gd M $Ifgdf $$Ifa$gddddOePeQeZe[e\e]e^eeeeeenfofxff޷ޭooaP? h"h#WCJOJQJ^JaJ hhh#WCJOJQJ^JaJhCJOJQJ^JaJ#h_?)h#W5CJOJQJ^JaJ h_?)h#WCJOJQJ^JaJhgtCJOJQJ^JaJh]hB8$CJOJQJhB8$CJOJQJ hHhB8$0JCJOJQJaJ+j_hHhB8$CJOJQJUaJ%jhHhB8$CJOJQJUaJhHhB8$CJOJQJaJffffffggg#gHghggggghh hh̻}kZI8 hhh#WCJOJQJ^JaJ hhh/_CJOJQJ^JaJ hhh]CJOJQJ^JaJ#h&h&CJH*OJQJ^JaJ h&h]CJOJQJ^JaJh]CJOJQJ^JaJ h]h]CJOJQJ^JaJh#WCJOJQJ^JaJ h Nh#WCJOJQJ^JaJ#h"h NCJH*OJQJ^JaJ h"h/_CJOJQJ^JaJ h"hK(9CJOJQJ^JaJhhhhhhhhi"i-i=iiiiiϾzeSB1 hP>hmJCJOJQJ^JaJ hDh#WCJOJQJ^JaJ#h_?)h#W5CJOJQJ^JaJ)h_?)h#WB* CJOJQJ^JaJphPhiJCJOJQJ^JaJ h_?)h#WCJOJQJ^JaJ&h_?)h#W5>*CJOJQJ^JaJ h#W5>*CJOJQJ^JaJ hdh#CJOJQJ^JaJ hhh#WCJOJQJ^JaJh&CJH*OJQJ^JaJ h]h#WCJOJQJ^JaJiijjjujvjwjjjjjjkkk6kAkBkkӬweVD5D5Dh#5CJOJQJ^JaJ#h"h5CJOJQJ^JaJh5CJOJQJ^JaJ#hzh#W5CJOJQJ^JaJ h_?)h#WCJOJQJ^JaJ htMhmJCJOJQJ^JaJ$hlhl0JCJOJQJ^JaJ)j,`hlCJOJQJU^JaJ#jhlCJOJQJU^JaJhlCJOJQJ^JaJ hP>hmJCJOJQJ^JaJhCJOJQJ^JaJhjllnnnMD $IfgdfkdZc$$Ifl4[ Frlx<z !0=    4 la $Ifgdgt $Ifgd8| $$Ifa$gdd $$Ifa$gdzkkll l!l,l-l\l]lwlxlllllmmmmnnnױ}eRA: hCh#W h_?)hgtCJOJQJ^JaJ$hHth#W0JCJOJQJ^JaJ/j[ahHthmJCJOJQJU^JaJhmJCJOJQJ^JaJ)jhHth#WCJOJQJU^JaJ hHth#WCJOJQJ^JaJ#hdh#W5CJOJQJ^JaJ'h"h0J5CJOJQJ^JaJ#h"h5CJOJQJ^JaJ,jh"h5CJOJQJU^JaJnnnnnn%n&nJnLnSnVn[nhninjnvnwn|n;n_n_nJ8#h}jB*CJOJQJ^JaJph)h"h#WB*CJOJQJ^JaJphh`5CJOJQJ^JaJ#h"h#W5CJOJQJ^JaJhmJCJOJQJ^JaJh&CJOJQJ^JaJ h"h#WCJOJQJ^JaJ h"h7CJOJQJ^JaJh"h7CJOJQJaJ)h"h#WB*CJOJQJ^JaJph3f h_?)h#WCJOJQJ^JaJh_?)h#WCJOJQJnnKnLnMnNnOnPnnnoonotoooooopp $IfgdGqD $Ifgd#W $$Ifa$gdGqD $$Ifa$gd#W $Ifgdq6 $$Ifa$gd` $Ifgd#W $Ifgd@m|n~nnnnnnnnnnnnnnnnnnnoooį㠏seQ㠏Ch%x+CJOJQJ^JaJ&h"h#W5CJOJQJ\^JaJhq6CJOJQJ^JaJhmJCJOJQJ^JaJh&CJOJQJ^JaJ h"h7CJOJQJ^JaJh"h7CJOJQJaJ)h"h#WB*CJOJQJ^JaJph3f h#W5>*CJOJQJ^JaJh`CJOJQJ^JaJ h"h#WCJOJQJ^JaJh}jCJOJQJaJonooosotooooooooooooopp.p/p0p1p2p͸ydVOD@h~Oh*hACJaJ hCh#WhGqDCJOJQJ^JaJ)h"h#WB*CJOJQJ^JaJph3fh%x+CJOJQJ^JaJ h"h7CJOJQJ^JaJh"h7CJOJQJaJ h"h#WCJOJQJ^JaJ)h"h#WB*CJOJQJ^JaJph h#W5>*CJOJQJ^JaJhq65CJOJQJ^JaJ#h"h#W5CJOJQJ^JaJp/p0p1p3p2(& _0gd#kdd$$Ifl4ֈrl#+4x<zppp0=4 la $$Ifa$gdGqD2p3p4p>p^p_p`p{p|p}p~ppppppppppppppppqq_qѱѣu`PhHhUCJOJQJaJh(jhHhUCJOJQJUaJhhHthU5OJQJaJhhe95OJQJaJh h~O5CJOJQJ\^JaJ hCh hCh'h'5CJOJQJ\aJ h'5CJOJQJ\^JaJ&ha>h'5CJOJQJ\^JaJ%ha>h'5CJOJQJ\aJhh'hn)3p>pGp`p|p$ = P $Ifa$gd\ $$Ifa$gd\$  ~= z9!v%$Ifa$gd\|p}p~p/$  ~= z9!v%$Ifa$gd\kdd$$Ifl44\r2-=U `(0>4 lap(ytS~pppppppppqrX$  ~= z9!v%$Ifa$gdUskdui$$Iflr=>  0>4 lap ytS $Ifgd'Ff^g $$Ifa$gd\ qqqqqqUrVrrr1s2ssttu & F_$7$8$If^_`gdU $IfgdU $Ifgdl ' $$Ifa$gdU $Ifgd $$Ifa$gdU  ~= z9!v%$IfgdU_q`qaqqqqqqqqqqqrHrIrJrSrTrVrWrrrӱ}kӱSӱӱ;.jmhHhUCJOJQJUaJh.jlhHhUCJOJQJUaJh#h>ehU0JCJOJQJaJh(j@kh>eCJOJQJUaJhh>eCJOJQJaJh"jh>eCJOJQJUaJhhHhUCJOJQJaJh#hHhU0JCJOJQJaJh(jhHhUCJOJQJUaJh.jjhHhUCJOJQJUaJhrrrrrrrsss.s/s0s1s2s3ssss̿vfSG1S+johHhlCJOJQJUaJhlCJOJQJaJ%jhHhUCJOJQJUaJhHhUCJOJQJaJhhHhCJOJQJaJh#hh0JCJOJQJaJh(jnhCJOJQJUaJh"jhCJOJQJUaJhhCJOJQJaJhhUCJOJQJaJh#hHhU0JCJOJQJaJh(jhHhUCJOJQJUaJhsssssssssdtfthtltnttttttȶjWGW6 h=hCJOJQJ^JaJhl '0JCJOJQJ^JaJ$hvhU0JCJOJQJ^JaJ/jAqhvhCJOJQJU^JaJhCJOJQJ^JaJ)jhvhUCJOJQJU^JaJ hvhUCJOJQJ^JaJ#hvhU5CJOJQJ^JaJ&hFghU5CJOJQJ\^JaJ%jhHhUCJOJQJUaJ hHhU0JCJOJQJaJttuuuuuvvvBvTvvvvvvvcwx±tbN*CJOJQJ^JaJ#hvhU5CJOJQJ^JaJ hvhUCJOJQJ^JaJ#hvhUCJH*OJQJ^JaJ$hOh R0JCJOJQJ^JaJ2jdrh RB* CJOJQJU^JaJphP,jh RB* CJOJQJU^JaJphP#h RB* CJOJQJ^JaJphPh RCJOJQJ^JaJKzLzMzNzOzkzlzmz|zzzzzzzzzzzz{ȳj[M;#hvhUCJH*OJQJ^JaJhKNCJOJQJ^JaJhvhUCJOJQJaJ)hvhUB* CJOJQJ^JaJphP hvhUCJOJQJ^JaJ hvhUCJOJQJ^JaJ#hvhU5CJOJQJ^JaJ)hFghUB*CJOJQJ^JaJph333 hHthUCJOJQJ^JaJ&hHthU5CJOJQJ\^JaJ#hHthU5CJOJQJ^JaJ{{ {1{?{{{{{{{{{{{ɴɢ|f||M6-hvhU@B*CJOJQJ^JaJph3f0hvhU5@B*CJOJQJ^JaJph3f*hvhU5@CJH*OJQJ^JaJ'hvhU5@CJOJQJ^JaJ#hvhU5CJOJQJ^JaJ#hvhUCJOJQJ\^JaJ)hvhUB*CJOJQJ^JaJph3f hvhUCJOJQJ^JaJ#hvhUCJOJQJ]^JaJ&hvhU6CJOJQJ]^JaJ1{{{{u||||}}klmȀɀʀ $Ifgd $IfgdU $IfgdU $$Ifa$gdU $Ifgd~ $IfgdU{{{{{r|t|u|||||||||||||s\ͻN<#hvhUCJH*OJQJ^JaJh^oCJOJQJ^JaJ,hvhUB*CJOJQJ\^JaJph#h~hCJOJQJ\^JaJ!h5@CJOJQJ^JaJ!hU5@CJOJQJ^JaJ'hvhU5@CJOJQJ^JaJ#hvhUCJOJQJ\^JaJ hvhUCJOJQJ^JaJhvhUCJOJQJaJ$hvhU@CJOJQJ^JaJ|||||}}}}'}/}3}}}}}}}{m_N= h^o5CJOJQJ\^JaJ h5CJOJQJ\^JaJhCJOJQJ^JaJhUCJOJQJ^JaJh~CJOJQJ^JaJ#hvhU5CJOJQJ^JaJ)hvhUB* CJOJQJ^JaJph hvhUCJOJQJ^JaJ#hvhUCJH*OJQJ^JaJ,hvhUB*CJH*OJQJ^JaJph)hvhUB*CJOJQJ^JaJph}}}}6~O~~~~~WXʶʟv^v^J7$hHthU@CJOJQJ^JaJ&h^oh5CJOJQJ\^JaJ/h^ohF s6>*B* CJOJQJ^JaJph^#h^ohF s6CJOJQJ^JaJ,jh^ohF s6CJOJQJU^JaJ,h^ohF s6B*CJOJQJ^JaJph&h^ohF s6CJOJQJ]^JaJ&h^oh^o6CJOJQJ]^JaJhF sCJOJQJ^JaJ&hF shF s5CJOJQJ\^JaJklmǀȀɀʀˀ܀빤ʓraZF1)hFghUB*CJOJQJ^JaJph333&hFghU5CJOJQJ\^JaJ hChU hs-hUCJOJQJ^JaJ0hHthU5@B* CJOJQJ^JaJphPhHthU5 hHthUCJOJQJ^JaJ)hvhUB* CJOJQJ^JaJphP hvhUCJOJQJ^JaJhUCJOJQJ^JaJ$hHthU@CJOJQJ^JaJ'hHthU5@CJOJQJ^JaJ<=PD;.; $IfgdU $IfgdU $$Ifa$gdUkdt$$Ifl4\r2-=U`0>4 lapytS-/;<=ASTV\]k޻̻{iT?)hvhUB*CJOJQJ^JaJph3f)hHthUB*CJOJQJ^JaJph3f#hHthUCJH*OJQJ^JaJh#5CJOJQJ^JaJ hFghUCJOJQJ^JaJ#h^ohU5CJOJQJ^JaJh^oCJOJQJ^JaJ hHthUCJOJQJ^JaJ#hlhU5CJOJQJ^JaJh^o5CJOJQJ^JaJ#hHthU5CJOJQJ^JaJ=>?@AS˂݂YZ $Ifgd# $IfgdU $IfgdUklrͿweVA,)hHthUB*CJOJQJ^JaJph)hHthUB*CJOJQJ^JaJphhUCJOJQJ]^JaJ#hHthUCJOJQJ]^JaJ&h#h#CJH*OJQJ]^JaJh#CJOJQJ]^JaJ hU7CJOJQJ\^JaJ&hHthU5CJOJQJ\^JaJhUCJOJQJ^JaJ hvhUCJOJQJ^JaJhvhUCJOJQJaJ#hG3aB*CJOJQJ^JaJph3fʂ˂݂ɶ}hYH4 &hFghU5CJOJQJ]^JaJ&hFghU5CJOJQJ\^JaJ hFghUCJOJQJ^JaJhFghUCJOJQJaJ)hFghUB*CJOJQJ^JaJph3f#hFghU5CJOJQJ^JaJ$hHthU@CJOJQJ^JaJ'hvhU6@CJOJQJ^JaJ$hvhU@CJOJQJ^JaJ)hHthUB*CJOJQJ^JaJph hHthUCJOJQJ^JaJ h_?)hUCJOJQJ^JaJ  -.24MXYZ[hqrݷݦvo[J9[ h5CJOJQJ\^JaJ hV35CJOJQJ\^JaJ&hFghF{5CJOJQJ\^JaJ hChU hs-hUCJOJQJ^JaJ hS~h#CJOJQJ^JaJh#CJOJQJ^JaJ hFgh#CJOJQJ^JaJ#hHth#CJOJQJ]^JaJ&h#h#CJH*OJQJ]^JaJh#CJOJQJ]^JaJ&hs-hU5CJOJQJ]^JaJZ[P=1 $$Ifa$gdUkdju$$Ifl4rr2-6=U i a0>4 lapytS~NPRT \^`bd҅ԅօ˵xfQA)Q.jwhFghF{CJOJQJU\aJhFghF{CJOJQJ\aJ(jhFghF{CJOJQJU\aJ"hFghF{5CJOJQJ\aJ#hHhF{0JCJOJQJaJh1jevhHhF{>*CJOJQJUaJh"hHhF{>*CJOJQJaJh+jhHhF{>*CJOJQJUaJh *hF{5OJQJaJh&hW hF{5CJOJQJ\^JaJ#hFghF{5CJOJQJ^JaJPR`b3rs#$ $IfgdU $$Ifa$gdU  ~= z9!v%$IfgdU օ123qrsȺ~m_N<+m hs-hF{CJOJQJ^JaJ# *h#hF{CJOJQJ^JaJ hKNhKNCJOJQJ^JaJhKNCJOJQJ^JaJ hFghF{CJOJQJ^JaJ)hs-hF{5>*CJOJQJ\^JaJ#hF{B*CJOJQJ^JaJph333)hFghF{B*CJOJQJ^JaJph333h6hF{OJQJ\aJhFghF{CJOJQJ\aJ(jhFghF{CJOJQJU\aJ#hFghF{0JCJOJQJ\aJ "$%&'4<Ȉ#±ᏈweQ?#hFghF{5CJOJQJ^JaJ&hFghF{5CJOJQJ\^JaJ#hrhF{5CJOJQJ^JaJ! *hhF{>*OJQJaJh hChF{ hs-hF{CJOJQJ^JaJ hS~hF{CJOJQJ^JaJ hS~hS~CJOJQJ^JaJ hS~hnCJOJQJ^JaJhnCJOJQJ^JaJ hFghF{CJOJQJ^JaJhF{CJOJQJ^JaJ$%&;!$  ~= z9!v%$Ifa$gdUkdex$$Ifl4\r2-=U 0>4 lapytS&'4߈$%^`,. $Ifgd R $IfgdMV $IfgdU #$%6$&(,JPR`n*.0ZͿ͙͙y͙j\jUEhFghU5OJQJ\aJ hChF{h:CJOJQJ^JaJh+}zhF{CJOJQJaJh=CJOJQJ^JaJ#hMVB* CJOJQJ^JaJphP)h+}zhF{B* CJOJQJ^JaJphP hMVhMVCJOJQJ^JaJhMVCJOJQJ^JaJ h+}zhF{CJOJQJ^JaJ hs-hF{CJOJQJ^JaJ h/&hF{CJOJQJ^JaJ.0\aG; $$Ifa$gdU$  ~= z9!v%$Ifa$gdUkduy$$Ifl4\r2-=U 0>4 laytSZ\123:;=>ŵ{l\\D2\#hxkhH 0JCJOJQJaJh.j{hxkhH CJOJQJUaJhhxkhH CJOJQJaJhhH 0JCJOJQJaJh.jzhxkhH CJOJQJUaJhhH CJOJQJaJh(jhxkhH CJOJQJUaJhhxkhH 5OJQJaJh#hxkhH 5CJOJQJ^JaJ hChU#hFghU5CJOJQJ^JaJhFghU>*OJQJaJh<=|eYYYY $$Ifa$gdU  ~= z9!v%$IfgdU $$Ifa$gdUvkd@z$$Ifl]0r=U560>4 laytSٌڌی)&*st|۝}hVhA/#hFghH CJOJQJ\^JaJ)h$hH B*CJOJQJ^JaJph#hH B*CJOJQJ^JaJph)hFghH B*CJOJQJ^JaJphhFghH 5CJH*aJ#hFghH 5CJOJQJ^JaJ&hFghH 5CJOJQJ\^JaJ#hxkhH 0JCJOJQJaJh.j|hxkhH CJOJQJUaJhhxkhH CJOJQJaJh(jhxkhH CJOJQJUaJh*& +tHʒ̒OPa $Ifgds & F$IfgdU $IfgdU$  ~= z9!v%$Ifa$gdUĵću`Q@,'h)hH 5@CJOJQJ^JaJ h)hH CJOJQJ^JaJh)hH CJOJQJaJ)h)hH B*CJOJQJ^JaJph3f#h)hH CJOJQJ]^JaJ'h)hH 0J5CJOJQJ^JaJ2j}h)hH 5CJOJQJU^JaJhH 5CJOJQJ^JaJ,jh)hH 5CJOJQJU^JaJ#h)hH 5CJOJQJ^JaJ#hxkhH CJOJQJ\^JaJ8DFHhȒȶ~raL~a9L~$h)hH @CJOJQJ^JaJ)h)hH B*CJOJQJ^JaJph h)hH CJOJQJ^JaJhH CJOJQJaJh)hH CJOJQJaJ)h)hH B*CJOJQJ^JaJph3f'h)hH 5@CJOJQJ^JaJ#hH B* CJOJQJ^JaJphP)h+}zhH B* CJOJQJ^JaJphP hMVhH CJOJQJ^JaJ!hH 5@CJOJQJ^JaJȒʒ̒BDFPRfįĘo[įL; h)hH CJOJQJ^JaJh)hH CJOJQJaJ'hs-hH 0J5CJOJQJ^JaJ2j~hs-hH 5CJOJQJU^JaJhH 5CJOJQJ^JaJ,jhs-hH 5CJOJQJU^JaJ)hs-hH B*CJOJQJ^JaJph3f#hs-hH 5CJOJQJ^JaJ)hs-hH B*CJOJQJ^JaJph'hshH 5@CJOJQJ^JaJʓΓ(,.LNP`abcdzɴq`OH6#hxkhU5CJOJQJ^JaJ hChH hs-hH CJOJQJ^JaJ h#hH CJOJQJ^JaJ#hs-hH 5CJOJQJ^JaJhH CJOJQJ^JaJ#h)hH CJH*OJQJ^JaJ h)hH CJOJQJ^JaJ)hs-hH B*CJOJQJ^JaJph3fh)hH CJOJQJaJ)h)hH B*CJOJQJ^JaJph3f#h)hH 5CJOJQJ^JaJabcdzޔPD8 $$Ifa$gd=; $$Ifa$gdUkdv$$Ifl \r2-=U0>4 laytS $Ifgds $IfgdUz{ӔԔՔܔݔޔߔ$%&)*+,yz{맏}e}UD *hU5CJOJQJ^JaJhxkhU5OJQJaJh.jEhxkhUCJOJQJUaJh#hxkhU0JCJOJQJaJh.jLhxkhUCJOJQJUaJhhxkhUCJOJQJaJhh>e0JCJOJQJaJh.j)hxkh>eCJOJQJUaJhh>eCJOJQJaJh(jhxkhUCJOJQJUaJhޔ+YvkdN$$Ifl0r=U560>4 laytS $IfgdU$  ~= z9!v%$Ifa$gdU $$Ifa$gdU!/0 ŸŦvevL.:hyYhZkB*CJOJQJ^JaJfHph333q 1hhZkCJOJQJ^JaJfHq hhZkCJOJQJ^JaJ hyYhZkCJOJQJ^JaJhZkCJOJQJ^JaJ hP>hZkCJOJQJ^JaJ#h hZk5CJOJQJ^JaJhZk5OJQJaJhha}hZk5OJQJaJh hChU hs-hUCJOJQJ^JaJ#hLJhU5CJOJQJ^JaJ0hjln(,.F vx $Ifgd> $IfgdM3 $IfgdU$  ~= z9!v%$Ifa$gdH XZ\dflnؚښͯ|n\Kn6$#hZkB*CJOJQJ^JaJph3f)h)hZkB*CJOJQJ^JaJph3f hFghZkCJOJQJ^JaJ#hP>hZk5CJOJQJ^JaJhZkCJOJQJ^JaJ&hZk>*B*CJOJQJ^JaJph=hLJhZk>*B*CJOJQJ^JaJfHphq ;jhLJhZk>*B*CJOJQJU^JaJph,hLJhZk>*B*CJOJQJ^JaJph5jhLJhZk>*B*CJOJQJU^JaJph ښ $(,.FH,.DFHDzǤ؍xdRRAR hFghZkCJOJQJ^JaJ#hZkB*CJOJQJ^JaJph&hZk5B*CJOJQJ^JaJph3f)h)hZkB*CJOJQJ^JaJph3f,h1hZk5B*CJOJQJ^JaJphhZkCJOJQJ^JaJ)h+}zhZkB* CJOJQJ^JaJphP h+}zhZkCJOJQJ^JaJ#hZkB*CJOJQJ^JaJph3f)h1hZkB*CJOJQJ^JaJphH`bd &m[J<')h)hZkB*CJOJQJ^JaJph3fhZkCJOJQJ^JaJ hFghZkCJOJQJ^JaJ#h9dhZk5CJOJQJ^JaJ#hP>hZk5CJOJQJ^JaJ#hs-hZk5CJOJQJ^JaJhZk5CJOJQJ^JaJhZkCJOJQJ\^JaJ#hvhZkCJOJQJ\^JaJ#hvhZkCJH*OJQJ^JaJ,hvhZkB*CJH*OJQJ^JaJph)hvhZkB*CJOJQJ^JaJph &(x|~]^bqج흋zi[I4II)hLJhZkB*CJOJQJ^JaJph#hZkB*CJOJQJ^JaJphhZkCJOJQJ^JaJ hFghZkCJOJQJ^JaJ hZkh CJOJQJ^JaJ#hs-hZk5CJOJQJ^JaJhZk5CJOJQJ^JaJ)h)hZkB*CJOJQJ^JaJph3f,h1hZk5B*CJOJQJ^JaJph)h1hZkB*CJOJQJ^JaJph#hZkB*CJOJQJ^JaJph3f]^rs $Ifgd2Z $IfgdlH4 $Ifgd $Ifgdo $Ifgd $Ifgd( $IfgdH $Ifgd $Ifgd>qrsҞӞמٞͻ☇veTFTFTF5 hS~h2ZCJOJQJ^JaJh2ZCJOJQJ^JaJ hFgh2ZCJOJQJ^JaJ hhZkCJOJQJ^JaJ hohZkCJOJQJ^JaJ hhZkCJOJQJ^JaJ h(hZkCJOJQJ^JaJ#hZkB*CJOJQJ^JaJph#hG@hZkCJOJQJ\^JaJ)h1hZkB*CJOJQJ^JaJphhZkCJ OJQJ^JaJhZk5CJOJQJ^JaJ !)*.3➗ufTfTB-)hLJhZkB*CJOJQJ^JaJph#hZkB*CJOJQJ^JaJph#h9dhZk5CJOJQJ^JaJhZk5CJOJQJ^JaJ#h hZk5CJOJQJ^JaJha}hZk5OJQJaJh hChZk hLJhZkCJOJQJ^JaJ hohZkCJOJQJ^JaJ hhZkCJOJQJ^JaJ h(hZkCJOJQJ^JaJhZkCJOJQJ^JaJh2ZCJOJQJ]^JaJ $Ifgdo $Ifgd $IfgdH $Ifgd($Ifgd(ovG $Ifgd ;!$  ~= z9!v%$Ifa$gdUkdT$$Ifl4ֈrq%2-6=Ui P0>4 laytS *xşٟڟ(:;Qbcd͡ߡ $Ifgd( $IfgdlH4 $Ifgd $Ifgd> $Ifgd7B $IfgdM3 $IfgdU34uxŸßğşɟ؟ܟ'(*9>؛~~l~WE~l~#hZkB*CJOJQJ^JaJph3f)h)hZkB*CJOJQJ^JaJph3f#hs-hZk5CJOJQJ^JaJhZk5CJOJQJ^JaJhZkCJOJQJ^JaJ h"hZkCJOJQJ^JaJ)hLJhZkB*CJOJQJ^JaJph,h1hZk5B*CJOJQJ^JaJph)h1hZkB*CJOJQJ^JaJph#hZkB*CJOJQJ^JaJph>L[\]^678NOPRab˶s`Q?0h#5CJOJQJ^JaJ#hs-hZk5CJOJQJ^JaJhZk5CJOJQJ^JaJ$hOhZk0JCJOJQJ^JaJ2j:hZkB* CJOJQJU^JaJphP#hZkB* CJOJQJ^JaJphP,jhZkB* CJOJQJU^JaJphP)h1hZkB*CJOJQJ^JaJphhZkCJOJQJ^JaJ hLJhZkCJOJQJ^JaJ)hLJhZkB*CJOJQJ^JaJph3fbcdfy̡͡ϡޡϽϽjXC2 hLJhZkCJOJQJ^JaJ)hLJhZkB*CJOJQJ^JaJph3f#hs-hZk5CJOJQJ^JaJ,h1hZk5B*CJOJQJ^JaJph)h1hZkB*CJOJQJ^JaJph#hZkB*CJOJQJ^JaJph3f)h)hZkB*CJOJQJ^JaJph3f#h9dhZk5CJOJQJ^JaJhZk5CJOJQJ^JaJ#hP>hO35CJOJQJ^JaJh2Z5CJOJQJ^JaJۢܢݢ ƴƇxfQ@,&h(hZkh CJOJQJ^JaJ hlH4hZkCJOJQJ^JaJ)h~hZkh 5CJOJQJ^JaJ#hs-hZk5CJOJQJ^JaJhZk5CJOJQJ^JaJ$hOhZk0JCJOJQJ^JaJ2jYhZkB* CJOJQJU^JaJphP#hZkB* CJOJQJ^JaJphP,jhZkB* CJOJQJU^JaJphP)h1hZkB*CJOJQJ^JaJphhZkCJOJQJ^JaJ ;!$  ~= z9!v%$Ifa$gdF{kdx$$Ifl4ֈrq%2-6=Ui P0>4 laytS LMNSTVWҤԤĬԚĂԚr]H]=h1hB*ph)h1hS~B*CJOJQJ^JaJph)h1hB*CJOJQJ^JaJphha}hU5OJQJaJh.j)hxkhUCJOJQJUaJh#hxkhU0JCJOJQJaJh.j^hxkhUCJOJQJUaJhhxkhUCJOJQJaJh(jhxkhUCJOJQJUaJhhxkhU5OJQJaJh hChZkUVԤ;<jA $Ifgd $IfgdU $IfgdU$  ~= z9!v%$Ifa$gdUԤ;<ijtvwOPQghijνv^M>/hs-hUCJOJQJaJhP>hUCJ4OJQJaJ hOh R0JCJOJQJaJ.jh RB* CJOJQJUaJphPh RB* CJOJQJaJphP(jh RB* CJOJQJUaJphP%h7jh RB*CJOJQJaJphh RhUCJOJQJaJ hs-hUCJOJQJ^JaJ hLJhUCJOJQJ^JaJhS~CJOJQJ^JaJ#hLJhU5CJOJQJ^JaJާߧͿ͕ͪ~lR~?~1ͪhS~CJOJQJ^JaJ$hOh0JCJOJQJ^JaJ2j#hB* CJOJQJU^JaJphP#hB* CJOJQJ^JaJphP,jhB* CJOJQJU^JaJphP)h1hB*CJOJQJ^JaJph)hLJhUB*CJOJQJ^JaJph3fhCJOJQJ^JaJ hLJhUCJOJQJ^JaJ#hLJhU5CJOJQJ^JaJh5CJOJQJ^JaJ#@AL̵vhSB1 hS~hS~CJOJQJ^JaJ hLJhCJOJQJ^JaJ)hLJhB*CJOJQJ^JaJph3fhS~CJOJQJ^JaJ$hOh0JCJOJQJ^JaJ2jBhB* CJOJQJU^JaJphP#hB* CJOJQJ^JaJphP,jhB* CJOJQJU^JaJphP)h1hB*CJOJQJ^JaJphhCJOJQJ^JaJ hLJhUCJOJQJ^JaJLMNnopt_M8)h=h=B*CJOJQJ^JaJph#hB*CJOJQJ^JaJph3f)h1hB*CJOJQJ^JaJph)hP>hB*CJOJQJ^JaJph3f)h=hB*CJOJQJ^JaJph3f hP>hUCJOJQJ^JaJ hLJhUCJOJQJ^JaJh%x+5CJOJQJ^JaJh%x+CJOJQJ^JaJ hP>hCJOJQJ^JaJhhCJOJQJ^JaJ uvw׽~iQ<*#hB*CJOJQJ^JaJph3f)h1hB*CJOJQJ^JaJph/hLJhhB*CJOJQJ^JaJph3f)hP>hB*CJOJQJ^JaJph3f,h1h5B*CJOJQJ^JaJph)h=h=B*CJOJQJ^JaJph$hOh=0JCJOJQJ^JaJ2jah=B* CJOJQJU^JaJphP#h=B* CJOJQJ^JaJphP,jh=B* CJOJQJU^JaJphP ªêĪڪ۪Ƶ~iYAi/i~#hQhGB0JCJOJQJaJh.j9hQhGBCJOJQJUaJhhQhGBCJOJQJaJh(jhQhGBCJOJQJUaJhhQhGB5OJQJaJh hChU#h~h[%5CJOJQJ^JaJhUCJOJQJ^JaJ hlhUCJOJQJ^JaJ)h{hGBB*CJOJQJ^JaJph3f#hGBB*CJOJQJ^JaJph3f#h{B*CJOJQJ^JaJph3fªêĪ٪ڪY???$  ~= z9!v%$Ifa$gd|kd$$Ifl\r2-=U0>4 laytS $IfgdU|}vx#$mn8ް 23 $IfgdGB $IfgdU $Ifgd|$  ~= z9!v%$Ifa$gdF{x-$mnx8b߻|e|e|N:&h#F5B*CJOJQJ^JaJph,hLhGB5B*CJOJQJ^JaJph,hLhGB>*B*CJOJQJ^JaJph)hLhGBB*CJOJQJ^JaJph)hLhGBB*CJOJQJ^JaJph)h1hGBB*CJOJQJ^JaJph#hQhGBCJOJQJ\^JaJ#hQhGB5CJOJQJ^JaJ hQhGBCJOJQJ^JaJhxkhGB5OJQJaJhڰް Կn\H1,hLhGB>*B*CJOJQJ^JaJph&h#F>*B*CJOJQJ^JaJph#h#FB*CJOJQJ^JaJph)hLh#FB*CJOJQJ^JaJph,hLh#F>*B*CJOJQJ^JaJph&hLhGB5CJOJQJ\^JaJ hLhGBCJOJQJ^JaJ)hLhGBB*CJOJQJ^JaJph)hLhGBB*CJOJQJ^JaJph,hLhGB5B*CJOJQJ^JaJph ԱڱղֲײǰlOl*B*CJOJQJ^JaJph#hLhGB5CJOJQJ^JaJ&hLhGB5CJH*OJQJ^JaJ34Dr˳̳ͳ,-}~ $IfgdGB $Ifgd7j ׳+,[{~ӴԴմ״Ƕ|xtbSBSb;bS hCh) h1h)CJOJQJ^JaJh)5CJOJQJ^JaJ#h1h)5CJOJQJ^JaJhjYhSh!V hChGBhS~CJOJQJ^JaJ#hs-hGB5CJOJQJ^JaJhGB5CJOJQJ^JaJ hQhGBCJOJQJ^JaJ#hGBhGB5CJOJQJ^JaJ hGBhGBCJOJQJ^JaJ)h4hGBB*CJOJQJ^JaJph~<:::::kd9$$Iflֈrq%2-6=Ui a0>4 laytSԴ $$Ifa$gd Դմִ״-!! $$Ifa$gdkd$$Ifl44T\rSw)x<``F `(0=4 laf4p(ytK ״$%rskd$$Ifl4rx<=  0=4 laf4p $IfgdyAFf $$Ifa$gd#$%Եï}pcN>hyYhCJOJQJaJh(jhyYhCJOJQJUaJhh5OJQJaJhh)5OJQJaJhha}h)5OJQJaJh hCh&h?5h5CJOJQJ\^JaJ hCha>&h?5ha>5CJOJQJ\^JaJ&h?5ht5CJOJQJ\^JaJ hCh)h)5CJOJQJ^JaJ#h1h)5CJOJQJ^JaJ۵/߶Gxrrri]]Qi d$IfgdH d$IfgdO5R $IfgdO5R$  ~= z9!v%$Ifa$gdPhskdZ$$Ifl4rx<=  0=4 laf4p Եյֵٵڵ۵-./߶:FGU]ӳydyOy:) hHh.CJOJQJ^JaJ)hHh)B*CJOJQJ^JaJph(hHhb3CJOJQJ^JaJmH sH (hHh8CJOJQJ^JaJmH sH (hHh)CJOJQJ^JaJmH sH &hHh)6CJH*OJQJ^JaJ hHh)CJOJQJ^JaJhhOJQJaJh#hyYh0JCJOJQJaJh(jhyYhCJOJQJUaJh.jhyYhCJOJQJUaJh]^byͷηܷݷ޷ʶjYHY3YH)hHh)B*CJOJQJ^JaJph hHh@CJOJQJ^JaJ hHh.CJOJQJ^JaJ)hHh)B*CJOJQJ^JaJph3f#hGqDh)CJOJQJ]^JaJ'hGqDhb3@CJOJQJ]^JaJ!h%x+@CJOJQJ]^JaJ'hGqDh)@CJOJQJ]^JaJ&hGqDh)>*CJOJQJ]^JaJ hHhb3CJOJQJ^JaJ hHh)CJOJQJ^JaJxyη78m $IfgdyA $IfgdO5R !8DEFMmnx}~޸ޠp`K;hLJhCJOJQJaJh(jhLJhCJOJQJUaJhhLJh5OJQJaJhhLJh}5OJQJaJhhLJhH65OJQJaJhhLJh)5OJQJaJh hCh) hHh@CJOJQJ^JaJ)hHh)B*CJOJQJ^JaJph3f hHhb3CJOJQJ^JaJ hHh)CJOJQJ^JaJ hHh.CJOJQJ^JaJmn<""$  ~= z9!v%$Ifa$gdPhkdˠ$$IflֈrS!w)4x<F#  q0=4 laytK ¸ŸƸǸȸɸ *+123oӱm[I[I[I7#hLJh5CJOJQJ^JaJ#hlhl0JCJOJQJaJh#hlh50JCJOJQJaJh(jshlCJOJQJUaJhhlCJOJQJaJh"jhlCJOJQJUaJhhLJh5CJOJQJaJhhLJhCJOJQJaJh#hLJh0JCJOJQJaJh(jhLJhCJOJQJUaJh.jhLJhCJOJQJUaJhǸȸ3op̹͹jkĻŻ~˼ $IfgdO5R $$Ifa$gdOl $IfgdOl $Ifgd^1 $IfgdH` $Ifgd$  ~= z9!v%$Ifa$gdPho˹̹͹Żѻ}~ппwfwTfBT#hLJhUS5CJOJQJ^JaJ#hLJh)5CJOJQJ^JaJ hLJhH6CJOJQJ^JaJ#hLJhH65CJOJQJ^JaJ hLJhCJOJQJ^JaJ h%x+h%x+CJOJQJ^JaJ&hyWh%x+5CJOJQJ\^JaJ hLJh%x+CJOJQJ^JaJh)CJOJQJ^JaJ hLJhHCJOJQJ^JaJ hLJh)CJOJQJ^JaJ~˼̼ܼ 234@I^_`abǶǥmmضǥ\J9 hLJhH6CJOJQJ^JaJ#hLJhH67CJOJQJ^JaJ jhHthV3UmHnHu#hLJh)5CJOJQJ^JaJ)hLJh9 B* CJOJQJ^JaJph hLJh9 CJOJQJ^JaJ hLJh|/$CJOJQJ^JaJ hLJh.CJOJQJ^JaJ hLJh)CJOJQJ^JaJ)hLJh)B*CJOJQJ^JaJph#hLJh.5CJOJQJ^JaJ˼̼ _bc:;<=ijk $IfgdO5R $Ifgd!m $Ifgdo $IfgdO5Rbqy9:;<Kȷ}ȦkYG2)hLJh)B*CJOJQJ^JaJph#hLJh)5CJOJQJ^JaJ#hLJh!V5CJOJQJ^JaJ#hLJh!m5CJOJQJ^JaJ&hLJh)5CJOJQJ\^JaJ)hLJh!mB* CJOJQJ^JaJph hLJh!mCJOJQJ^JaJ hLJh7CJOJQJ^JaJ hLJh)CJOJQJ^JaJ hLJh.CJOJQJ^JaJ)hLJh)B*CJOJQJ^JaJph3fKLSjw89:=>?H²gUB6hHht6CJaJ% *hHhUY5CJOJQJaJh#hhUY0JCJOJQJaJh.jIhhUYCJOJQJUaJhhhUYCJOJQJaJh(jhhUYCJOJQJUaJhhhUYOJQJaJhhht5OJQJaJh hCh))hLJh)B*CJOJQJ^JaJph3f hLJh.CJOJQJ^JaJ hLJh)CJOJQJ^JaJ<"$  ~= z9!v%$Ifa$gdPhkdz$$IflֈrS!w)4x<F#  q0=4 laytK ?pͿοRS&' x $IfgdO5R $Ifgdxf& & Fd $Ifgdtm$& & Fd $If]gdHm$& & Fd $If]gdtm$$  ~= z9!v%$Ifa$gdUY$  ~= z9!v%$Ifa$gdUY H˿̿ͿοQRS%'̹}hSB hHhxfCJOJQJ^JaJ)h7hxfB* CJOJQJ^JaJphP)hHhtB*CJOJQJ^JaJphh7htB*CJaJph *h'\ h_5CJaJhHhOt5CJaJhHCJaJhHh/CJaJhHh_CJaJh-@CJaJhP>h-@CJaJh-@CJH*aJhtCJH*aJhHhtCJH*aJhHhtCJaJ 7ef $Ifgdo $Ifgdxf $IfgdO5R& & Fd $Ifgdxfm$ $IfgdO5R $$Ifa$gdxf567EdefrɴydOH:*hxkhaG5OJQJaJhhxkhaG5OJQJaJ hCht)hHhtB*CJOJQJ^JaJph3f)hHhtB*CJOJQJ^JaJphhHhxfCJH*aJhHhxfCJaJh7hxfB*CJaJph)hHhxfB*CJOJQJ^JaJph3f)hHhxfB*CJOJQJ^JaJph hHhxfCJOJQJ^JaJ)h7hxfB* CJOJQJ^JaJphP hHhtCJOJQJ^JaJ<"$  ~= z9!v%$Ifa$gdPhkd:$$Ifl ֈrS!w)4x<F#  q0=4 laytK a ﮝzgXBg1g hh0JCJOJQJaJ+jhhCJOJQJUaJhhCJOJQJaJ%jhhCJOJQJUaJ h5,ha}h5B*CJOJQJ^JaJph hChaG hxkhaGCJOJQJ^JaJ hHhVCJOJQJ^JaJ hHhCJOJQJ^JaJhHCJOJQJ^JaJ hHh9!CJOJQJ^JaJ hHh{fCJOJQJ^JaJsYY?$  ~= z9!v%$Ifa$gdPh$  ~= z9!v%$Ifa$gd $$Ifa$gdvkd $$Ifl0rSx<%60=4 laytK $Ifgdr O45KLMqs~=?υsY=Y=Ys6h7h0J5>*B*CJaJmHnHphtH u3h7h0J>*B*CJaJmHnHphtH u#h7hCJaJmHnHtH u&h7hCJH*aJmHnHtH u6jh7h0J>*CJH*UaJmHnHtH uh7hCJaJjh7hCJUaJ&h7h5CJaJmHnHtH uhxkh5OJQJaJhwjhCJOJQJaJs? $IfgdNa $Ifgdr O $Ifgd& & Fd$If]gdm$& & Fd $If]gdm$?ZҺkZBk/kZ( hCh$hh0JCJOJQJ^JaJ/juhhCJOJQJU^JaJ hhCJOJQJ^JaJ)jhhCJOJQJU^JaJ%hNaCJOJQJ^JaJmHnHu+hhCJOJQJ^JaJmHnHu hHhCJOJQJ^JaJ/h7h57B*CJOJQJ^JaJph+h7hCJOJQJ^JaJmHnHu.h7h5CJOJQJ^JaJmHnHuN4+ $Ifgdr O$  ~= z9!v%$Ifa$gdPhkdF$$Ifl4FrSx<F# 0=    4 lapytK $%^`+78IμΪΛÛhQ<(h@hB* CJaJmHnHphPu,h@hB* CJaJmHnHphPtH u-h7h0J>*CJH*aJmHnHtH u6jh7h0J>*CJH*UaJmHnHtH ujh7hCJUaJ#h7hzFCJaJmHnHtH u h7hh7hCJaJ#h7hCJaJmHnHtH u hHhCJOJQJ^JaJhxkh5OJQJaJno 78 $Ifgdr O $Ifgd $Ifgd& & Fd$Ifgdm$& & Fd$If]gdm$ITUoz ǫ~hWB1 h7hCJOJQJ^JaJ)h7hB*CJOJQJ^JaJph3f hHhCJOJQJ^JaJ+h7hCJOJQJ^JaJmHnHu(h>*CJOJQJ^JaJmHnHu.h7h>*CJOJQJ^JaJmHnHu7h7h>*B* CJOJQJ^JaJmHnHphPu#h7hCJaJmHnHtH uh7hCJaJmHnHu,h7hB* CJaJmHnHphPtH u 6789?@Astuxyz~kP~?~1hxkh5OJQJaJ hB<h0JCJOJQJaJ4jhB<hB*CJOJQJUaJph%hB<hB*CJOJQJaJph.jhB<hB*CJOJQJUaJph&h5B*CJOJQJ^JaJph,ha}h5B*CJOJQJ^JaJph hCh hHhCJOJQJ^JaJ h7hCJOJQJ^JaJ)h7hB*CJOJQJ^JaJph 89@zRSTaU;UUU$  ~= z9!v%$Ifa$gd $$Ifa$gdkdC$$Ifl4\rSw)x<F0=4 laytK zBCQRWXYnpq±tcKt8t$hB<hK 0JCJOJQJ^JaJ/jmhB<hK CJOJQJU^JaJ hB<hK CJOJQJ^JaJ)jhB<hK CJOJQJU^JaJhK 5CJOJQJ^JaJ#ha}hK 5CJOJQJ^JaJ hCh hs-hK CJOJQJ^JaJhK CJOJQJ^JaJ h$hCJOJQJ^JaJhCJOJQJ^JaJ hs-hCJOJQJ^JaJTUVWXYopsjjjj $Ifgdvkd֪$$Ifl0rSx<%60=4 laytK $Ifgd#F $$Ifa$gd WXǹǑـkSk@kٹ$hs-hK 0JCJOJQJ^JaJ/jhs-hK CJOJQJU^JaJ)jhs-hK CJOJQJU^JaJ hk/hK CJOJQJ^JaJ$hehK 0JCJOJQJ^JaJ)jRhK CJOJQJU^JaJhK CJOJQJ^JaJ#jhK CJOJQJU^JaJ hs-hK CJOJQJ^JaJ)hEIhK B*CJOJQJ^JaJph_`^_`abc45B[a $Ifgd $IfgdCDE\]^`k̶t̶[tII#hG@hK >*CJOJQJ^JaJ1jh CJOJQJU^JaJmH sH ,hyWhK 0JCJOJQJ^JaJmH sH 1jh CJOJQJU^JaJmH sH "h CJOJQJ^JaJmH sH +jhyWCJOJQJU^JaJmH sH (hG@hK CJOJQJ^JaJmH sH hG@hK CJOJQJ^JaJhyWCJOJQJ^JaJ"#JKLQRS]bcᾬt_tLt=hK CJOJQJ\^JaJ$hGqDhK 0JCJOJQJ^JaJ)jhK CJOJQJU^JaJ#jhK CJOJQJU^JaJ hs-hK CJOJQJ^JaJ)hs-hK B*CJOJQJ^JaJph#hs-hK 5CJOJQJ^JaJ hk/hK CJOJQJ^JaJ#hG@hK 5CJOJQJ^JaJ hG@hK CJOJQJ^JaJhK CJOJQJ^JaJc Ͻs\H6$#hs-hK 5CJOJQJ^JaJ#hs-hK CJOJQJ\^JaJ&hs-hK 6CJOJQJ\^JaJ,hs-hK B*CJOJQJ\^JaJph3f&hs-hK 5CJOJQJ\^JaJ hK 5CJOJQJ\^JaJ&h+}zhK 5CJOJQJ\^JaJ hHhK CJOJQJ^JaJ#hGqDhK CJOJQJ\^JaJh2CJOJQJ\^JaJhK CJOJQJ\^JaJ#hG@hK CJOJQJ\^JaJ 345BOPZ[`aopŴנxcUDU6h2CJOJQJ^JaJ hG@hK CJOJQJ^JaJhK CJOJQJ^JaJ)hG@hK B*CJOJQJ^JaJph3f&hG@hK 57CJOJQJ^JaJ&hs-hK 6CJOJQJ\^JaJ&hs-hK 5CJOJQJ\^JaJ hs-hK CJOJQJ^JaJ#hs-hK 5CJOJQJ^JaJ#hs-hK CJOJQJ\^JaJ,hs-hK B*CJOJQJ\^JaJph3f#|}~TUVWXY $IfgdK $Ifgd $Ifgd#YƲzlWzDz2#hG@hK CJOJQJ\^JaJ$hlhK 0JCJOJQJ^JaJ)jhlCJOJQJU^JaJhlCJOJQJ^JaJ#jhlCJOJQJU^JaJ hG@hK CJOJQJ^JaJ)hG@hK B*CJOJQJ^JaJph3f&hG@hK 5CJOJQJ\^JaJ,hG@hK B*CJOJQJ\^JaJph3f#hG@hK 5CJOJQJ^JaJ hG@h2CJOJQJ^JaJYZyz{|~(/𾰡ziXFX8X8XhnCJOJQJ^JaJ#hP>hK 5CJOJQJ^JaJ hP>hK CJOJQJ^JaJ hs-hK CJOJQJ^JaJ)hs-hK B*CJOJQJ^JaJph#hs-hK 5CJOJQJ^JaJhn5CJOJQJ^JaJhK CJOJQJ^JaJ hHhK CJOJQJ^JaJ#hGqDhK CJOJQJ\^JaJhCJOJQJ\^JaJhK CJOJQJ\^JaJ/03;STYŴţsb[I7#jhp0JCJOJQJU^J#hphp5CJOJQJ^JaJ hChK hHhK CJOJQJ^JaJ h\Mh\MCJOJQJ^JaJhS~CJOJQJ^JaJ h\MhK CJOJQJ^JaJ h\Mh[1CJOJQJ^JaJ hs-hK CJOJQJ^JaJhK CJOJQJ^JaJ hP>hK CJOJQJ^JaJhnCJOJQJ^JaJhNaCJOJQJ^JaJ<0$0 $$Ifa$gdp $$Ifa$gd6kdj$$IflֈrS!w) 4x<F*  k0=4 laytK  9:;>?@˺˥rdOr>-r hP>h0JCJOJQJ^J hph0JCJOJQJ^J)jh0JCJOJQJU^Jh0JCJOJQJ^J#jh0JCJOJQJU^Jhp5CJOJQJ^JaJ#hphp5CJOJQJ^JaJhp hP>hp0JCJOJQJ^J hphp0JCJOJQJ^J#jhp0JCJOJQJU^J)j?hp0JCJOJQJU^Jhp0JCJOJQJ^J ?A$ 6Us $IfgdlH4& & Fd $IfgdlH4m$ $Ifgdp $$Ifa$gd $$Ifa$gd6@Ao"#$&/@CXabckعث؝nj~~mث^R^hpB* CJaJphPh1hpB*CJaJph hnhnCJOJQJ^JaJhnCJOJQJ^JaJ h%g7hpCJOJQJ^JaJh%g7CJOJQJ^JaJhpCJOJQJ^JaJh%x+CJOJQJ^JaJ hphpCJOJQJ^JaJ hP>hpCJOJQJ^JaJ,h1xh5B* CJOJQJ^JaJphP 6CTUVrstɺɺ{tbSA3h V0JCJOJQJ^J#jh V0JCJOJQJU^Jh V5CJOJQJ^JaJ#hh V5CJOJQJ^JaJ hChp hlH4hpCJOJQJ^JaJ h9dhpCJOJQJ^JaJhpCJOJQJ^JaJh7h%g7B* CJaJphPh1h%g7B*CJaJphh%g7B* CJaJphPhpB* CJaJphPh1hpB*CJaJphh1hnB*CJaJphstbVVVMMMM $Ifgd V $$Ifa$gd Vkdٴ$$Ifl\rSw)x<F0=4 laytK '();ǶؤraraSB4rarah?CJOJQJ^JaJ h2h2CJOJQJ^JaJh2CJOJQJ^JaJ hh VCJOJQJ^JaJh VCJOJQJ^JaJ#h2h25CJOJQJ^JaJ#h2h V5CJOJQJ^JaJ#hph V5CJOJQJ^JaJ hP>h V0JCJOJQJ^J hph V0JCJOJQJ^J#jh V0JCJOJQJU^J)jh V0JCJOJQJU^J;H_`j.& & Fd $Ifgd Vm$ $Ifgd V;HISTju-.W\_|sbQCsh\MCJOJQJ^JaJ hQh\MCJOJQJ^JaJ hQh VCJOJQJ^JaJh VCJOJQJ^JaJ5h1h VB*CJOJPJQJ^JaJnH phtH 5h1xh VB*CJOJPJQJ^JaJnH phtH h1xh VB*CJaJphh1xh VB* CJaJphPh9dh VB* CJaJphPh VB* CJaJphPh1h VB*CJaJph|}cG+6h$5B*CJOJQJ^JaJmH nH phsH tH 6hs%75B*CJOJQJ^JaJmH nH phsH tH <hE%hD5B*CJOJQJ^JaJmH nH phsH tH  hCh1J.h1J.5CJOJQJ\aJh&ha>h1J.5CJOJQJ\^JaJ%ha>h1J.5CJOJQJ\aJhhzhh V hCh Vh VCJOJQJ^JaJ hQh VCJOJQJ^JaJhS~CJOJQJ^JaJ<:::::kde$$IflֈrS!w) 4x<Foo k0=4 layt V$ = P $Ifa$gdyA $$Ifa$gdyA$  ~= z9!v%$Ifa$gdPh?@AQEEEEEE $$Ifa$gdPhkd,$$Ifl4YFrTx<d! 0=    4 lap =>DEGͪ̈́hL-<hE%hE%5B*CJOJQJ^JaJmH nH phsH tH 6h$5B*CJOJQJ^JaJmH nH phsH tH 7hE%h$0J5CJOJQJ^JaJmH nH sH tH KjhE%h$5B*CJOJQJU^JaJmH nH phsH tH EjhE%h$5B*CJOJQJU^JaJmH nH phsH tH <hE%h$5B*CJOJQJ^JaJmH nH phsH tH &hE%h$5CJOJQJ\^JaJ ABCDEFGHIJKLMNOPQRSTUVWXY $$Ifa$gdPhGKWXYZuvwȩp\UG<1h&5OJQJaJh^5OJQJaJha}h^5OJQJaJ hCht&ha>ht5CJOJQJ\^JaJ ht5CJOJQJ\^JaJ&h29hs%75CJOJQJ\^JaJ&hQ0hs%75CJ OJQJ\^JaJ<hl\h` 5B*CJOJQJ^JaJmH nH phsH tH 6h$5B*CJOJQJ^JaJmH nH phsH tH 6hE%5B*CJOJQJ^JaJmH nH phsH tH  YZv} $$Ifa$gdPhvkd$$Ifl4rx<=  0=4 laf4p ytE%vw67rrri``iiW $Ifgd29 $IfgdbF $Ifgd29$  ~= z9!v%$Ifa$gdPhskd0$$Ifl4rx<=  0=4 laf4p 567즓l\lI6I$hxkh^@CJ OJQJ^JaJ $hxkh^@CJOJQJ^JaJhbF@CJOJQJ^JaJ$hs-hbF@CJOJQJ^JaJ'hs-hbF5@CJOJQJ^JaJ$hs-h^@CJOJQJ^JaJh&h&CJOJQJaJh hbFh&0JCJOJQJaJ+jػhbFh&CJOJQJUaJhbFh&CJOJQJaJ%jhbFh&CJOJQJUaJI̻m]m]J:Jh@CJOJQJ^JaJ$hGqDhGqD@CJOJQJ^JaJhGqD@CJOJQJ^JaJ$hs-h^@CJOJQJ^JaJ'hs-h^5@CJOJQJ^JaJ'hs-h^5@CJOJQJ^JaJ$hs-h^CJOJQJaJmHsH hs-h^CJOJQJ^JaJhzFCJOJQJ^JaJ$hs-h^@CJ OJQJ^JaJ $hs-h^@CJOJQJ^JaJ: $Ifgdlu $Ifgd] $Ifgd29 $Ifgd)q $Ifgd29 IWMNڳzjWB1 hG@h^CJOJQJ^JaJ)jhG@h^CJOJQJU^JaJ$hG@h^@CJOJQJ^JaJhmO@CJOJQJ^JaJ$hs-h^@CJOJQJ^JaJ $hs-h)@CJOJQJ^JaJ$h)h)@CJOJQJ^JaJh^@CJOJQJ^JaJ-hs-h^@B* CJOJQJ^JaJphP$hs-h^@CJOJQJ^JaJ$hs-hj)@CJOJQJ^JaJ 9:ҿҮ~mfmP=, hs-h^CJOJQJ^JaJ$hG@h^@CJOJQJ^JaJ+hG@h^5CJOJQJ^JaJmH sH hG@h hG@hCJOJQJ^JaJ hG@hGqDCJOJQJ^JaJ hG@hHCJOJQJ^JaJh}jCJOJQJ^JaJ hG@h^CJOJQJ^JaJ$hG@h^0JCJOJQJ^JaJ)jhG@h^CJOJQJU^JaJ/jhG@h^CJOJQJU^JaJ:;QRlmnx^ULUUUU $IfgdK $Ifgd29$  ~= z9!v%$Ifa$gdxkkd$$Ifl!FrTx<d!0=    4 la:;PQR2Bkln̺oZoI6$hs-h^@CJ OJQJ^JaJ hs-h^CJOJQJ^JaJ)hG@h^B*CJOJQJ^JaJph hG@h^CJOJQJ^JaJ&hG@h^6CJOJQJ]^JaJ&hG@hK6CJOJQJ]^JaJ#hG@hKCJOJQJ]^JaJ#h[hKCJOJQJ]^JaJ&hs-h^6CJOJQJ]^JaJhbFhj&5OJQJaJhbF5OJQJaJ hCh^ nyz"F $Ifgda & F$IfgdV & F$IfgdLL $IfgdLL <$Ifgdz $Ifgd29 $Ifgd{hKnAKyz{}ȵퟋ|eO8e-hs-h^6@CJH*OJQJ]^JaJ*hs-h^6@CJ OJQJ]^JaJ -hs-h^@B*CJOJQJ^JaJph3fhs-h^@OJQJ^J'hs-h^6@CJOJQJ^JaJ*hs-h^6@CJOJQJ]^JaJ$hs-h^@CJOJQJ^JaJ hs-h^CJOJQJ^JaJ&hs-h^6CJOJQJ]^JaJ$hs-h^@CJOJQJ^JaJBתׁnU>n)(hs-h^CJOJQJ^JaJmH sH -hs-h^@B*CJOJQJ^JaJph3f0hs-h^@B*CJOJQJ]^JaJph3f$hs-h^@CJOJQJ^JaJ$h'W6@CJOJQJ]^JaJ*h'Wh^6@CJOJQJ]^JaJ*h'Whj&6@CJOJQJ]^JaJ-hs-h^6@CJH*OJQJ]^JaJ*hs-h^6@CJOJQJ]^JaJ$hzh^@CJOJQJ^JaJ BLh!"-.GѿybK20hG@hG0J$5B*CJOJQJ^JaJph-hY.<hG0J$B* CJOJQJ^JaJphP-hY.<hLL0J$B* CJOJQJ^JaJphP hzh^CJOJQJ^JaJ'hs-h^@CJH*OJQJ^JaJ$hs-h^@CJOJQJ^JaJhzCJOJQJ^JaJ"hzCJOJQJ^JaJmH sH (hs-h^CJOJQJ^JaJmH sH 1hs-h^B* CJOJQJ^JaJmH phPsH  GHIвvXvA0 hG@hLLCJOJQJ^JaJ,hG@hLLB*CJOJQJ\^JaJph:hG@h~<B*CJOJQJ^JaJfHphq :hG@hGB*CJOJQJ^JaJfHphq :hhB*CJOJQJ^JaJfHphq :hG@hLLB*CJOJQJ^JaJfHphq -hG@hLL0J$B*CJOJQJ^JaJph0hG@hLL0J$5B*CJOJQJ^JaJph ͼxe^JC0$ha}h^5B*OJQJaJph hCht&hs-ht5CJOJQJ\^JaJ hCh^$hs-h$@CJOJQJ^JaJh1t@CJOJQJ^JaJh^@CJOJQJ^JaJ$hs-h^@CJOJQJ^JaJ hG@hj&CJOJQJ^JaJ hG@hLLCJOJQJ^JaJ hG@hGCJOJQJ^JaJ hG@h$:CJOJQJ^JaJ hG@hVCJOJQJ^JaJ xl $$Ifa$gdPhkd$$IflFrTx<d!0=    4 larrXOOOOO $Ifgd29$  ~= z9!v%$Ifa$gd!V$  ~= z9!v%$Ifa$gdPhskd2$$Ifl4rx<=  0=4 laf4p ȸraN=, hs-h^CJOJQJ^JaJ hs-h^CJ OJQJ^JaJ %h!Vhw5DB*CJOJQJaJph hw5Dh<0JCJOJQJaJ4jڿhw5Dh<B*CJOJQJUaJph%hw5Dh<B*CJOJQJaJph.jhw5Dh<B*CJOJQJUaJphh<5B*OJQJaJphh^5B*OJQJaJph$ha}h^5B*OJQJaJph(ha}h^5@B*OJQJaJph 3>NեufuR:R/hs-h^5B*CJOJQJ\^JaJph&hs-h^5CJOJQJ\^JaJh ]5CJOJQJ^JaJ#hs-h^5CJOJQJ^JaJh+_5CJOJQJ^JaJhs-h^CJOJQJaJ(hs-h^6B*CJ OJQJaJ ph4jhs-h+JCJOJQJU^JaJmHnHu)hs-h^B*CJOJQJ^JaJph)hs-h^B*CJOJQJ^JaJph8OI% $Ifgd29 <$Ifgd29 $Ifgd29 $IfgdyA $IfgdyA NOIuɸ۸}l[J9 hG@h\MCJOJQJ^JaJ hG@hZCJOJQJ^JaJ hG@h^CJOJQJ^JaJ hxkh^CJOJQJ^JaJ*hs-h^5@CJOJQJ\^JaJ&hs-h^5CJOJQJ\^JaJ hs-h\MCJOJQJ^JaJ hs-h^CJOJQJ^JaJ#hs-h^CJOJQJ\^JaJ#hs-h^5CJOJQJ^JaJ#hs-h^>*CJOJQJ^JaJ "#$%&YZijͻxq]VH=h295OJQJaJha}h295OJQJaJ hCht&hs-ht5CJOJQJ\^JaJ hCh^ hZh+_CJOJQJ^JaJ$htOh+_0JCJOJQJ^JaJ hG@h+_CJOJQJ^JaJh+_CJOJQJ^JaJ#jh+_CJOJQJU^JaJ hG@hHCJOJQJ^JaJ hG@hZCJOJQJ^JaJ hG@h~<CJOJQJ^JaJ%&Yxo $IfgdyAkd$$Ifl9FrTx<d!0=    4 laYZjJKrr[RII $Ifgd; $IfgdNS  ~= z9!v%$Ifgd+_$  ~= z9!v%$Ifa$gdPhskd$$Ifl4rx<=  0=4 laf4p jk 023Iw}𷥗n`n`RD`n```RDhCJOJQJ^JaJh-#CJOJQJ^JaJh}jCJOJQJ^JaJ hG@h;CJOJQJ^JaJ hG@h; hG@h CJOJQJ^JaJh+_CJOJQJ^JaJ"hHh<7CJOJQJaJhhyWh%x+0JCJ hyWhyW0JCJOJQJaJ#j`hyWhyW0JCJUhyWhyW0JCJjhyWh%x+0JCJUKQRby $Ifgdp$skd]$$Ifl_0rTx<$60=4 la $Ifgd}jPQRacstɸu^@u(u/h%rh!m0JCJOJQJ^JaJmHnHu;jh%r0J>*CJOJQJU^JaJmHnHu,h%r0J>*CJOJQJ^JaJmHnHu5jh%r0J>*CJOJQJU^JaJmHnHu&hPh5CJOJQJ\^JaJ&hs-h:35CJOJQJ\^JaJ h7z5CJOJQJ\^JaJ hCh29 hs-h+_CJOJQJ^JaJ hG@h CJOJQJ^JaJh}jCJOJQJ^JaJ bcrsbczmd $Ifgd^& & Fd $Ifgd^m$ $$Ifa$gd+_skd$$Ifl4rx<=  0=4 laf4p PQR`abҷjRҷ4R;jfh%r0J>*CJOJQJU^JaJmHnHu/h%rh%r0JCJOJQJ^JaJmHnHu/h%rh!m0JCJOJQJ^JaJmHnHu;j{h%r0J>*CJOJQJU^JaJmHnHu,h%r0J>*CJOJQJ^JaJmHnHu5jh%r0J>*CJOJQJU^JaJmHnHu,h+_0J>*CJOJQJ^JaJmHnHu,h!m0J>*CJOJQJ^JaJmHnHubcwz{ƮtpaO@&2jh`Ph%x+5CJU\aJmHnHtH uh%x+CJaJmHnHtH u#h-hCJaJmHnHtH uhNaCJaJmHnHtH uhhCJaJmHnHtH u)h-h57CJOJQJ\^JaJ+hPhCJOJQJ^JaJmHnHu.hPh5CJOJQJ^JaJmHnHu#hPhCJaJmHnHtH u&hPh5CJaJmHnHtH u&hPh!m5CJOJQJ\^JaJ z{N& & Fd $If]gdRm$& & Fd $If]gd *m$ $Ifgd *FGHKLMORSͳ~l]lL@LhPh5CJaJ jhPh5CJUaJhCJaJmHnHtH u#h-hCJaJmHnHtH uhCJaJmHnHtH uh%x+CJaJmHnHtH u-h`Ph%x+0J5CJ\aJmHnHtH u2jh`Ph%x+5CJU\aJmHnHtH u8jOh`Ph%x+5CJU\aJmHnHtH u)h`Ph%x+5CJ\aJmHnHtH u =?i®tiWLD<1LWhG@hA8CJaJh%x+CJaJh`PCJaJhG@h(CJaJ#hG@hCJaJmHnHtH uhG@hCJaJ,hY.<hB* CJaJmHnHphPtH uhCJaJmHnHtH u&hPh5CJaJmHnHtH u&hPh5CJOJQJ\^JaJhs-h5CJ\aJ#hRhCJaJmHnHtH u9jhPh0J5>*CJH*UaJmHnHtH uPG4& & Fd $Ifgd^m$ $Ifgdp$kd$$Ifl4xFrTx<d! 0=    4 laf4p!@Q $Ifgd& & Fd$Ifgdm$& & Fd $If]gdm$i|!)5?@ʸަ}gLg6+hPhCJOJQJ^JaJmHnHu4hY.<hB* CJOJQJ^JaJmHnHphPu+hG@hCJOJQJ^JaJmHnHuhG@hA8CJaJh%x+CJaJmHnHtH uh`PCJaJmHnHtH u#hG@h(CJaJmHnHtH u#hG@hA8CJaJmHnHtH u&hG@hCJH*aJmHnHtH u#hG@hCJaJmHnHtH uhLfCJaJmHnHtH u@PQhʹrcLr8'h9h0JCJaJmHnHtH u,jTh9CJUaJmHnHtH uh9CJaJmHnHtH u&jh9CJUaJmHnHtH uhs-h5CJ\aJ&hzh1t5CJaJmHnHtH u h`P5CJaJmHnHtH u h1t5CJaJmHnHtH u&hPh5CJaJmHnHtH uh}jCJaJmHnHtH u#hPhCJaJmHnHtH uGeOO;;;&$ & Fd$Ifa$gdm$&$ & Fd $Ifa$gdm$kd$$Ifl4FrTx<d!0=    4 laf4p89:EFGHSƷs_M9%&hPh5CJaJmHnHtH u&hPh5CJOJQJ\^JaJ#hPh9CJaJmHnHtH u'h9h90JCJaJmHnHtH u3j%h90J>*CJUaJmHnHtH u$h90J>*CJaJmHnHtH u-jh90J>*CJUaJmHnHtH uhCJaJmHnHtH u&jh9CJUaJmHnHtH u'h9h0JCJaJmHnHtH u!h0JCJaJmHnHtH u GH.& & Fd $IfgdNam$& & Fd $Ifgd *m$& & Fd$If]gd7zm$& & Fd $If]gd7zm$ $$Ifa$gdSTU`b,.e̺u^SA#hG@hA8CJaJmHnHtH uhG@hCJaJ,hY.<hB* CJaJmHnHphPtH uhs-h5CJ\aJhNaCJaJmHnHtH u&hPh5CJaJmHnHtH u&hPhCJH*aJmHnHtH u#hG@hCJaJmHnHtH u#hG@h(CJaJmHnHtH uh(CJaJmHnHtH u#hPhCJaJmHnHtH uP=&& & Fd $If]gd7zm$& & Fd $Ifgd7zm$kd$$Ifl4FrTx<d! 0=    4 laf4pG& & Fd $Ifgdm$& & Fd$If]gdm$& & Fd$Ifgdm$EL[\]ѽѮѮїѽїьzkz]I&hG@hZ5CJOJQJ\^JaJhs-h5CJ\aJhLCJaJmHnHtH u#hPhCJaJmHnHtH uhG@hCJaJ,hY.<hB* CJaJmHnHphPtH uh$CJaJmHnHtH u&hG@hCJH*aJmHnHtH u#hG@hCJaJmHnHtH u#hG@h(CJaJmHnHtH uhG@hA8CJaJe\ $IfgdCkd$$Ifl4,FrTx<d!0=    4 laf4p:Oyyff& & F#d $IfgdeNm$& & Fd $Ifgd7zm$skd$$Ifl4rx<=  0=4 laf4p *I+9:FQR012MNOPQ˱ˠ˱seWHhH5CJOJQJ^JaJhs-hZ5CJ\aJhG@h0^5CJ\aJ j[heNCJU\aJheNh0^0JCJ\aJheNheN0JCJ\aJ jvheNCJU\aJjheNCJU\aJhG@h0^CJ\aJheNCJ\aJhG@h/ICJ\aJhG@hZCJ\aJ&hs-hZ5CJOJQJ\^JaJOPQRco $&`#$/IfgdV3 gd! gdG@jkd$$Ifl4rx<=0=4 laf4p QRd?wx ')*\`o,̛̺yj޺YYYYYWU hhV3CJOJQJ^JaJhV35CJOJQJ^JaJ hvhV3CJOJQJ^JaJ h`hV3CJOJQJ^JaJhV3CJOJQJ^JaJ hvhV3CJOJQJ^JaJ#hHhV35CJOJQJ^JaJ#hvhV35CJOJQJ^JaJ#hvhV35CJOJQJ^JaJhqm5CJOJQJ^JaJ"cdxl\\\\\\$&`#$/IfgdV3 $&`#$/IfgdV3~kd4$$Iflx<<  t 6` 0<644 lap *-q]M]]]]$&`#$/IfgdV3 $&`#$/IfgdV3kd$$Ifl0x<e6 t 6`0<644 lap Infection Prevention and Control Team(IPCT) Tel: 020 3299 4374 Email:  HYPERLINK "mailto:kch-tr.KCH-IC-Nurses@nhs.net" kch-tr.KCH-IC-Nurses@nhs.net References HYPERLINK "https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-care"Public Health England: Managing common infections: guidance for primary care  Updated September 2019 British National Formulary. Available online via  HYPERLINK "https://bnf.nice.org.uk/" https://bnf.nice.org.uk/ British National Formulary for Children. Available online via  HYPERLINK "https://bnfc.nice.org.uk/" https://bnfc.nice.org.uk/ South East London Integrated Guideline for the Management of Asthma in adults (18 years old and over). April 2019. Available online via:  HYPERLINK "https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical%20guidelines%20and%20pathways/SEL%20Asthma%20Guideline%20Apr%202019.pdf" https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical%20guidelines%20and%20pathways/SEL%20Asthma%20Guideline%20Apr%202019.pdf South East London Integrated Guideline for the Management of COPD. April 2019. Available online via:  HYPERLINK "https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical%20guidelines%20and%20pathways/SEL%20COPD%20guideline%20Apr%202019.pdf" https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical%20guidelines%20and%20pathways/SEL%20COPD%20guideline%20Apr%202019.pdf BTS Guidelines for the Management of Community Acquired Pneumonia in Adults, 2009 update. Available online via  HYPERLINK "http://www.brit-thoracic.org.uk" www.brit-thoracic.org.uk NICE  HYPERLINK "http://www.nice.org.uk/guidance/CG69" Guideline 69: Respiratory Tract Infections (self-limiting): prescribing antibiotics (July 2008). NICE  HYPERLINK "https://www.nice.org.uk/guidance/NG115" Guideline 115 : Chronic obstructive pulmonary disease in over 16s: diagnosis and management (June 2010) NICE  HYPERLINK "http://www.nice.org.uk/guidance/CG102" Guideline 102: Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (updated February 2015) SIGN  HYPERLINK "https://www.sign.ac.uk/assets/sign88.pdf" Guideline 88: Management of suspected bacterial urinary tract infections in adults. Updated July 2012  HYPERLINK "https://uroweb.org/wp-content/uploads/EAU-Guidelines-Urological-Infections-2016-1.pdf" European Association of Urology Guideline on Urological Infections (2016)  HYPERLINK "https://www.gov.uk/government/publications/clostridium-difficile-infection-guidance-on-management-and-treatment" Public Health England and Department of Health Guidance: Clostridium difficile infection: How to deal with the problem Updated June 2013 NICE Clinical Knowledge Summaries. Available online via  HYPERLINK "http://www.evidence.nhs.uk" www.evidence.nhs.uk HYPERLINK "https://www.gov.uk/government/publications/meningococcal-disease-guidance-on-public-health-management"Public Health England. Guidance for public health management of meningococcal disease in the UK. Updated March 2012 All resources last accessed on 22/08/2019       PAGE 19 People > 65 years: do not treat asymptomatic bacteriuria; it is common but is not associated with increased morbidity If slow response, continue treatment for a further 7 days. Skin changes (such as discolouration) may persist for months or longer following severe cellulitis and do not necessarily require ongoing antibiotics. ARRANGE URGENT TRANSFER TO HOSPITAL ,-0GHyz­o`N9( hNahCJOJQJ^JaJ)jhNahgUCJOJQJU^JaJ#hNah<5CJOJQJ^JaJhT5CJOJQJ^JaJ#hmhV35CJOJQJ^JaJ4hvhV3CJOJQJ\^JaJeh@r@ hvhV3CJOJQJ^JaJ)jhvhV3CJOJQJU^JaJ#hV3B*CJOJQJ^JaJph333)hvhV3B*CJOJQJ^JaJph333,hHhV35B*CJOJQJ^JaJph333 {tobbVJJ> & F gd:k & F gd$~ & F gdgU h^hgdeNkd~$$Ifl0x<e6 t 6`0<644 lapS`bckuvyzҿқ||kZI4)jhNahCJOJQJU^JaJ hNahgUCJOJQJ^JaJ hNahzCJOJQJ^JaJ hNah<CJOJQJ^JaJ hNahCJOJQJ^JaJhlCJOJQJ^JaJ hNahgUCJOJQJ^JaJ$hNah0JCJOJQJ^JaJ$hNahgU0JCJOJQJ^JaJ)jhNahgUCJOJQJU^JaJ/j*hNahCJOJQJU^JaJԽս./0WXqrstھܾ|eeeTCTCTCT hNah;CJOJQJ^JaJ hNah:kCJOJQJ^JaJ-jhNah0JCJOJQJU^JaJ hNahCJOJQJ^JaJ hNahzCJOJQJ^JaJ hNah<CJOJQJ^JaJ hNahgUCJOJQJ^JaJ hNah$hNah0JCJOJQJ^JaJ)jhNahCJOJQJU^JaJ hNahCJOJQJ^JaJ׿ؿ  IJǴǴyyhWBWB)jhNahgUCJOJQJU^JaJ hNahgUCJOJQJ^JaJ hNah<CJOJQJ^JaJ$hNah.J0JCJOJQJ^JaJ-jhNah.J0JCJOJQJU^JaJ hNah.JCJOJQJ^JaJ$hNah;0JCJOJQJ^JaJ-jhNah;0JCJOJQJU^JaJ hNah:kCJOJQJ^JaJ hNah4}CJOJQJ^JaJdsM6`bcefhiklp$ r =]a$gd( $ a$gd$ & F gd< & F gdgU & F gd4}Jbcdij;<=HǶvǶaP8av/jFhNahGCJOJQJU^JaJ hNahGCJOJQJ^JaJ)jhNahGCJOJQJU^JaJ$hNah<0JCJOJQJ^JaJ/jshNah<CJOJQJU^JaJ)jhNah<CJOJQJU^JaJ hNah<CJOJQJ^JaJ hNahgUCJOJQJ^JaJ)jhNahgUCJOJQJU^JaJ$hNahgU0JCJOJQJ^JaJHJKLs&rxyǶxeSEhlCJOJQJ^JaJ#jhlCJOJQJU^JaJ$hNah<0JCJOJQJ^JaJ/jhNah<CJOJQJU^JaJ)jhNah<CJOJQJU^JaJ hNahgUCJOJQJ^JaJ hNah<CJOJQJ^JaJ hNahGCJOJQJ^JaJ)jhNahGCJOJQJU^JaJ$hNahG0JCJOJQJ^JaJ}~شvcPcP=c=c=$hNahu/0JCJOJQJ^JaJ$hNahgU0JCJOJQJ^JaJ$hNah<0JCJOJQJ^JaJ/jhNahu/CJOJQJU^JaJ)jhNahu/CJOJQJU^JaJ hNahu/CJOJQJ^JaJ hNah<CJOJQJ^JaJ$hlh<0JCJOJQJ^JaJ#jhlCJOJQJU^JaJ)jhlCJOJQJU^JaJHIJP78KLMɱڞwfQfQ>Qf$hNahz0JCJOJQJ^JaJ)jhNahzCJOJQJU^JaJ hNahzCJOJQJ^JaJ'hNah<0J6CJOJQJ^JaJ$hNahu/0JCJOJQJ^JaJ$hNah<0JCJOJQJ^JaJ/jhNahu/CJOJQJU^JaJ hNahu/CJOJQJ^JaJ)jhNahu/CJOJQJU^JaJ hNah<CJOJQJ^JaJMN6U_`acdfgijlnopٝ~vrvrvrvriXIh5CJOJQJ^JaJ jhghUmHnHuhmHnHuh {jh {U hh$CJOJQJ^JaJhlCJOJQJ^JaJ hNah$CJOJQJ^JaJ$hNah<0JCJOJQJ^JaJ/jkhNah<CJOJQJU^JaJ hNah<CJOJQJ^JaJ)jhNah<CJOJQJU^JaJpqr $ a$gd$$a$gd<*gdzF$a$gdUgd(  r x<gd;X$ r =a$gdapqstu{|~®—…m\J8#hLJh5CJOJQJ^JaJ#h@h5CJOJQJ^JaJ h@hCJOJQJ^JaJ&h@h5CJOJQJ\^JaJh {#hO7sh5CJOJQJ^JaJ,h65#5apyt-#DyK acutesorethroat{DyK  scarletfeveruDyK  InfluenzaDyK CommunityAcquiredPneumoniaDyK Acutecoughbronchitis$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK acuterhinosinusitiskDyK COPD$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK acuteotitismedia$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK acuteotitisexterna$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#$$If!vh#v#v"#v:V lO tj>655"5apyt-#kDyK UTIsDyK SKININFECTIONSs$$If!vh#v##v:V l> tj>65#5apyt-#sDyK  impetigo$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK RecurrentUTIinwomenDyK RecurrentUTIinmenwDyK  CellulitissDyK  Mastitis$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK Lowerutiinchildren{DyK  diabeticfoot$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK upperutiinchildrenkDyK Acne$$If!vh#v#v"#v#va:V l_ tj>655"55aap(yt-#DyK AcuteprostatitisoDyK Eczema$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK AcutepyelonephritisDyK HumananimalbitesDyK VaricellaHerpesDyK TickbitesLymedisease$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#$$If!vh#v#v"#v#va:V lO tj>655"55aap(yt-#DyK GASTROINTESTINALINFECTIONSDyK InfectiousdiarrhoeaDyK Clostridiumdifficile}DyK EYECONDITIONS}DyK ConjuctivitisyDyK  Blepharitiss$$If!vh#v##v:V l$ tj>65#5apyt-#DyK DENTALINFECTIONS$$If!vh#v#v"#v:V lO tj>655"5apyt-#DyK Suspectedmeningococcaldisease$$If!vh#v#v"#v:V lO tj>655"5apyt-#iDyK STIDyK MRSAinfectionss$$If!vh#v##v:V lF tj>65#5apyt-#$$If!vh#v#v"#v:V l_ tj>655"5apyt-#*$$If!vh#v#v#v#vB:V l44 `(0j>6++,5555@4ap(yt-#j$$If!vh#v#v#v#v#v#v:V l44 ``<0j>6++,555554ap<yt-#kd+$$Ifl44ֈ,0$,Z5= ``<0j>64 lap<yt-#$$If!vh#vj>:V l  0j>6,5h>4ap yt-#%DyK yK https://www.nice.org.uk/guidance/ng84/resources/visual-summary-pdf-4723226606yX;H,]ą'cDyK yK jhttp://cks.nice.org.uk/sore-throat-acuteyX;H,]ą'cDyK yK dhttps://www.nice.org.uk/guidance/ng84yX;H,]ą'cDyK yK thttps://ctu1.phc.ox.ac.uk/feverpain/index.phpyX;H,]ą'cDyK yK http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashxyX;H,]ą'cDyK yK nhttps://www.nhs.uk/conditions/sore-throat/yX;H,]ą'c$$If!vh#v#v#v!:V l4 0j>6++,555!4apyt-#$$If!vh#v#v#v#v#v#v:V l4G0j>6++,555554ap<yt-#5DyK yK https://www.gov.uk/government/publications/scarlet-fever-symptoms-diagnosis-treatmentyX;H,]ą'c$$If!vh#v#v:V l40j>6!++,554aytC$$If!vh#v#v#v#v#v#v:V l40j>6++,555554ayt-#WDyK yK https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agentsyX;H,]ą'cWDyK yK https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agentsyX;H,]ą'c$$If!vh#v#v8:V lH0j>6,5584aytDyK yK dhttps://www.nice.org.uk/guidance/ng79yX;H,]ą'cDyK yK Zhttp://cks.nice.org.uk/sinusitisyX;H,]ą'cDyK yK http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashxyX;H,]ą'cDyK yK https://patient.info/treatment-medication/steroids/steroid-nasal-spraysyX;H,]ą'c%DyK yK https://www.nice.org.uk/guidance/ng79/resources/visual-summary-pdf-4656316717yX;H,]ą'cDyK yK https://www.nhs.uk/conditions/sinusitis-sinus-infection/yX;H,]ą'c$$If!vh#v#v#v!:V l4 0j>6++,555!4apyt-#$$If!vh#v#v#v#v#v#v:V l40j>6++,555554ayt-#DyK yK lhttp://cks.nice.org.uk/otitis-media-acuteyX;H,]ą'cDyK yK dhttps://www.nice.org.uk/guidance/ng91yX;H,]ą'cDyK yK fhttps://www.nice.org.uk/guidance/cg160yX;H,]ą'cDyK yK http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashxyX;H,]ą'cDyK yK https://www.nhs.uk/conditions/middle-ear-infection/yX;H,]ą'c$$If!vh#v#v#v!:V l4! 0j>6++,555!/ 4apyt-#$$If!vh#v#v#v#v#v#v:V l460j>6++,,555554ayt-#DyK yK dhttp://cks.nice.org.uk/otitis-externayX;H,]ą'c$$If!vh#v#v#v!:V l4 0j>6++,555!4apyt-#$$If!vh#v#v#v#vB:V l40j>6++,5555@4ayt-#$$If!vh#vz#v#v,#v:V l44} `(0=++,5z55,54ap(V$$If!vh#vz#v#vp#v#vp:V l44} ``<0=++,5z55p55p4ap<kdO$$Ifl44}ֈrl#+4x<zppp ``<0=4 lap<$$If!vh#v=:V l}  0=,5=4ap DyK yK Fhttps://www.brit-thoracic.org.uk/standards-of-care/guidelines/bts-guidelines-for-the-management-of-community-acquired-pneumonia-in-adults-update-2009/yX;H,]ą'cDyK yK fhttps://www.nice.org.uk/guidance/cg191yX;H,]ą'c$$If!vh#vz#v#v,#v:V l40=++,5z55,54a$$If!vh#vz#v#vp#v#vp:V l40=++,5z55p55p4aDyK yK Thttps://cks.nice.org.uk/coughyX;H,]ą'cDyK yK vhttps://cks.nice.org.uk/chest-infections-adultyX;H,]ą'cDyK yK dhttps://www.nice.org.uk/guidance/CG69yX;H,]ą'cDyK yK http://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashxyX;H,]ą'cDyK yK bhttps://www.nhs.uk/conditions/cough/yX;H,]ą'c$$If!vh#vz#v#v !:V l4 0=++,5z55 !4ap$$If!vh#vz#v#vp#v#vp:V l40=++,5z55p55p4ap<DyK yK fhttps://www.nice.org.uk/guidance/cg101yX;H,]ą'c'DyK yK http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/yX;H,]ą'c/DyK yK https://www.nice.org.uk/guidance/ng114/resources/guide-to-resources-pdf-6602624893yX;H,]ą'cDyK yK https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical guidelines and pathways/SEL COPD guideline Apr 2019.pdfyX;H,]ą'c$$If!vh#vz#v#v !:V l4[ 0=++,5z55 !4a$$If!vh#vz#v#vp#v#vp:V l40=++,5z55p55p4a"$$If!vh#vU#v#v#v:V l44 `(0>++,5U5554ap(ytSj$$If!vh#vU#v#v#v#vi #va:V l44 ``<0>++,5U5555i 5a4ap<ytSkde$$Ifl44ֈrq%2-6=Ui a ``<0>4 lap<ytS$$If!vh#v>:V l  0>,5>4ap ytS#DyK yK https://www.gov.uk/government/publications/urinary-tract-infection-diagnosisyX;H,]ą'cWDyK yK http://www.sign.ac.uk/sign-88-management-of-suspected-bacterial-urinary-tract-infection-in-adults.htmlyX;H,]ą'cDyK yK http://cks.nice.org.uk/urinary-tract-infection-lower-womenyX;H,]ą'cDyK yK http://cks.nice.org.uk/urinary-tract-infection-lower-menyX;H,]ą'cADyK yK https://rcgp.org.uk/clinical-and-research/resources/toolkits/target-antibiotic-toolkit.aspxyX;H,]ą'coDyK yK https://www.sapg.scot/media/4653/alternative-management-of-lower-urinary-tract-infection-in-non-pregnant-women.pdfyX;H,]ą'c#DyK yK https://www.gov.uk/government/publications/urinary-tract-infection-diagnosisyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'c$$If!vh#vU#v#v#v:V l40>++,,5U5554apytS$$If!vh#vU#v#v#vi #va:V l40>++,,,5U555i 5a4apytS~#DyK yK https://www.gov.uk/government/publications/urinary-tract-infection-diagnosisyX;H,]ą'cDyK yK lhttp://www.rcgp.org.uk/TARGETantibiotics/yX;H,]ą'c$$If!vh#vU#v#v#v:V l4 0>+++,5U5554apytS$$If!vh#vU#v#v#v:V l40>+++,,5U5554aytS$$If!vh#vU#v56:V l]0>,5U5564aytS#DyK yK https://www.gov.uk/government/publications/urinary-tract-infection-diagnosisyX;H,]ą'cDyK yK http://cks.nice.org.uk/urinary-tract-infection-childrenyX;H,]ą'c DyK yK https://www.nice.org.uk/guidance/cg54?unlid=9336988692016286120yX;H,]ą'cDyK yK Lhttps://bnfc.nice.org.uk/yX;H,]ą'cDyK yK Lhttps://bnfc.nice.org.uk/yX;H,]ą'c$$If!vh#vU#v#v#v:V l 0>,5U5554aytS#DyK yK https://www.gov.uk/government/publications/urinary-tract-infection-diagnosisyX;H,]ą'cDyK yK http://cks.nice.org.uk/urinary-tract-infection-childrenyX;H,]ą'c DyK yK https://www.nice.org.uk/guidance/cg54?unlid=9336988692016286120yX;H,]ą'c$$If!vh#vU#v56:V l0>,5U5564aytSoDyK _blankyK https://www.guysandstthomas.nhs.uk/resources/patient-information/urology/bladder/my-catheter-passport.pdfyX;H,]ą'c$$If!vh#vU#v#v#v#vi #vP:V l40>++++,5U5555i 5P4aytSDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'c$$If!vh#vU#v#v#v#vi #vP:V l40>++++,5U5555i 5P4aytSDyK yK Zhttps://www.bashh.org/guidelinesyX;H,]ą'cDyK yK jhttp://cks.nice.org.uk/prostatitis-acuteyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'c$$If!vh#vU#v#v#v:V l0>,,5U5554aytSDyK yK phttp://cks.nice.org.uk/pyelonephritis-acuteyX;H,]ą'cDyK yK https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsyX;H,]ą'c$$If!vh#vU#v#v#v#vi #va:V l0>,,5U5555i 5a4aytS$$If!vh#v#vF#v#v:V l44T `(0=++55F554af4p(ytK g$$If!vh#v#vF#v# #v#v #vq:V l44 ``<0=++55F5# 55 5q4af4p<ytK kd/$$Ifl44ֈrS!w)4x<  F#  q ``<0=4 laf4p<ytK $$If!vh#v=:V l4  0=,5=4af4p $$If!vh#v=:V l4  0=,5=4af4p DyK yK Xhttp://cks.nice.org.uk/impetigoyX;H,]ą'c$$If!vh#v#vF#v# #v#v #vq:V l0=,55F5# 55 5q4aytK DyK yK hhttp://cks.nice.org.uk/cellulitis-acuteyX;H,]ą'cDyK yK https://www.lymphoedema.org/images/pdf/CellulitisConsensus.pdfyX;H,]ą'c$$If!vh#v#vF#v# #v#v #vq:V l0=,55F5# 55 5q4aytK DyK yK https://cks.nice.org.uk/mastitis-and-breast-abscessyX;H,]ą'c$$If!vh#v#vF#v# #v#v #vq:V l 0=,55F5# 55 5q4aytK $$If!vh#v#v%6:V l0=,55%64aytK DyK yK dhttps://cks.nice.org.uk/acne-vulgarisyX;H,]ą'cDyK yK `https://www.nhs.uk/conditions/Acne/yX;H,]ą'c$$If!vh#v#vF#v#:V l4 0=++,55F5#4apytK $$If!vh#v#vF#v#v:V l40=++,55F554aytK DyK yK bhttp://cks.nice.org.uk/eczema-atopicyX;H,]ą'c$$If!vh#v#v%6:V l0=,55%64aytK DyK yK thttp://cks.nice.org.uk/bites-human-and-animalyX;H,]ą'cKDyK yK https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-bookyX;H,]ą'cEDyK yK http://legacytools.hpa.org.uk/AboutTheHPA/WhatTheAgencyDoes/LocalServices/SouthEastLondonHPT/yX;H,]ą'cDyK FuC:\Users\NADATIA\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Outlook\K2AJ3201\phe.slhpt@nhs.net DyK F{C:\Users\NADATIA\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.Outlook\K2AJ3201\slhpt.oncall@phe.gov.ukDyK yK Lhttps://bnfc.nice.org.uk/yX;H,]ą'cDyK yK Lhttps://bnfc.nice.org.uk/yX;H,]ą'c$$If!vh#v#vF#v* #v#v #vk:V l0=,,55F5* 55 5k4aytK DyK yK ^https://cks.nice.org.uk/chickenpoxyX;H,]ą'cDyK yK Zhttps://cks.nice.org.uk/shinglesyX;H,]ą'c$$If!vh#v#vF#v#v:V l0=,,55F554aytK DyK yK bhttps://cks.nice.org.uk/lyme-diseaseyX;H,]ą'c$$If!vh#v#vF#vo#v #vk:V l0=,,55F5o5 5k4ayt V$$If!vh#v#vd#v!:V l4Y 0=,55d5!4apiDyK yK https://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/lambeth-borough-prescribing-committee/Lambeth Borough Prescribing Committee/Clinical Guidelines/Sexually Transmitted Infections quick reference treatment guideline 2019.pdfyX;H,]ą'c$$If!vh#v=:V l4  0=,5=4af4p ytE%$$If!vh#v=:V l4  0=,5=4af4p DyK yK fhttp://cks.nice.org.uk/gastroenteritisyX;H,]ą'cEDyK yK http://legacytools.hpa.org.uk/AboutTheHPA/WhatTheAgencyDoes/LocalServices/SouthEastLondonHPT/yX;H,]ą'c$$If!vh#v#vd#v!:V l!0=,55d5!4a$$If!vh#v#vd#v!:V l0=,55d5!4a$$If!vh#v=:V l4  0=,5=4af4p ?DyK yK https://www.gov.uk/government/collections/meningococcal-disease-guidance-data-and-analysisyX;H,]ą'c$$If!vh#v#vd#v!:V l90=,55d5!4a$$If!vh#v=:V l4  0=,5=4af4p DyK  yK rhttps://cks.nice.org.uk/mrsa-in-primary-careyX;H,]ą'c !diagnosis$$If!vh#v#v$6:V l_0=,55$64a$$If!vh#v=:V l4  0=,5=4af4p DyK yK thttps://www.nhs.uk/conditions/conjunctivitis/yX;H,]ą'cDyK yK zhttps://cks.nice.org.uk/conjunctivitis-infectiveyX;H,]ą'cDyK yK xhttps://cks.nice.org.uk/conjunctivitis-allergicyX;H,]ą'c;DyK yK https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2017/09/spotty-book-2018.pdfyX;H,]ą'c$$If!vh#v#vd#v!:V l4x 0=++,55d5!4af4p$$If!vh#v#vd#v!:V l40=++,55d5!4af4pDyK yK `https://cks.nice.org.uk/blepharitisyX;H,]ą'cDyK yK nhttps://www.nhs.uk/conditions/blepharitis/yX;H,]ą'c$$If!vh#v#vd#v!:V l4 0=++,55d5!4af4p$$If!vh#v#vd#v!:V l4,0=++,55d5!4af4p$$If!vh#v=:V l4  0=,5=4af4p DyK yK thttps://www.nhs.uk/conditions/Dental-abscess/yX;H,]ą'cCDyK yK https://bda.org/dentists/advice/Documents/NHS patient information leaflet on antibiotics.pdfyX;H,]ą'c$$If!vh#v=:V l40=,5=4af4p $$If!vh#v<:V l  t 6` 0<65

A?Picture 8"RIMf֓3%FMf֓3JFIFExifMM*>F(iNx28Photoshop 3.08BIM8BIM%ُ B~2x" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyzC  C  ?j8E?޻}qgƏ$emM^ya@?6~7eRcbKs(8?!_u< " Kd0U6퟈3X߷?-{ৌ .&Vt1tfeOu52W?=2LCS )'-&+8'ߍ<>aa"ԣgz|WxGL!nmccZgrk{xq<*'Rijlq"ݯݿx/ ;V*X@N_`i_Dn8 pXLV6-ٻj։j~)|Ks n<ۧRc||9^OƾOĶMmZt#pXBʎz`WN?N ']BHCE=z^sx|7UYͪ:ڨtz.4Vu5x~_yw<)n~d㑚GVA[\&BQ+a_YVH$xΪ%}E[-*wixôskWMƟ'5~"XcFWfs2{W'~)|csmfRw5}n@·n֖,j$rB2I$J$0e*-*kK%TϼTNN뫓WOK]_Yl1zQ S3Q6 #b W|f~1o=.T<s9p~xefh'BI" G^ޛ[ T<<ޫG~g? xo3+nC*4?2H_$kSV)-Q"D<0ecexZoF7MOsH& 7njD_@Z|*<+ ÐaPo[ B+~@њ{ߵWt߯hþFeoo|Er,:J/3o0<ٮ7JK#OlM)%֓#FHJ{o_گ=1%$JeIR+kWʼnǶ5庮nݙ49#F[ɞdRreRc)7%y&i8$OEM? w~-6iks 8fX-@9ug+__O/½+vs#7Ń۬y?W̟Q}b}J9l˩^-]"uW'H4QW>YoJNߑ}1~e -_iG/9CߴwԚE#|Hޘֽ:<>,4[q"zW!kKx>4 C#Ҿ'3Y;Tnk{|,z,맗maLO_ퟄ9a#| _I[6V+pF3"#s?kԞK*d1r{qҾ-+5j,\\*1 b5yW6&8,~VV{>f#gic0VRww[7*Ji݂!G*?M_ќI0q_Cx { Eq3lιϺljud|;krO$-+;Ɵd^xVJjl4Gٺ<+/ľ1Dv?:,sWAye,N K{dƾ%մ{)<#!>׻os$g͙ynf;o xGN\dlIjx\*XI]&ѯMϿ~K)1iz|N8Ϯ3_A\$nuؿU;~W?嶫զYi ?n|SCjӭϘT$' /]޼+*N*[- ]?N{;><|4+QԮ{w@ ,K)9tMrV0ൡ?%=qGtaj:faX@P!$2ko)acD|RԖ^z/utS\-[N8i]=p4/)՟ZeCc5#j תџ?ᆷjWqGwi<pĒQ 1=y"=U(-/-0%b\ugğ;gڜ B1WXVJ]ۦ$zex J[h]Yppv,]ֵ֧+f? gٻwodn.%9y$ݏbx;!k8#qė9O@ B4ot?7 wC]ӿ&( . G ^wNHS/л$?Mx;!k9O@ B4ot?7 wC]ӿ&(e;!iG wCUEL^. 666666666vvvvvvvvv666666>666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ Nk"NormalCJ_HaJmH sH tH `@` +& Heading 2$<@&$56CJOJPJQJ\]^JaJX@X W Heading 3$$@&a$5>*CJ OJQJ^JaJtH @@@ W Heading 8 <@&6]\ @\ W Heading 9 $@&'5>*B*CJOJQJ^JaJphtH DA`D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List jj W Table Grid7:V04@4 W0Header  9r 4 @4 WFooter  9r vO"v W Preformatted( # ~= z9!v%CJOJQJ^JaJhtH 0U`10 W Hyperlink>*B*TP@BT a> Body Text 2!B*CJOJQJ^JaJphtH VoRV a>Default 7$8$H$!B*CJ_HaJmH phsH tH B'`aB a>Comment ReferenceCJaJL@rL a> Comment TextCJOJQJ^JaJtH H@H a> Balloon TextCJOJQJ^JaJ.)@. a> Page NumberPj@qrP jComment Subject5OJQJ\^JtH >Q@> f Body Text 3xCJaJ4O4 O5RcbndPxd\$2B2 -M Body TextxFV`F RFollowedHyperlink >*B* ph6o6 .0 Header CharCJaJ.X`. Z;IEmphasis6]JJ@J "Z;ISubtitle!$<@&a$OJPJQJ^JJo!J !Z;I Subtitle CharCJOJPJQJ^JaJB^2B <0 Normal (Web)#dd[$\$*W`A* <`Strong5\B/QB <apple-converted-space^Ob^ 'tPHE Bulletpoint& & Fdm$OJPJQJ^JtH \oq\ &tPHE Bulletpoint CharCJOJPJQJ^JaJtH @@@ t List Paragraph (^rOr *7zPHE Secondary Heading)d%B* CJOJPJQJ^JaJph.tH ror )7zPHE Secondary Heading Char%B* CJOJPJQJ^JaJph.tH XoX &Heading 2 Char$56CJOJPJQJ\]^JaJRoR +_0Unresolved MentionB*phq D`D0Revision-CJ_HaJmH sH tH PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] {Ou5{Oux5 !!!$ Q _ "qyLKf!"{$$L%%P&&G''4(l)*o**`++,-->..F/001j3l556Y7-88:g::;<p=g@BtCDDENFFLGGHb ԤL׳Ե]o~bKH?IzcY/@;|G:nBGjbi@SQ,JHMp~    $%&')*+-./024568:;>@BDEFGIKMNOPRSWXYZ\^_`abcfghikprsuwyz|} '$)&&'^'c''~(0** +j+,,-{..C/H///0>351688;:W;<=CCMGmHH)LLM#N&NVPYPQRRR&XX[]#^bcddhnp3p|p~pqu1{=ZP$&.aޔ 3~Դ״xm˼ 8TsAYv:n%YKbzGOcp  !"#(,1379<=?ACHJLQTUV[]dejlmnoqtvx{~.T(g Be) |$GKn ')Qim F[d|  4 = A h ! !%!.!2!X!n!q!!!!!!!" ""2"D"G"a"h"l""""""" #C#E#m######$,$.$V$$$$$$$%%/%;%C%g%y%%%%%% &&1&A&'c'g'j'''''''$(.(1(((,,,/0/0b2222\3s33333444o44"9y999$:3:t:::?????@@=@U@X@@@@A&AAEvEzEI\J`JcJJJh#" `?   X1?jText Box 2S"`?   ^1?jText Box 2S"`?   R?jText Box 2C"?   R?jText Box 2C"? B S  ?S EJn-5A-tH #tMHxUtM&!^t"$ t _Hlt499817477 _Hlt499817478 _Hlt499817384 _Hlt499817385 _Hlt507139076 _Hlt507139077 _Hlt15287833 _Hlt15287834 _Hlt10193447UTIs _Hlt511371174 _Hlt511371192 _Hlt16078036 _Hlt16078037 _Hlt16078220 _Hlt16078279 _Hlt16078120 _Hlt511371202upperrespiratorytractinfectionsacutesorethroat _Hlt10119793 _Hlt10119794 _Hlt10119717 _Hlt10119718 _Hlt511836135 _Hlt511836136 _Hlt467849271 _Hlt467849272 _Hlt501009680 _Hlt501009679 _Hlt501009664 _Hlt501009665 scarletfever _Hlt511836414 _Hlt511836415 _Hlt17372266 _Hlt17372267 _Hlt15288520 _Hlt15288521 _Hlt499811828 _Hlt499811829 _Hlt15288512 Influenza _Hlt17372247 _Hlt17372248acuterhinosinusitis _Hlt511836143 _Hlt511836144 _Hlt501012200 _Hlt501012201 _Hlt504638519 _Hlt504638520 _Hlt511836431 _Hlt511836432 _Hlt18312621 _Hlt18312622 _Hlt511836435 _Hlt511836436 _Hlt499817980 _Hlt501009952 _Hlt501009953 _Hlt17377197 _Hlt17377198 _Hlt499817943 _Hlt499817944 _Hlt499818028 _Hlt511836440 _Hlt511836441acuteotitismedia _Hlt17377210 _Hlt511836451 _Hlt511836452 _Hlt17377216 _Hlt17377217 _Hlt511836464 _Hlt511836465 _Hlt511836072 _Hlt511836073 _Hlt17377222 _Hlt17377223 _Hlt17377227 _Hlt17377228 _Hlt17377235 _Hlt504732527 _Hlt504732528 _Hlt511836457 _Hlt511836458acuteotitisexterna _Hlt17377244 _Hlt17377245 _Hlt507153408 _Hlt507153409LOWERRESPIRATORYTRACTINFECTIONSCommunityAcquiredPneumonia _Hlt511836514 _Hlt511836515 _Hlt17377278 _Hlt17377279 _Hlt511836176 _Hlt511836177 _Hlt511836476 _Hlt511836477 _Hlt511836551 _Hlt511836552 _Hlt511836159 _Hlt511836160 _Hlt17377294 _Hlt17377295Acutecoughbronchitis _Hlt511836631 _Hlt511836632 _Hlt511836648 _Hlt511836649 _Hlt18316792 _Hlt18316793 _Hlt17377311 _Hlt17377312 _Hlt18316800 _Hlt18316801 _Hlt17377317 _Hlt17377318 _Hlt17377328 _Hlt17377329 _Hlt511836774 _Hlt511836775 _Hlt17377335 _Hlt17377336 _Hlt511836781 _Hlt511836782 _Hlt505092412 _Hlt505092413COPD _Hlt511836810 _Hlt511836811 _Hlt17377345 _Hlt511836792 _Hlt511836793 _Hlt511836818 _Hlt511836819 _Hlt17377353 _Hlt17377354 _Hlt18313207 _Hlt18313208 _Hlt507153671 _Hlt507153672 _Hlt17377389 _Hlt17377390 _Hlt10123806 _Hlt494801089 _Hlt494801090 UTIinadults _Hlt17377467 _Hlt499820488 _Hlt499820489 _Hlt511836841 _Hlt511836829 _Hlt511836830 _Hlt17377475 _Hlt17377476 _Hlt511836835 _Hlt511836836 _Hlt511836895 _Hlt511836896 _Hlt17377485 _Hlt17377486 _Hlt511836907 _Hlt511836908 _Hlt17377492 _Hlt17377493 _Hlt17377627 _Hlt17377561 _Hlt17377562 _Hlt511836920 _Hlt511836921 _Hlt384886575 _Hlt384886576 _Hlt10206850 _Hlt10206851 _Hlt399230619 _Hlt399230620 _Hlt399230639 _Hlt399230640RecurrentUTIinwomen _Hlt17377659 _Hlt501101281 _Hlt501101282 _Hlt511836929 _Hlt511836930 _Hlt17377664 _Hlt17377665 _Hlt511836934 _Hlt511836935RecurrentUTIinmenLowerutiinchildren _Hlt17377750 _Hlt17377751 _Hlt17377754 _Hlt17377755 _Hlt511836993 _Hlt511836994 _Hlt17377761 _Hlt17377762 _Hlt511837004 _Hlt511837005 _Hlt17377688 _Hlt17377689 _Hlt17377747 _Hlt17377748 _Hlt507145794 _Hlt507145795upperutiinchildren _Hlt17377772 _Hlt17377773 _Hlt511837015 _Hlt511837016 _Hlt511837018 _Hlt511837019 _Hlt17377776 _Hlt17377777 _Hlt511837023 _Hlt511837024 _Hlt17377781 _Hlt17377782Catheterinsitu _Hlt17377791 _Hlt17377792 _Hlt17377821 _Hlt17377822 _Hlt17377808Acuteprostatitis _Hlt17377939 _Hlt17377940 _Hlt511837028 _Hlt511837029 _Hlt511837101 _Hlt511837102 _Hlt17378052 _Hlt17378053 _Hlt511837111 _Hlt511837112Acutepyelonephritis _Hlt511837117 _Hlt511837118 _Hlt17378074 _Hlt17378075SKININFECTIONSimpetigo _Hlt511837122 _Hlt511837123 _Hlt17378083 _Hlt17378084 cellulitis _Hlt17378089 _Hlt17378090 _Hlt511837126 _Hlt511837127 _Hlt511837131 _Hlt511837132 _Hlt17378096 _Hlt17378097Mastitis _Hlt17378146 _Hlt511837141 _Hlt511837142 diabeticfootAcne _Hlt17378156 _Hlt17378157 _Hlt511837148 _Hlt511837149Eczema _Hlt511837155 _Hlt511837156 _Hlt17378163 _Hlt17378164Humananimalbites _Hlt511837159 _Hlt511837160 _Hlt17378178 _Hlt17378179 _Hlt17378171 _Hlt17378172 _Hlt17378182 _Hlt17378183 _Hlt17378347VaricellaHerpes _Hlt17378365 _Hlt17378366 _Hlt17378380 _Hlt17378381TickbitesLymedisease _Hlt17378388 _Hlt17378389 _Hlt22214329 _Hlt22214330GASTROINTESTINALINFECTIONSInfectiousdiarrhoea _Hlt511837163 _Hlt511837164 _Hlt17378396 _Hlt17378397 _Hlt469577223 _Hlt469577224 _Hlt17378425ClostridiumdifficileSuspectedmeningococcaldisease _Hlt17378444 _Hlt17378445 _Hlt511837182 _Hlt511837183%METHICILLINRESISTANTSTAPHYLOCOCCUSAURMRSAinfections EYECONDITIONS Conjuctivitis _Hlt17378476 _Hlt17378477 _Hlt511837188 _Hlt511837189 _Hlt17378481 _Hlt17378482 _Hlt511837192 _Hlt511837193 _Hlt511837197 _Hlt511837198 _Hlt17378485 _Hlt17378486 Blepharitis _Hlt17378492 _Hlt17378493 _Hlt510871456 _Hlt510871457 _Hlt511837202 _Hlt511837203 _Hlt510871493 _Hlt510871503 _Hlt511837207 _Hlt511837208 _Hlt17378496 _Hlt17378497DENTALINFECTIONS _Hlt511837218 _Hlt511837219 _Hlt17378504 _Hlt17378505 _Hlt511837227 _Hlt511837228 _Hlt511837300 _Hlt511837301 _Hlt17378507 _Hlt17378508 _Hlt17378525 _Hlt17378542 _Hlt17378543 _Hlt17378547 _Hlt17378548 _Hlt13652326 _Hlt13652327 _Hlt17378553 _Hlt17378554 _Hlt17378564 _Hlt501105919 _Hlt501105921 _Hlt501105917 _Hlt501105918 _Hlt17378595 _Hlt507154140 _Hlt507154141 _Hlt507154079 _Hlt507154080 _Hlt501105932 _Hlt501105933 _Hlt17378602 _Hlt17378603 _Hlt507154075 _Hlt507154076 _Hlt17378607 _Hlt17378608 _Hlt501105939 _Hlt501105940 _Hlt14076322 _Hlt14076323 _Hlt17378626 _Hlt17378627 _Hlt507154071 _Hlt507154072 _Hlt14076411 _Hlt14076412 _Hlt501105943 _Hlt501105944 _Hlt17378636 _Hlt17378637 _Hlt17378699 _Hlt14076455 _Hlt14076456 _Hlt507154064 _Hlt507154065 _Hlt17378641 _Hlt501105947 _Hlt501105948 _Hlt507154058 _Hlt507154059 _Hlt501105953 _Hlt501105954 _Hlt17378707 _Hlt14076601 _Hlt507154054 _Hlt507154055 _Hlt501105959 _Hlt501105960 _Hlt14076607 _Hlt14076608 _Hlt17378724 _Hlt501105969 _Hlt501105970 _Hlt17378737 _Hlt17378738 _Hlt507154109 _Hlt17378752 _Hlt17378753 _Hlt507154049 _Hlt507154050 _Hlt14076617 _Hlt14076618 _Hlt501105973 _Hlt501105974d8 *#*#3##5%%&&e'e'f'f'''+(+(((((/"0"0"0"0&0&0*0*0,0X2o3o33333333333344}4444444444n??????@@@@E@E@@@A A A"A"A&ExExEyEyEYI}I^J^J^J^J_J_JJJJJJJJJ#SkSkSlSlSnSnSpSpSSSSSSSTTpTpT}T}TWWYYYYYYUZUZWZWZ__bbbbbbbedfefefsfyfyfffffOgOgPgPggggghhhhh:i:immtttt[wwxxxxcxcxdxdxB|k|||0}0}1}1}}}}}Z΁΁ρρuu}}%%??֍FFGGHH P؝ƠƠTT'wxxЪKKLLu ̳̳++yyccw3TTbBBFF))**..88xx||6ssyy||k!!K||!!""##$$%%yy~~ 6@@@@@@@@@ @ @ @ @@@@@@@@@@@@@@@@@ !@"@#@$@%@&@'@(@)@*+@,@-.@/@0@1@2@3@4@5@6@7@8@9@:@;@<@=@>@?@@@A@B@C@DE@F@G@L@M@H@I@J@K@N@O@P@Q@R@S@T@U@V@WX@Y@Z@[@\]^@_@`@a@b@c@d@e@f@g@h@i@j@k@lm@n@o@p@q@r@s@t@u@v@w@x@y@z@{@|@}@~@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@  @ @ @ @@@@@@@@@@@@@@@@ @!@"#@$@%@&@'()@*@+@,@-@.@/@014@5@2@3@6789:@;@<@=@>@?@@@A@B@C@D@E@FG@H@I@J@K@L@M@N@O@P@Q@R@ST@U@V@W@X@Y@Z@[@\@]@^@_@`@a@b@c@d@e@f@g@h@i@j@k@l@m@n@o@p@q@r@s@t@u@v@w@x@y@z@{@|@}@~@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@9 +#+#4##6%%&'f'f'g'g''',(,(((((/#0#0#0#0'0'0+0+0-0a2p3p33333333333344~4444444444????@@@@@@F@F@@@A!A!A#A#A@EyEyEzEzE{II_J_J_J_J`J`JJJJJJJJJ;SlSlSmSmSoSoSqSqSSSSSTTTTqTqT~T~TWWYYYYYYVZVZXZXZ__bbbbbbbeeffffftfzfzfffffPgPgQgQggggghhhhh;i;immttttrwwxxxxdxdxexexW||||1}1}2}2}}}}}pρρЁЁvv~~&&@@׍GGHHIIϕ_Š\\gg1xyyLLMM| ͳͳ,,zzddSCCGG****//88yy}}Ittzz}}l""L}}""##$$%%&&zz 6WZ %(.([)d)G,M,g6s6cDDGGNNppvv.{4{(,cmEN:<ik36 ))//!2"285C5cDDGGRR\\ o#opp_ydyIJ$7y1736333333333333333333333WWXX ''"99?@cJJiB]DpwDȅd>Ak̻ƙ&cDpGL#ar'&q*+M. C1B-xh+9ķB-Ar;bo6==6y!i>2I?CNn9DzȿFIR(nXJ0P%Ouq-V^Ϭ/ZMU`8ل&K,2dl#`gB)$&Gg$tjuipwRmȑ:js@L[.sz! B]qC1FIL#w+9q-Vn9D/ZAkwRm&c&GgK,2d=U`?jsjuiiF?C %O &xo6=_[M/Y] '6|N ]ilL8R_%ruF (6AlpzCHy369/?(@B+FW|{PYVjYjezYf7Z)hwpz !;^o 7BVmw|S~)T')ABM  9"}R}9Yp6x(2l{|"'D` !e;jv p  . !^!"!2!9!""Y""/"9"cE"_"Nk" #2#p2#I4#XS#|/$B8$NI$^Z$fZ$wu$%%A%E%L%]%&y&6L&P&M[&t&l '/'9' B'V'W'(7(9(@(k(|(f)b))R)3&)_?)n)(* * *8.*;*_*h*i*Fq*u*u*s2+[G+W+0u+%x+J,,7*,G,4-s-I(-,- 2-L-CR-S-t-u-=(.(.=.1J.S.W.X.=/!/ ]/u/.0A0Q01X0&k0v0&41`=1j1~1(2@2H2f\2wl2l23-323:3>3a3%e3 4 4k'4M34lH4Y4)\4 ^4Fi45&5I1525?5[5Qb5& 6\6H6S6DV6e6q6{6&~6M!7s%7d0737@7e7%g78l8i8`#8#48=8A8Q8]8Qf8Fs8Fw8<|8\|89 99K(929K9e9'|9::$:+:N:g:;;9;=;>>;O;T;e;g;7<<<$<Y.<B<8J<~<=/=/=I=t=x=a>;!>/>(G>7O>P>WR>S>\>;u>}>~> ??%?9?r?z?? @R$@-@ :@E@= AuAAA B0B%6BgOB#QBetB C#CVC`CxCUDD03Dw5D!>D_ODCUD`DppDGqDE;EPEFmEzE F F#FLF]FbFgF qFGt#G3G:GjGlGuGH+H?.H]?],f]s]Nt]^ ^ Z^ic^Qn^_m__r__C:_/?_EM_f_m ``O`z2`H```Zr``aG3a5aCau\aMcabAbEb[bebTgbm>cd(.d3d|lmn"m'/m@mOmLYm^Zmqma-n3nTVnrntnQ~noo oJoAooj$o&o.o86o:oIosoVp1p8p ApQpkhp"q)q;q|DqHqIqoTqYqeqgqiq8pqkuq2r&rRrcarFhrF ss$sU,sO7s7sLsOsUstt&t1t8tEtHtOtWtgtzt~tF uu>uyPuZuhulu| v1v2v5v9vovo w ww>wHww0wF6wHwHwMMwhwVqwwwAyw~ws!x7x>xeVx{]xQixrx yy&yq0y.HyTSyjyzC/z~7zI@z%^zdqz+}z{* {x{ {/#{l-{o-{-{F{Z{z{}{|||8|"a|^}$}&}4}:U}z}$~&g~/+6;$Lczf>~31,:To01l7@ks_ "+cO"]lw=8j^{m-rtw#0n)<*1\+}K 6@LV]hUns+2:kIgcn}6(9EyIRpJ`3eBQ5m^tQ*M3E[V[L\`Mk!,2HkqY"q)6n/&6@A Wij2  0zFVM5]LJMN'W/_5vC/B'7cZ.^Unp 78Qz8lHaAN_Ph@091:;DSf} ZV mpa*JPzetgHj&7;#FVjq {.} '</S(+0Mgsm~W 9@T8].ee~[P')US>ei 18Q >M Vz)0=SVkOn2M(3DenfIu e(LWot->*+0O3T3bU `1EG7@+JMQ[dH T"m#=@7IL2Zd`ixgy!"V5yTu?+J`\tek}MfWvX*[[llt^&<KT9v]k#-}4]ehJ|J (+LLn( ;Bql>Odt :Uq[d6O-3/45BDLEKWCXZab T 2Zdt+4Fg n{v {$M2c pszyi/ L*@Bkp9'7:<~BNSo`vzLF334vYAci {,.j5W7YJdvc)<YIIUe+)",_eGiq uwwN(k/>>tNVWWXdz|b%MLRPexv)_+:~#R$&(DGdr*u !89k:mOcUq a"<+/[1737GIpf}~Dy!(.4@Ff%@Nkt7z#fg*@/LL'_a7uTDNGox =a{ -=gi'kk,-P/BZgs(*2x<<2 6Y8j@+FqVDbe+;;d>BRIjK }t 1GJT6qDN ~&xEGRRa^5?xfqmR^( ZN T`4qyuN &ET hqzq- _!:m@lz 6+7G@I)[~ +`<>oBaGXYkl+J1_z g..?@GN)OP-#5>1IPfsf~^z#F(GtMMVPYlx/d#1NA[i/|l&'0eG{ s;D.S}H !<dHi!m+3  GYj"@Hs{e"p$R&/2~I`PRNaq}(/LGnWu(K)C]j! 5"j)<A NQR[%*48cEVPgpuwSy|/~<6>5DxZZ_xc+fv <@K\byefgg{f^1BXOli|@A3TrUX0^i_Q6'B8J\-h!W% *6W:qMVRClp(t}4L;iJQUh3->aeBu|!%)SEHRI`GkM q*E3>yAiVb^mw!&M(x/)5`99EInYYd/OQSKrwS;Bt1 Bo\$R^X# )JLNO?RbNfWxCjhttps://www.guysandstthomas.nhs.uk/resources/patient-information/urology/bladder/my-catheter-passport.pdfda;@https://www.nice.org.uk/guidance/cg54?unlid=9336988692016286120&*88http://cks.nice.org.uk/urinary-tract-infection-childrenZ5Mhttps://www.gov.uk/government/publications/urinary-tract-infection-diagnosis2https://bnfc.nice.org.uk//https://bnfc.nice.org.uk/da,@https://www.nice.org.uk/guidance/cg54?unlid=9336988692016286120&*)8http://cks.nice.org.uk/urinary-tract-infection-childrenZ&Mhttps://www.gov.uk/government/publications/urinary-tract-infection-diagnosisF#*http://www.rcgp.org.uk/TARGETantibiotics/Z Mhttps://www.gov.uk/government/publications/urinary-tract-infection-diagnosis!c'https://www.nice.org.uk/guidance/ng110!b'https://www.nice.org.uk/guidance/ng111{7https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effectsZMhttps://www.gov.uk/government/publications/urinary-tract-infection-diagnosis1~shttps://www.sapg.scot/media/4653/alternative-management-of-lower-urinary-tract-infection-in-non-pregnant-women.pdfl}\https://rcgp.org.uk/clinical-and-research/resources/toolkits/target-antibiotic-toolkit.aspxK 9http://cks.nice.org.uk/urinary-tract-infection-lower-men}<;http://cks.nice.org.uk/urinary-tract-infection-lower-women~sghttp://www.sign.ac.uk/sign-88-management-of-suspected-bacterial-urinary-tract-infection-in-adults.htmlZMhttps://www.gov.uk/government/publications/urinary-tract-infection-diagnosiscdhttps://www.lambethccg.nhs.uk/news-and-publications/meeting-papers/south-east-london-area-prescribing-committee/Documents/Clinical guidelines and pathways/SEL COPD guideline Apr 2019.pdfM+"mailto:Souccg.respiratory@nhs.netC,"mailto:lamccg.respiratory@nhs.net uShttps://www.nice.org.uk/guidance/ng114/resources/guide-to-resources-pdf-66026248938-Ohttp://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/ o'https://www.nice.org.uk/guidance/cg101%https://www.nhs.uk/conditions/cough/n=Ghttp://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashxY&https://www.nice.org.uk/guidance/CG69x?/https://cks.nice.org.uk/chest-infections-adultRhttps://cks.nice.org.uk/cough)o'https://www.nice.org.uk/guidance/cg191r=https://www.brit-thoracic.org.uk/standards-of-care/guidelines/bts-guidelines-for-the-management-of-community-acquired-pneumonia-in-adults-update-2009/&http://cks.nice.org.uk/otitis-externap=4https://www.nhs.uk/conditions/middle-ear-infection/n=Ghttp://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashx&n'https://www.nice.org.uk/guidance/cg160[&https://www.nice.org.uk/guidance/ng91[*http://cks.nice.org.uk/otitis-media-acute9https://www.nhs.uk/conditions/sinusitis-sinus-infection/ Nhttps://www.nice.org.uk/guidance/ng79/resources/visual-summary-pdf-4656316717nzHhttps://patient.info/treatment-medication/steroids/steroid-nasal-spraysn=Ghttp://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashxF!http://cks.nice.org.uk/sinusitisU&https://www.nice.org.uk/guidance/ng79s7ghttps://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agentss7ghttps://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agentsFHVhttps://www.gov.uk/government/publications/scarlet-fever-symptoms-diagnosis-treatment;k+https://www.nhs.uk/conditions/sore-throat/n=Ghttp://www.rcgp.org.uk/~/~/media/2E1292605D174B318A5302223B04C175.ashx D.https://ctu1.phc.ox.ac.uk/feverpain/index.phpZ&https://www.nice.org.uk/guidance/ng84E)http://cks.nice.org.uk/sore-throat-acuteNhttps://www.nice.org.uk/guidance/ng84/resources/visual-summary-pdf-4723226606upMRSAinfectionsstSTI SuspectedmeningococcaldiseaseDENTALINFECTIONSi} BlepharitisConjuctivitisEYECONDITIONSClostridiumdifficilehuInfectiousdiarrhoeakd~GASTROINTESTINALINFECTIONS{TickbitesLymedisease~xVaricellaHerpesuHumananimalbites|`rAcutepyelonephritisrgoEczemalAcuteprostatitisiAcneafupperutiinchildrenc diabeticfoot``Lowerutiinchildren] MastitiszbZ CellulitisWRecurrentUTIinmenutTRecurrentUTIinwomen Q impetigoz}N UTIinadultsqfKSKININFECTIONSHUTIsqzEacuteotitisexternaBacuteotitismedia ?COPDm<acuterhinosinusitis9Acutecoughbronchitisvs6CommunityAcquiredPneumonia3 Influenza 0 scarletfever|q-acutesorethroatyo* LOWERRESPIRATORYTRACTINFECTIONSgp' upperrespiratorytractinfections$bhttp://www.southwarkccg.nhs.uk/your-health/health-services-in-southwark/Pages/Pharmacy-First.aspx7!!#https://www.nhs.uk/pages/home.aspxThttp://www.selfcareforum.org/MSjhttp://www.southwarkccg.nhs.uk/news-and-publications/publications/leaflets-flyers/Documents/Self-care.pdf dhttp://www.lambethccg.nhs.uk/your-health/keeping-well/PublishingImages/Pages/Self-care/NHS Lambeth CCG Self Care Leaflet A5 Oct 17.pdf/,`https://www.gov.uk/government/publications/managing-common-infections-guidance-for-primary-careahttps://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-bookgd?https://www.gov.uk/government/collections/annual-flu-programme https://bnfc.nice.org.uk/F )http://www.rcgp.org.uk/targetantibiotics6e0https://www.nice.org.uk/guidance/ng51/resources=S,mailto:LAMCCG.medicinesoptimisation@nhs.net+-mailto:SOUCCG.Medicines-Optimisation@nhs.netL0x010100179E83ECB8342B42B2F908690F0D6B21004D7E6148B920774E99FA58D786900BEB16Y6V7A2CY6M6-979601937-183%a04193da-2d8c-4ebf-a34d-fa89272fc6adhttps://wwwauthor.lambethccg.nhs.uk/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijkmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123T<=>]ABCDEFGHIJKLMNOPQRUYZ[\^?SRoot Entry FP_ݿXData 1Tablel WordDocument?SummaryInformation(DocumentSummaryInformation8DsMsoDataStorePڿPڿVU13FGUOEAMZ0JT==2 PڿPڿItem  PropertiesPXKWVUG3GBHP4==2 PڿPڿItem  @%Properties Y4PAKGSBC3GQ==2PڿPڿItem  Properties*W1ZOFFUKPJDA==2PڿPڿItem 6Properties8 This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision. / DocumentLibraryFormDocumentLibraryForm/xs:attribute> name="BDCEntity"> news-and-publications/meeting-papers/lambeth-borough-prescribing-committee/_layouts/15/DocIdRedir.aspx?ID=6Y6V7A2CY6M6-979601937-183, 6Y6V7A2CY6M6-979601937-183e> Id4" type="xs:string">   !"#$%&)(+,-/0134579:;ce/2006/metadata/contentType"/> ds:schemaRefs> repoint/v3/contenttype/forms">DocumentLibraryFDocument ID GeneratorSynchronous100011000Microsoft.Office.DocumentManagement, Version=15.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100021001Microsoft.Office.DocumentManagement, Version=15.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100041002Microsoft.Office.DocumentManagement, Version=15.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100061003Microsoft.Office.DocumentManagement, Version=15.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlertorSynchronous lass>Microsoft.Office.DocumentManagement.Internal.DocIdDocumentLibraryF